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Rachel Ann Harry Abstract
Abstract
The presence of inflammatory cells within the central nervous system (CNS) 
including the retina is characteristic o f disease states such as human uveitis and 
multiple sclerosis, both CD4+ T cell mediated immune inflammatory diseases. 
Normal CNS is devoid of inflammatory cells and is maintained by the specialized 
nature o f the isolated microenvironments. The blood brain and blood retinal barriers 
(BBB, BRB) composed of highly specialized endothelial cells physically protect the 
CNS by regulating immune cell entry. The CNS is actively protected by immune 
privilege in which the local environment is able to suppress potentially devastating 
immune reactions, through the local expression of FasL and production of cytokines 
such as TGF-p. Additionally a role for a group of compounds called Statins has been 
described in the prevention of leukocyte migration from blood vessels to the sites of 
atherosclerotic lesions.
This study aims to determine potential mechanisms by which microvascular 
endothelial cells (EC) of the CNS are able to regulate T lymphocyte function, and 
whether these mechanisms are implicated in disease. The effects of statins on an 
inflammatory disease of the CNS were also investigated.
An in vitro model o f the BBB was used to investigate the immunomodulatory effects 
of EC upon T cells. A transwell insert system was employed to investigate the effects 
on T cells o f co-culture with EC whilst preventing cell-to-cell contact and also, the 
effect of transmigration through EC monolayers. Studies were also undertaken to 
investigate potential mechanisms by which this regulation may occur.
The effect of statins was investigated using two models of Experimental Autoimmune 
Uveoretinitis (EAU) as a model of human posterior Uveitis. EAU was induced using 
SAg peptide or IRBP peptide and the effects of daily administration o f statin were 
assessed using Fluorescein Angiography. Retinal sections were also examined by 
classical histology. The effects of statins were also investigated using an in vitro 
model of the BRB, time lapse microscopy and flow cytometry. The effects of statins 
on T cell function were assessed ex vivo by splenocyte proliferation assays.
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1.1 The Immune System
The immune system is the term given to the complex, intricate network o f cells and 
chemical messengers, which defend the human body against infection and disease. 
Immunity, a state of protection, is achieved by the close interaction o f the innate and 
adaptive immune system. The innate or “non-specific” immune system is present at 
birth and generally functions as the first line of defence against infection. Innate 
immunity is achieved by the presence of physical barriers including the skin and 
mucous membranes but also by cells of the immune system including macrophages, 
neutrophils, eosinophils and basophils. In contrast the adaptive or “specific” immune 
system, responds to antigens in a highly regulated manner. Re-exposure to an antigen 
results in a rapid and highly specific immune response, which develops by the 
process of immunological memory.
The adaptive immune system is mediated by two main cell types, T and B 
lymphocytes. T and B lymphocytes also known as T and B cells generate immunity 
by two separate but interconnected processes. B cells mediate humoral immunity 
through the generation of highly specific soluble receptors termed antibodies (Ab). 
Binding of an antibody to its specific antigen acts as a signal to other cells o f the 
immune system for its removal. In contrast to B cells, T cells only recognise antigen 
via the T cell receptor (TCR) when it is complexed to a self polypeptide molecule 
termed the major histocompatibility complex (MHC) which is expressed by antigen 
presenting cells (APC) such as dendritic cells (DC). The full proliferative response of 
a naive T cell is only achieved upon additional ligand-receptor interactions in a 
process termed co-stimulation (Schwartz 1992). Stimulation o f T cells is therefore 
restricted to sites such as the lymph nodes and spleen where DC’s, which express 
self-MHC and co-stimulatory molecules, reside (Steinman 1991).
Cellular immunity is generated by two functionally distinct subsets of T cells, these 
are CD4+ T cells which recognise antigen in the context o f MHC class II molecules 
and generally function as T helper cells to amplify the immune response while CD8+ 
T cells recognise antigen in the context of MHC class I molecules and generally
20
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cytotoxic. Many T cell effector functions are achieved through the production of pro- 
inflammatory, anti-inflammatory or regulatory cytokines, which help to amplify or 
modulate the immune response.
1.2 Immune Surveillance
Memory T cells specific for a given antigen are present at low numbers circulating 
throughout the body. In an attempt to ensure activation of the required T cell in 
response to antigen-bearing APC, lymphocytes circulate from the blood to the 
lymphoid system via high endothelial venules (HEV) of the afferent lymph vessels 
(Marchesi and Gowans 1964, Girard and Springer 1995). Once within the lymphoid 
system, comprised of lymph nodes and the spleen, T cells which encounter antigen 
are sequestered within the lymphoid organs where they are thought to divide and 
differentiate to become effector cells. In contrast, T cells which do not encounter 
antigen regain access to the bloodstream via the efferent lymphatic system. This 
process therefore ensures widespread distribution o f T cell receptor specificities 
throughout the immune system.
1.3 The immune system within the CNS
The central nervous system (CNS) including the retina is protected from the normal 
immune system at the level of the blood vessels by the presence o f specialized 
endothelia characterised by tight intercellular junctions, which form the blood-brain 
(BBB) and blood-retinal (BRB) barriers. Where once it was thought that the CNS 
was devoid of immune surveillance, it is now accepted that immune surveillance of 
the CNS by activated lymphocytes occurs, albeit at a low level (Hickey et al 1991). 
However, it is recognised that the CNS may be adapted to prevent adverse immune 
responses such as suppression of antigen presentation by the low-level expression of 
MHC class II (Zamvil and Steinman 1990) and a higher threshold for antigen-elicited 
immune responses (Matyszak and Perry 1996, Matyszak 1998).
There are two major subgroups o f glial cells within the CNS: these are the macroglia 
such as astrocytes, oligodendrocytes and ependymal cells and the microglia.
21
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Astrocytes, the most abundant glial cell, are thought to play a role in the maintenance 
of the BBB which is proposed to be mediated either by direct contact with the 
endothelium (Janzer and Raff 1987) or through secretory factors (Arthur et al 1987). 
Astrocytes have been shown to express MHC class I and class II antigen in response 
to stimulation (Fierz et al 1985, Fontana et al 1986) and also have the capacity to 
secrete cytokines. Oligodendrocytes are responsible for myelin formation within the 
CNS, while microglia are considered the resident macrophage o f the brain (Sedgwick 
et al 1993). It is thought that microglia may play a role in the inflammatory reaction 
within the CNS because of their phagocytic ability, release of proteinases, the 
production o f oxidative radicals, expression of MHC antigens upon activation, ability 
to act as APC and also to respond to cytokine.
Immune-mediated inflammatory disorders of the CNS and retina such as multiple 
sclerosis (MS) and posterior uveitis are characterised by an increased infiltration of 
leukocytes to these sites due to a compromised barrier. Subsequent activity of 
leukocytes within the CNS is thought to contribute to the onset and progression of 
disease and numerous studies have demonstrated the presence o f pro-inflammatory 
cytokines within the CNS. During diseases such as MS, IL-1, IFN-y, IL-2, TNF-a 
and TNF-p have been shown to localise to areas of MS plaques (Hofman et al 1986, 
Traugott and Lebon 1988, Selmaj et al 1991, Hofman et al 1989) and increased levels 
of IL-6 have been observed within the CNS during an experimental model of MS, 
experimental autoimmune encephalomyelitis (EAE; Maimone et al 1991, Gijbels et 
al 1990). Production of these cytokines has been attributed to activated T cells and 
macrophages which infiltrate the CNS and also to resident astrocytes and microglia.
1.4 Cytokines and the CNS
The cytokine family is a complex network of small proteins which are generally 
produced during the effector phase of an immune response and function to regulate 
inflammatory responses. Pro-inflammatory cytokines such as interleukin-1 (IL-1), 
IL-2, IL-6, interferon-y (IFN-y) and tumour necrosis factor-a (TNF-a) play an 
important role in inflammatory diseases of the CNS such as MS and posterior uveitis,
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while modulatory cytokines such as transforming growth factor-p (TGF-p) and IL-10 
are known to play a role in the normal homeostasis of the CNS. The effects of some 
of these cytokines will now be discussed.
1.4.1 TNF-a
TNF-a is produced by activated macrophages, T cells, astrocytes and microglia. 
Shown to influence EC by increased permeability (Brett et al 1989), increased 
expression o f cell adhesion molecules (Pober et al 1986) and increased immune cell 
adhesion to EC (Pohlman et al 1986) all o f which when combined, facilitate 
transendothelial migration of leukocytes across the BBB. TNF-a may also play a 
role in the upregulation of MHC molecules on astrocytes and microglia and thereby 
increase the capacity for antigen presentation within the CNS. It has also been shown 
that antibodies blocking TNF-a inhibit the development of EAE, an effect that may 
be the result of blocking the ability of TNF-a to upregulate adhesion molecule 
expression by EC (Fabry et al 1994; Hughes et al 1988).
1.4.2 IFN-y
IFN-y is characteristically produced by both CD4+ and CD8+ T cells as a result of 
activation. It upregulates MHC class I expression on astrocytes, oligodendrocytes 
and microglia (Hirayama et al 1985, Suzumura et al 1986, Wong et al 1984) and 
MHC class II expression upon astrocytes, microglia, pericytes, RPE cells and EC 
(Fabry et al 1994, Jorgenssen et al 2001). IFN-y production correlates with increased 
encephalitogenicity and may contribute to disease by upregulating adhesion 
molecules on EC, thereby facilitating migration of lymphocytes into the CNS (Dittel 
2000).
1.4.3 IL-1
IL-1 is produced predominantly by activated macrophages but also by EC, B cells, 
microglia and astrocytes in response to stimulation. As a major co-stimulatory 
cytokine for T cell activation it allows antigen stimulated T cells to proliferate. It is
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also thought to potentiate the immune response within the CNS by the induction of 
other inflammatory mediators such as prostaglandin and collagenase, by an increase 
in EC leukocyte adhesion and the induction of further pro-inflammatory cytokines 
such as TNF-a (Chung and Benveniste 1990) and IL-6 (Benveniste et al 1990). IL-1 
has been shown to play a role in EAE (Jacobs et al 1991).
1.4.4 IL-6
IL-6 produced by immune cells including monocytes and macrophages and also EC, 
is a pleiotropic cytokine, which is able to act in a pro- and anti-inflammatory manner. 
Readily induced by TNF-a, IFN-y and IL-1, IL-6 has been shown to stimulate 
production of acute phase proteins such as fibrinogen and C-reactive protein (Castell 
et al 1988). IL-6 is known to play a role in the activation of T cells and macrophages 
but is also known to play a key role in the differentiation of B cells to 
immunoglobulin-secreting plasma cells and may therefore contribute to the 
production of antibodies within the CNS.
1.4.5 TGF-p
TGF-p is a multifunctional, hormone-like peptide that controls cell proliferation and 
differentiation of fibroblasts (Lyons and Moses 1990) but shown to inhibt 
proliferation of epithelial cells (Barnard et al 1988). It has since been recognised that 
TGF-p also elicits highly immunosuppressive effects upon T and B cell proliferation, 
maturation of cytotoxic T cells and is capable of inhibiting the effects of TNF-a. 
TGF-P is produced locally within the eye, at levels far in excess of that determined in 
the periphery. The production of TGF-P is now thought to be closely associated to a 
subset of T cells deemed regulatory T cells (Wahl et al 2004).
1.4.6 IL-10
IL-10 is produced by cells o f the monocyte and macrophage lineage and has been 
shown to demonstrate immunosuppressive effects within the CNS and periphery 
(Fabry et al 1994). Induction of IL-10 has previously been shown to correlate with
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the down regulation of pro-inflammatory cytokines during EAE and recovery from 
disease. More recently production of IL-10 has been associated with functional 
regulatory T cells (Jonuleit et al 2000).
1.5 Immune privilege
Peter Medawar, in 1948, first described the phenomenon of immune privilege as the 
“protection against rejection conferred upon foreign tissue when grafted to a 
particular site”. This he hypothesised from observations upon the longevity of 
survival of allogeneic or xenogeneic transplants to immune privileged sites such as 
the eye, testis or brain and surmised was a result of a lack o f lymphatic drainage and 
physical isolation of the organ by means of a cellular barrier, such as the BRB or 
BBB, and thus evasion from the immune system.
Since these initial findings, it is now thought that the phenomenon of immune 
privilege is not simply due to physical isolation of these organs. Research has shown 
that tissue grafts to immune privileged sites are capable of initiating an antigen- 
specific immune response but are able to endure a greater survival time (Kaplan and 
Streilein, 1977) and the discovery of extensive lymphatic drainage in immune 
privileged sites such as the testis (Neaves and Billingham, 1979) provided some 
evidence as to the complexity of the generation and maintenance of immune 
privileged sites.
Immune privileged sites and tissues have since been characterised and the ability to 
accept foreign grafts is now thought to be due to multiple features. The ability of 
immune privileged sites or tissues to accept foreign grafts is no longer thought to be 
simply due to the presence of isolating cellular barriers and lack of efferent 
lymphatics. Various other factors have also been identified as contributing factors 
that, to a lesser or greater extent confer immune privilege. This includes the direct 
drainage of fluid into the blood stream, generation of an immunosuppressive 
microenvironment by the local production and secretion of cytokines such as TGF-P 
(Wilbanks and Streilein, 1991, Cousins et al 1991), the presence of neuropeptides
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such as a-melanocyte stimulating hormone and vasoactive intestinal peptide (Taylor 
and Streilein, 1994), soluble and membrane bound inhibitors of complement 
(Shimada, 1970 and Bora et al 1993), the presence of intratissue barriers i.e. tight 
junctions in Sertoli cells and retinal pigment epithelial cells, reduced or absent MHC 
expression secretion of corticosteroids and Fas ligand expression (FasL; Bellgrau et 
al 1995, Griffith et al 1995, Bechmann et al 1999).
Current research suggests that the CNS and retina are constantly surveyed for foreign 
antigen by activated T cells (Hickey et al 1991). Although these cells are able to 
enter the CNS, several mechanisms are thought to prevent T-cell-initiated immune 
responses. Two known mechanisms of T cell downregulation within the CNS are the 
presence of downregulatory cytokines and the induction of apoptosis (Pender et al 
1993). Evidence suggests the induction of apoptosis, as a mechanism of immune 
privilege, is crucial for the protection of the delicate microenvironment of the eye and 
brain for the preservation of organ function (Griffiths et al 1995).
1.5.1 Anterior chamber associated immune deviation (ACAID)
Immune privilege within the eye is an active immunoregulatory process that is 
thought to be achieved in part by the induction of a deviant form of systemic
immunity in response to antigens present in the eye (Streilein 1987). AC AID is a
stereotypic antigen-specific systemic immune response to eye-derived antigens that is 
characterised by the selective deficiency of Thl type antigen-specific delayed 
hypersensitivity and B-cell-derived complement-fixing antibodies. ACAID is 
observed when a variety of antigens including viruses, corneal allografts, tumour 
cells and hapten-derived spleen cells are introduced into the anterior chamber 
(Streilein et al 1997) and relies upon the eye-spleen axis to remain anatomically 
intact for 4-5 days post inoculation (Streilein and Niederkom 1981, Niederkom and 
Streilein 1982). Eyes of EAU animals are unable to support the induction of ACAID, 
which is believed to be due to the disruption of important parameters of immune 
privilege, which may include breakdown of the blood-ocular barrier and loss o f an
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immunosuppressive microenvironment (Ohta et al 1999). Regulatory T cells have 
also been shown to influence the induction of ACAID (Sonoda et al 2001).
1.6 The Blood-Brain Barrier (BBB)
The defining feature of the CNS is the presence of the blood-brain barrier (BBB) or 
blood-retinal barrier (BRB) formed by endothelial cells (EC) which functions to 
protect the CNS from harmful substances in the blood stream whilst allowing the 
passage of nutrients essential for CNS function. The existence of a BBB was first 
described by Ehrlich in the 19th century. He observed that water soluble dyes given 
peripherally were unable to permeate to the CNS while Goldmann in 1909 showed 
that these dyes if injected into the CNS stained only the brain and CSF.
1.6.1 Structure o f  the B B B
Like peripheral capillaries, EC form a cylindrical shape to allow blood flow through 
the centre of the cylinder or the lumen of the capillary. These EC are highly 
specialised for this function and can be characterised by the presence of tight 
continuous intercellular junctions between cells (Reese et al 1971; Figure 1.1). The 
tight junctions (TJs) provide the BBB with a high electrical resistance and help to 
limit paracellular diffusion. The presence of TJs also results in the formation of a 
polarised endothelium, which is capable of displaying different cell surface molecules 
at the luminal (blood) and abluminal (brain) surface. EC of the BBB possess no 
fenestrations, few vesicles and no fluid-filled bulk transport channels, which again 
aid to prevent transendothelial transport. The BBB is also able to exclude large 
molecules, neurotransmitters and toxins as a result of forming a physical barrier and 
by lacking the typical transport mechanisms that operate in blood vessels in other 
regions of the body. However EC of the BBB possess higher mitochondrial content 
than in peripheral tissues (Oldendorf et al 1977), which is suggestive of EC energy- 
dependent transcapillary transport systems. It is known that the BBB is absent from 
a small region of the brain called the circumventricular organs (CVO), which is an 
area which functions to release neurosecretory products into the blood stream. 
However substances, which enter the CNS via the CVO, are restricted from the
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extended brain by the presence of specialised ependymal cells called tanycytes, which 
impede diffusion to the rest of the brain and cerebrospinal fluid (CSF; Maness et al
1998). EC forming the BBB are surrounded by a number o f accessory structures, 
which are thought to regulate the development of the BBB. These include pericytes, 
perivascular macrophages, astrocytes and the basal lamina. Evidence suggests that 
EC placed in the brain develop characteristics of EC of the BBB (Stewart and Wiley 
1981).
1.6.1.1 Pericytes
Pericytes are a group of functionally and structurally heterogeneous cells, which 
cover approximately 20-30% of the microvascular circumference (Frank et al 1987) 
and are completely embedded in the basement membrane (Graeber et al 1989; Figure 
1.1). These cells are thought to regulate EC proliferation, survival, migration and 
differentiation (Hellstrom et al 2001), are known to be phagocytic and therefore 
considered as a second line of defence preventing transport into the CNS parenchyma 
(Cancilla et al 1972, Broadwell and Salcman 1981) and also play a role in the 
immune response within the CNS (Fabry et al 1993, Angelov et al 1998).
1.6.1.2 Perivascular Macrophages
Perivascular macrophages (PVM) are a subset of CNS macrophage, which line the 
vasculature of the CNS except that of capillaries (Mato et al 1986). PVM are 
phagocytic cells which express MHC class I and II (Hickey et al 1992), and as such 
are thought to be capable of antigen presentation.
1.6.1.3 Astrocytes
The BBB is almost completely surrounded by astrocyte foot processes (Figure 1.1), 
and it is thought that astrocytes may induce BBB properties in brain EC (Cancilla and 
DeBault 1983, Goldstein 1988) without contributing to the physical barrier o f the 
BBB (Brightman and Reese 1969). Co-culture of astrocytes with human umbilical
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Figure 1.1 Capillaries of the BBB.
Cerebral capillaries o f the BBB are lined by specialise EC that lie on a basal lamina 
in which are embedded pericytes and perivascular macrophages. Abbreviations: P; 
pericyte, BM; basement membrane (basal lamina), TJ; tight junction, A; astrocyte. 
Adapted from Bradbury 1985.
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vein endothelial cells has been shown to result in a decrease in EC permeability 
(Rubin et al 1991, Hurst and Fritz 1996).
1.6.1.4 The basal lamina
Surrounding the EC and pericytes is the thin basement membrane termed the basal 
lamina (Figure 1.1), a network of fine protein filaments consisting of a number of 
glycoproteins including laminin, collagens, and proteoglycan. The region between 
the basal lamina and the EC is known as the Virchow-Robin space. The basal lamina 
functions to provide mechanical support for the EC, however it is also thought to 
regulate EC differentiation, migration and proliferation.
1.6.1.5 Brain EC
EC forming the BBB are a highly active interface between the blood and the CNS. 
These cells are selectively able to regulate the exchange of substances between these 
two sites. Under normal conditions BEC are thought to be less adhesive than non- 
CNS vascular beds (Hughes et al 1988, Male et al 1990) through the low level 
expression of cellular adhesion molecules such as intercellular adhesion molecule 1 
(ICAM-1, CD54) as compared with non-CNS endothelium (dos Santos et al 1996), 
thereby minimising leukocyte interaction and traffic across the endothelial 
monolayer. Expression of the immunoglobulin superfamily molecules such as 
ICAM-1 and vascular cell adhesion molecule 1 (VCAM-1) expression is modulated 
in response to the local microenvironment, and is known to be upregulated in 
response to inflammatory cytokines (McCarron et al 1993, Reviewed in Roebuck and 
Finnegan, 1999). CNS EC are also known to express low levels of MHC antigens, 
which explains their poor ability to support T cell proliferation (Pryce et al 1989, 
Wang et al 1995). However, expression is known to be upregulated in response to 
pro-inflammatory cytokines (Male et al 1987), which suggests that CNS EC are 
capable of a pro-inflammatory role during inflammation.
30
Rachel Ann Harry General Introduction
1.6.1.6 Retinal EC (REC)
REC of the retinal vascular endothelium form the anterior blood-retinal barrier 
(BRB). REC which are thought to share numerous properties with BEC of the BBB, 
are known to be in direct contact with circulating leukocytes and are thus thought to 
mediate control of leukocyte extravasation. Entry into the retina involves leukocyte 
transmigration across the BRB characterised by the presence of tight junctions. REC 
have been found to be poor at binding lymphocytes (Hughes et al 1999, Male et al 
1990, Wang et al 1993) and under normal conditions are thought to be low expressors 
of MHC class II. However an enhanced expression of MHC class II is associated 
with the onset of EAU (Liversidge and Forrester 1988) and ICAM-1 can be induced 
upon REC in response to IFN-y (Liversidge et al 1990).
1.6.1.7 Retinal Pigment Epithelium (RPE)
Cells of the retinal pigment epithelium form the posterior BRB. In contrast, to the 
vascular endothelium the RPE lies beyond the vasculature within the cellular 
architecture of the eye. It is therefore thought that leukocyte recruitment at the 
posterior BRB is in part regulated by the choroidal endothelium as a result of 
cytokine influence from the RPE (Devine et al 1996). During the course o f EAU the 
RPE is thought to be activated and is induced to express MHC class II antigens (Chan 
et al 1986) and has been shown to be capable o f antigen presentation as a result of 
trypsin treatment of cells (Liversidge et al 1993).
1.6.2 BBB/BRB Physiology
Permeability of an endothelium is influenced by a number of factors, however one 
key factor is the intercellular junctions between EC which gives rise to the measure of 
electrical resistance. EC o f the BBB have been reported to exhibit extremely high 
electrical resistance of between 1500-2000 ohms per squared cm (Q cm2) which is in 
contrast to values of 3-33 Q/cm2 for that of non-CNS endothelia (Crone and 
Christensen 1981, Butt et al 1990). Several other factors, which influence BBB 
permeability, include specialised transport and enzymatic systems.
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1.6.2.1 Endothelial Junctions
Endothelial permeability is in part regulated by intercellular junctions, complex 
structures formed by adhesive transmembrane molecules which are linked to a 
network of cytoplasmic or cytoskeletal proteins within the cell. At least four different 
types of endothelial junctions have been described these are, tight junctions, gap 
junctions, adherens junctions and desmosomes. Each type of junction is 
characterised by the expression of specific junctional proteins (Dejana et al 1995) and 
has a specific role in junctional permeability. Expression of the different forms of 
junctions is thought to be spatially isolated in epithelial cells, however this is not 
thought to be true for endothelial cells (Schulze and Firth 1993).
1.6.2.1.1 Desmosomes
Desmosomes are localized patches that hold two cells tightly together. They are 
common in epithelia such as the skin and are linked to the intermediate filaments o f 
keratin in the cytoplasm.
1.6.2.1.2 Gap junction
Gap junctions are intercellular channels composed of a single protein of the connexin 
family which permit the free passage of ions and small molecules, up to a molecular 
weight of about 1000 Daltons between the cells (Beyer 1993). These junctions 
permit changes in membrane potential to pass from cell to cell.
1.6.2.1.3 Adherens junction
Located at the basal side of the EC, adherens junctions are junctions formed by the 
interactions of cadherins. Cadherins are single chain transmembrane glycoproteins 
which exhibit homophilic calcium dependent binding (Takeichi 1991, Kemler 1993). 
The intracellular domain of cadherin is linked to the actin cytoskeleton via a network
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of proteins called catenins (Tsukita et al 1992, Kemler 1993). It is thought that 
adherens junctions play a role in cell contact inhibition.
1.6.2.1.4 Tight junction (TJ)
Tight junctions or the zonula occludens are the close connections between epithelial 
and endothelial cells that generally comprise CNS endothelia. The majority o f our 
understanding about tight junctions comes from studies of epithelia. The TJ consists 
of three integral membrane proteins, namely, claudin, occludin, and junction adhesion 
molecules, and a number of cytoplasmic accessory proteins including ZO-1, ZO-2, 
ZO-3, cingulin, and others (Figure 1.2).
Claudins-1 and -2 were first identified as integral components o f the TJ, in 1998, by 
Furuse et al. At least 24 members of the claudin family have since been identified 
and have been shown to bind homotypically to claudins on adjacent endothelial cells 
to form the primary seal o f the TJ (Furuse et al 1999) and to bind to ZO-1, ZO-2, and 
ZO-3 intracellularly (Furuse et al 1999). Occludin was identified as the first integral 
protein localized at the TJ (Furuse et al 1993, Ando-Akatsuka et al 1996). Occludin is 
thought to contribute to the generation o f electrical resistance given that the two 
extracellular loops of occludin and claudin, although originating from neighbouring 
cells, form the paracellular barrier of the TJ (Hirase et al 1997, Sonoda et al 1999). 
Occludin expression is greater in BEC as compared to non-neural tissues. The third 
TJ-associated membrane protein is the junctional adhesion molecule (JAM; (Martin- 
Padura et al 1998). Three JAM’s have been identified (Palmeri et al 2000, Aurrand- 
Lions et al 2000) all o f which belong to the immunoglobulin superfamily.
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Figure 1.2 Proposed interactions of junctional complex proteins in EC  of the 
BBB.
At tight junctions, claudins have been proposed to function as the backbone by 
binding to claudins on adjacent cells and thus forming a seal. Claudins also bind to 
occludin, which functions as a regulatory protein. O ccludin’s presence in the 
membrane correlates with increased electrical resistance across the membrane and 
decreased permeability. Occludin is thought to be involved also in the fence function 
o f tight junctions. JAM is involved in cell-cell adhesion and contributes to 
permeability control. A series o f  cytoplasmic proteins ZO-1, ZO-2 and ZO-3 form the 
submembraneous plaque o f  tight junctions. These proteins belong to the M AGUK 
family (membrane-associated guanylate kinase proteins) and are involved in the 
coupling o f  transmembrane proteins to the cytoskeleton actin. Several cytoplasmic 
accessory proteins have been identified at tight junctions, including AF6, 7H6 and 
cingulin. The adherens junctions are composed o f  transm em brane glycoproteins o f  
the cadherin super family, which are linked to the cytoskeleton via cytoplasmic 
anchor proteins, (3-catenin, y-catenin (plakoglobin) and p l2 0 ctn that belong to the 
Armadillo protein family. (3-catenin and y-catenin bind to a-catenin , which is an 
actin-binding and actin-bundling molecule linking the adhesive cadherin/catenin 
complex to the F-actin-based cytoskeleton. Taken from Petty and Lo (2002).
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Cytoplasmic proteins involved in TJ formation include zonula occludens proteins 
(ZO-1, ZO-2, and ZO-3), cingulin, 7H6, and several others. ZO-1, -2, and -3 have 
sequence similarity with each other and belong to the family of proteins known as 
membrane-associated guanylate kinase-like protein (MAGUKs; Anderson 1996). 
These proteins have been shown to form the submembraneous plaque of tight 
junctions and function to couple transmembrane proteins with the cytoskeleton 
(Haskins et al 1998, Fanning et al 1998, Itoh et al 1999, Ebnet et al 2000). Cingulin 
is a phosphoprotein which localises to the cytoplasmic surface of tight junctions and 
interacts with ZO-1, -2 and -3 and as a result is thought to act as a scaffold at the tight 
junction (Cordenonsi et al 1999). 7H6 is a phosphoprotein found at tight junctions 
which are impermeable to ions and macromolecules however its role remains to be 
elucidated (Satoh et al 1996).
1.6.3 BBB permeability in response to inflammation
One additional factor known to influence BBB permeability is the exposure of EC to 
inflammatory mediators such as cytokines and chemokines, produced by leukocytes 
of the immune system and also by CNS resident cells.
1.6.3.1 Cytokines
Although cytokines play numerous roles, a key role for cytokines during 
inflammation within the CNS is their effect upon BBB permeability. Pro- 
inflammatory cytokines such as TNF-a, IFN-y, IL-1 and IL-6, produced by both 
immune cells and glial cells, are thought to play a major role in inflammation within 
the CNS (Benveniste, 1992). In vitro treatment of rat cerebral EC (RCEC) with TNF- 
a , IL-1 p and IL-6 resulted in a significant decrease in electrical resistance (de Vries 
et al 1996), while in vivo administration of TNF-a, IL-1 p and IL-6 has also been 
shown to result in increased permeability of the BBB (Wright and Merchant 1994, 
Claudio et al 1994, Saija et al 1995).
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1.6.3.2 Chemokines
Chemokines (chemotactic cytokines) are a family o f small-secreted polypeptides, 
which function to recruit leukocytes to sites of infection and inflammation, including 
the CNS. Many chemokines are known to be produced during an inflammatory 
reaction and can be produced by EC in response to cytokines such as TNF-a and IL- 
1. Chemokines are known to play a major role in the control o f leukocyte adhesion, 
chemotaxis and activation (Eugenin and Berman 2003) and have also been shown to 
influence the expression of tight junctional proteins such as ZO-1 and occludin, 
thereby influencing BBB permeability (Song and Pachter 2004).
It is possible to classify chemokines both structurally and functionally. Structural 
classification of chemokines broadly reveals four families based on the configuration 
of cysteine residues near the NF^-terminus of the amino acid structure. The largest 
family consists of two cysteine residues adjacent to each other and are termed CCL 
chemokines while CXCL chemokines have two cysteine molecules separated by an 
intervening amino acid. Two smaller families consist of one member each, these are 
the XCL family possessing only two cysteine residues and the CX3CL family with 
three intervening amino acids between cysteine residues (Campbell and Butcher 
2000).
Functional classification of chemokines reveals two main types of chemokines. 
These are the constitutive and inducible chemokines, although a small number of 
chemokines exhibit functions of both groups and are therefore considered to have 
dual-function (Moser et al 2004). Constitutive chemokines also known as 
homeostatic or lymphoid chemokines, are proposed to play a role in the regulation of 
lymphocyte migration under normal conditions. These are known to be produced in 
discrete microenvironments within lymphoid or non-lymphoid tissue such as the skin 
and mucosa and play a role in the positioning of cells of the adaptive immune system 
during haematopoiesis, antigen sampling in secondary lymphoid organs and immune 
surveillance of healthy peripheral tissues. In contrast, inducible chemokines also 
called inflammatory chemokines, are generally expressed during periods of infection,
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tissue injury or inflammation and comprise most of the chemokine family. Inducible 
chemokines produced in inflamed tissues by both resident and infiltrated cells are 
thought to play a role in the recruitment of effector cells such as monocytes, 
granulocytes and activated T cells. Dual function chemokines have been shown to 
predominantly act upon T lymphocytes, playing a role in homing during development 
and also recruitment during an inflammatory response (Moser et al 2004).
Chemokines elicit their action via high-affinity seven-transmembrane spanning G- 
protein coupled receptors which are classified by means of the chemokines which 
they recognise followed by R for receptor, namely CCR, CXCR, XCR, CX3CR and a 
number in order in which they were identified. Several second messengers of G- 
protein coupled receptors are known to be activated as a result of chemokine receptor 
ligation including, phospholipase C|3 (PLCp) isoforms, serine-threonine kinases, 
phosphatidylinositol 3-kinase-y (PI3Ky) and c-Src-related non-receptor tyrosine 
kinases (Loetscher et al 2000, Thelen 2001).
The chemokine network displays a high degree of functional redundancy, in that a 
given chemokine may be capable of binding several members of the same chemokine 
receptor family and that one receptor may bind several related chemokines (Rossi and 
Zlotnik 2000). In general, inflammatory chemokines and receptors tend to participate 
in overlapping and redundant pairing, whereas those involved in homeostatic homing 
tend to show more exclusive interactions (Moser and Loetscher 2001; Table 1.1). 
Mutations in homeostatic chemokine genes are therefore thought to be more 
detrimental, as has been demonstrated using the pit mouse whereby a mutation in the 
SLC gene results in a lack o f lymphocyte homing to secondary lymphoid organs 
(Nakano etal 1997).
One main function of chemokines is the chemotaxis of receptor expressing cells 
toward higher levels of chemokines. Chemokines have also been implicated in 
lymphocyte differentiation and effector functions (Luther and Cyster 2001). 
However chemokines have recently been shown to play a key role in the regulation of
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Chemokine Chemokine(s) bound Functional
Receptor Classification
CXCR1 CXCL2 (GROp, MIP-2a), CXCL3 (GROy, MIP-2p), CXCL5 
(ENA-78), CXCL6 (GCP-2), CXCL7 (NAP-2), CXCL8 (IL-8).
Inducible
CXCR2 CXCL1 (GROa, MGSA), CXCL2, CXCL3, CXCL5, CXCL6, 
CXCL7, CXCL8.
Inducible
CXCR3 CXCL9 (Mig), CXCL10 (IP-10), CXCL11 (I-TAC). Dual
CXCR4 CXCL12 (SDF-1). Constitutive
CXCR5 CXCL13 (BLC, BCA-1). Constitutive
CXCR6 CXCL16 Dual
CCR1 CCL3 (M IP-la), CCL5 (RANTES), CCL7 (MCP-3), CCL14 
(HCC-1, CK.pi), CCL15 (HCC-2, Lkn-1, MIP-5), CCL16 (HCC- 
4, LEC, Mtn-1), CCL23 (MPIF-1, ckp81).
Inducible
CCR2 CCL2 (MCP-1, MCAF), CCL7, CCL12, CCL13 (MCP-4). Inducible
CCR3 CCL5, CCL7, CCL8 (MCP-2), CCL13 (MCP-4), CCL15, CCL24 
(MPIF-2, eotaxin-2), CCL26 (eotaxin-3, MIP-4a).
Inducible
CCR4 CCL17 (TARC), CCL22 (MDC, STCP1). Dual
CCR5 CCL3, CCL4 (MIP-ip), CCL5. Inducible
CCR6 CCL20 (MIP-3a, LARC). Dual
CCR7 CCL19 (MIP-3p, ELC, ckpi 1), CCL21 (6Ckine, SLC, ckp9). Constitutive
CCR8 CCL1 (1-309), CCL4 (MIP-ip). Dual
CCR9 CCL25 (TECK, ckpl5). Dual
CCR10 CCL27 (CTACK, ILC, ESkine). Inducible
XCR1 XCL1 (Lymphotactin, ATAC). Inducible
CX3CR1 CX3CLI (fractalkine). Inducible
Table 1.1 Chemokine receptors and their chemokines.
GRO, growth-related oncogene; MGS A, melanoma growth stimulatory activity; MIP, 
macrophage inflammatory protein; PF, platelet factor; ENA, epithelial cell-derived 
neutrophil-activating factor; LIX, lipopoly saccharide-induced CXC human 
chemokine; GCP, granulocyte chemotactic protein; CK, chemokine; NAP, 
neutrophil-activating protein; IL, interleukin; Mig, monokine induced by Y-interferon; 
IP-10, 7 -interferon-inducible protein; I-TAC, interferon-inducible T-cell
chemoattractant; SDF, stromal cell-derived factor; BCA-1, B-cell-activating 
chemokine; BLC, B-lymphocyte chemoattractant; BRAK, breast and kidney 
expressed chemokine; TCA, T-cell-activation protein; MCP, monocyte 
chemoattractant protein; MCAF, monocyte chemotactic and activating factor; 
RANTES, regulated on activation normal T-cell expressed and secreted; MRP, MIP- 
related protein; HCC, hemofiltrate CC chemokine; Lkn, leukotactin; LEC, liver 
expressed chemokine; Mtn, monotactin; LCC, liver-specific CC chemokine; TARC, 
thymus- and activation-related chemokine; DC-CK, dendritic cell chemokine; PARC, 
pulmonary- and activation-regulated chemokine; ELC, Epstein-Barr virus-induced 
receptor ligand chemokine; LARC, liver- and activation-induced chemokine; 6Ckine, 
6 cysteine chemokine; SLC, secondary lymphoid tissue chemokine; MDC, 
macrophage-derived chemokine; STCP, stimulated T-cell chemotactic protein; MPIF, 
myeloid progenitor inhibitory factor; TECK, thymus-expressed chemokine; CTACK, 
cutaneous T cell-attracting chemokine; ILC, interleukin 11 receptor alpha-locus 
chemokine; ESkine, embryonic stem cell chemokine; 1-309, ATAC, derived from 
gene names.
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leukocyte migration out of the bloodstream in the ‘address code’ theory o f leukocyte 
homing (Butcher et al 1999, von Andrian and Mackay, 2000; further discussed in 
section 1.7.2).
1.7 Leukocyte migration
Recruitment of leukocytes from the circulation to peripheral tissues is a key event in 
the development of inflammatory disease including inflammatory diseases of the 
CNS such as multiple sclerosis (MS) and posterior uveitis. Under normal conditions 
very few leukocytes are detectable within the CNS (Hickey et al 1991), however an 
increased number of inflammatory cells are present during CNS disease. Leukocyte 
migration from the bloodstream into the CNS depends upon the interaction of 
activated leukocytes with EC that form the BBB and the BRB. The process of entry 
to peripheral tissues is termed extravasation, diapedesis or transendothelial migration 
(TEM; Figure 1.3). The process of lymphocyte TEM is well characterised and it is 
known that EC of the BBB play a major role in the regulation of leukocyte entry to 
the CNS. Leukocyte TEM is also known to be regulated by the leukocyte. A 
“multistep paradigm” for leukocyte migration was first described by Springer in 
1994. This consisted of four sequential stages for leukocyte interaction with the 
endothelium; these are, leukocyte tethering and rolling, EC signalling to leukocytes, 
firm adhesion and diapedesis. However it has since been shown that leukocytes are 
able to signal to the endothelium and therefore there are five main stages involved in 
leukocyte TEM.
1.7.1 Leukocyte tethering and rolling
The initial stages of the adhesion cascade are mediated by adhesion molecules known 
as the selectins. These are a family of transmembrane molecules, expressed on the 
surface of leukocytes and activated EC, which bind to carbohydrates. Selectin- 
mediated interactions between the EC and leukocyte are rapid and short-lived and 
result in the characteristic slowing down of circulating lymphocytes and rolling along 
the surface of the endothelium (Lawrence and Springer 1991). There are three
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Figure 1.3 Leukocyte TEM.
The leukocyte adhesion cascade is a sequence of adhesion and activation events, 
which ends with extravasation of the leukocyte, whereby the cell exerts its effects on 
the local environment. Five main steps are involved in leukocyte adhesion to and 
migration out of the vascular endothelium: (1) Tethering and rolling, in which 
selectins and glyco-conjugated selectin-ligands are involved, (2) signalling of the 
endothelium to the leukocyte, mediated by soluble and/or membrane-bound 
chemoattractants such as chemokines, (3) Firm adhesion (4) signalling of the 
leukocyte to the endothelium and (5) Transmigration or diapedesis, which are 
mediated by integrins and their ligands, e.g. intercellular adhesion molecules.
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members of the selectin family: L-selectin (leukocyte-selectin) expressed on all 
circulating leukocytes except for a subpopulation of memory lymphocytes; P-selectin 
(platelet-selectin), so-called because it was first observed upon platelets, but now also 
observed within Weibel-Palade bodies of EC; E-selectin (endothelial-selectin) 
expressed by inflamed vascular endothelium (Springer 1994). L-selectin (CD62L) 
binds to its ligands, glycosylation-dependent cell adhesion molecule-1 (GlyCAM-1; 
Lasky et al 1992), CD34 (a cell surface molecule; Lanza et al 2001) and mucosal 
addressin cell adhesion molecule (MAdCAM-1; Rosen 1999) and has been shown to 
exhibit greater activity in response to cytokines prior to its shedding (Griffin et al
1990). E-selectin (CD62E) is readily inducible by pro-inflammatory cytokines 
(Bevilacqua et al 1987) as is P-selectin (CD62P) which is readily expressed by EC in 
response to thrombin, histamine or complement proteins (Geng et al 1990) during an 
inflammatory response, where it binds to its ligand P-selectin glycoprotein ligand-1 
(PSGL-1) upon the leukocyte. E-selectin has also been shown to bind to PSGL-1 
(Asa et al 1995). It has recently been suggested that selectins may participate in the 
activation of leukocyte integrins (Vestweber and Blanks 1999).
The control of systemic immune responses is dependent upon the regulated 
trafficking of leukocytes. This is achieved by means of a homing system which is in 
part facilitated by selectin molecules. In order for an activated leukocyte to interact 
with an endothelium, leukocytes must express the requisite molecules for recognition 
of the endothelium. Selectin interactions play a key rold in the first stage of 
leukocyte TEM during tissue specific lymphocyte homing (Butcher and Campbell 
1996). The interaction of lymphcoyte L-selectin with EC PNAd or MAdCAM-1 is 
responsible for the homing of naive B and T lymphocytes to peripheral lymph nodes 
and Peyers patches respectively (Butcher and Picker 1996). Expression of cutaneous 
lymphcoyte antigen (CLA) and its interaction with E-selectin is known to play a key 
role in the tissue specific homing of skin homing memory cells to skin (Picker 1994) 
while a4p7 binding of MAdCAM-1 is thought to play a role in the homing of 
memory cells to the lamina propria o f the small intestine (Berlin et al 1995).
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1.7.2 Signalling to the leukocyte
Selectin interactions are thought to bring the leukocyte and EC into close proximity 
and result in the exposure of leukocytes to chemoattractants expressed or secreted by 
the endothelium as it is proposed that chemokines expressed upon the surface of the 
endothelium may influence leukocyte migration (Rot 1992, Tanaka et al 1993). It 
has been shown that EC exposed to inflammatory cytokines such as TNF-a and IL-1 
produce chemokines such as monocyte chemotactic proteins (MCP’s), RANTES, 
fractalkine and macrophage inflammatory proteins (MIP; Baggiolini 1998, Ben- 
Baruch et al 1995). Chemokines are known to elicit multiple functions including 
directing the migration of leukocytes however, it has been shown that signalling of 
chemokines such as stromal derived factor (SDF-1), 6-C-kine and MIP-3J3 via its 
respective G-protein coupled receptor expressed upon the leukocyte induces the rapid 
activation of leukocyte integrins resulting in an increase in integrin avidity for its 
receptor. This is thought to function as a checkpoint prior to the firm adhesion of 
reversibly adhered leukocytes (Campbell et al 1998). Chemokines, like selectins are 
thought to play a role in the regulation of tissue-specific lymphocyte homing 
(Campbell et al 1999) at the level of endothelium-leukocyte signalling. The SLC- 
CCR7 interaction is known to play an essential role in the TEM of naive T cells to 
peripheral lymph nodes and has shown to result in the rapid adhesion o f T cells to 
HEV (Wamock et al 2000). Homing of skin memory T cells to inflamed skin is 
known to be mediated by interaction of TARC with its receptor CCR4 (Campbell et 
al 1999) while homing of gut memory T cells to the small intestine lamina propria is 
elicited by the interaction of TECK with CCR9 (Zabel et al 1999). Leukocytes that 
do not express the requisite chemokine receptors fail to undergo subsequent integrin 
activation and therefore are unable to mediate firm adhesion to and subsequently 
migration through the endothelium.
1.7.3 Firm adhesion
Firm adhesion of the leukocyte to the endothelium is mediated by binding o f the 
integrin family of molecules expressed by the leukocyte with their corresponding
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ligands, members of the immunoglobulin (Ig) superfamily, expressed on the 
endothelium. Circulating leukocytes maintain their integrins in a non-adhesive state 
in order to prevent non-specific attachment to the endothelia of blood vessels. 
However integrins can readily be activated by the action of endothelium derived 
chemoattractants such as chemokines. It is this activation o f leukocyte integrin 
molecules, which permits firm adhesion of the leukocyte to the endothelium and 
subsequently leukocyte transmigration.
A number of integrins are known to play a role in leukocyte-endothelial interactions; 
these include very late antigen-4 (VLA-4), leukocyte function antigen-1 (LFA-1), 
Mac-1 and LPAM-1 (lymphocyte Peyer’s patch HEV adhesion molecule (Larson and 
Springer 1990, Stewart et al 1995). Several members of the Ig superfamily have been 
implicated in leukocyte TEM, including ICAM-1 and 2 and also VCAM-1 
(Vonderheide and Springer 1992). ICAM-1 is expressed at low levels upon the 
vascular endothelium and has been shown to be upregulated in response to pro- 
inflammatory cytokines (Dustin et al 1986, Wellicome et al 1990). ICAM-1 binds to 
LFA-1 and has been shown to be essential for TEM into the CNS both in vivo 
(Whalen et al 2000) and in vitro (Greenwood et al 1995), as demonstrated by 
antibody-mediated blockade of LFA-1 and ICAM-1 mediated antigen-specific T cell 
migration across primary retinal (Greenwood et al 1995) and primary cerebral 
endothelium (Pryce et al 1997). In contrast, ICAM-2, also known to bind LFA-1, is 
constitutively expressed and is thought to play a role in lymphocyte recirculation in 
uninflammed tissues (Springer 1994). VCAM-1 is a ligand for VLA-4 and LPAM-1 
(Chan et al 1992, Ruegg et al 1992) and its expression has been shown to be 
upregulated in response to pro-inflammatory cytokines (Dustin et al 1986, Wellicome 
et al 1990).
1.7.4 Signalling to the endothelium
Binding of leukocyte LFA-1 to ICAM-1 upon the EC has recently been demonstrated 
to result in conformational changes within both the leukocyte and EC in order to 
permit TEM. It has since been shown that this is as a result o f ICAM-1 ligation-
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induced signalling pathways, which are thought to play a role in TJ permeability (see 
chapter 5).
1.7.5 Diapedesis
Diapedesis through the vascular endothelium is the final stage in TEM. It is not 
entirely clear how leukocytes mediate this stage. However, two possible mechanisms 
include intercellular transmigration and intracellular transmigration. Intercellular or 
paracellular migration is the most characterised route for TEM (Johnson-Leger et al 
2000), although EC junctions are known to express numerous proteins which function 
to maintain endothelium integrity through the formation o f TJ. It has previously been 
reported that neutrophils migrate through the endothelium at the junction of three EC 
(Bums et al 1997). It has been suggested that leukocyte migration into the CNS 
results in the activation of signal transduction cascades which lead to the loss of TJ- 
associated molecules including occludin and ZO-1 and subsequent BBB breakdown 
(Bolton et al 1998). A significant body of evidence exists to support migration 
directly through EC (Greenwood et al 1994, Feng et al 1998, Wong et al 1999). This 
is thought to be due to active remodelling of the EC membrane causing invagination 
and fusion of the luminal and abluminal surface of the EC (Feng et al 1998).
1.7.6 Migration through the basement membrane
Once through the endothelium, leukocytes must traverse the basement membrane, 
which is composed of a network of glycoproteins. Migration at this stage is thought 
to rely upon a number of proteolytic systems such as heparanase, plasmin and A 
disintegrin and metalloproteinases (ADAMs). Goetzl et al in 1996 demonstrated a 
clear role for matrix metalloproteinases (MMP’s), in particular MMP2 and MMP9, in 
lymphocyte migration through the basement membrane.
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1.8 Leukocyte trafficking during CNS disease
Increased trafficking into the CNS is thought to occur following infection, ischemia, 
trauma and autoimmunity. Each of these events results in signalling at the vascular 
endothelium to which immune system cells respond by the process of TEM. 
Although all cells of the immune system are able to enter in response to inflammation 
autoimmune inflammation within the CNS as is proposed to occur during MS and 
uveitis is predominantly due to T lymphocytes and cells of the monocyte/macrophage 
lineage.
1.8.1 T lymphocytes
All activated T cells express the capacity to migrate across the BBB and BRB 
independent of antigen specificity and subtype (Hickey et al 1991, Wekerle et al
1991). Initial activation of T cells is thought to occur in the periphery and it is 
proposed that antigen recognition within the CNS occurs as a result of molecular 
mimicry between a microbial antigen and a CNS antigen (Bamaba and Sinigaglia 
1997, Hafler 1999), as a result o f cross reactivity with bacterial or viral peptides 
(Goverman et al 1993), as a result of activation by bacterial superantigens (Brocke et 
al 1995) or due to cytokines released in response to an unrelated inflammatory 
reaction (Gutierrez-Ramos et al 1992). Activation of the T cells results in an 
upregulation of cell adhesion molecules, interaction with the CNS endothelium, TEM 
and entry into the CNS parenchyma. Once within the CNS, T cells are thought to 
encounter MHC class II+ perivascular macrophages where it is believed that T cells 
recognise their specific antigen, which results in the local activation of the T cell, the 
stimulus for the subsequent inflammatory cascade, and ultimately damage to the 
CNS. T cell recognition of antigen results in pro-inflammatory cytokine production, 
which results in the activation o f the BBB by an increased expression of ICAM-1 
(Matsuda et al 1994) and VCAM-1 (Wong et al 1999) and induction of chemokine 
production by astrocytes and microglia (Fuentes et al 1995), which combine to 
further recruit leukocytes into the CNS. Cytokine production by T cells also results 
in an increased capacity for antigen presentation by resident cells such as astrocytes 
and microglia of the brain (Benveniste and Benos 1995). T cells are also directly able
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to mediate oligodendrocyte death (Jurewicz et al 1998, Jewtoukoff et al 1989, Selmaj 
et al 1991, Antel et al 1994), which in turn results in the characteristic myelin loss 
observed in MS and EAE. It has been suggested that the chronicity observed in some 
instances may be as a result of a phenomenon of epitope spreading as new self 
peptides emerge as a result of tissue damage (Lehman et al 1992, McRae et al 1995, 
Tuohy et al 1999).
1.8.2 Monocytes and Macrophages
Cells of the monocyte/macrophage lineage comprise a resident population within the 
CNS in the form of microglial cells and perivascular macrophages (Hickey and 
Kimura 1988) and, as a result, it is accepted that monocytes enter the CNS in order to 
differentiate into these cells (Lassmann et al 1991). However, during inflammation 
of the CNS, monocytes are thought to migrate to the CNS, differentiate to become 
macrophages or microglia and contribute to the destruction of neuronal myelin either 
by phagocytosis or by the production of cytokines (Bauer et al 1994, Ruuls et al 
1995, Chia et al 1983). This is a major factor in the progression of CNS diseases 
such as MS. CNS microglial cells have been shown to play an important role in the 
effector stage of EAE (Sedgwick et al 1987).
1.9 Immune mediated diseases of the CNS and Retina
A number of disorders are associated with the CNS including Stroke, Alzheimer’s 
Disease, Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency 
syndrome (AIDS). These diseases may arise as a result o f immune dysregulation or 
immune cell infiltration to these sites as a consequence o f the disease. However a 
group of T cell-mediated autoimmune diseases exists and it is T cell migration across 
the blood-brain and blood-retinal barriers, which results in the generation of an 
immunopathological response. Evidence suggests an increased incidence of 
lymphocyte extravasation to sites such as the brain or retina results in immune- 
mediated diseases of the CNS such as MS and posterior uveitis.
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1.9.1 M S
MS is a chronic, often relapsing condition, which damages the white matter of the 
CNS, the brain and spinal cord, affecting approximately 85,000 people in the UK 
alone (MS Society website). First described by Charcot in 1868, MS was the term 
given to a condition characterised by neurological symptoms and intention tremors 
which at post mortem revealed disseminated lesions in the white matter of the brain. 
Several factors have since been shown to influence MS; these include genetics, 
gender and environmental triggers.
Susceptibility to MS is linked to genes within the MHC complex on chromosome 6 
(Haines et al 1996, Sawcer et al 1996, Ebers et al 1996) while epidemiological 
studies have shown a link between the incidence of MS and distance from the 
equator. These studies revealed that the incidence of MS is higher in the UK, North 
America and Scandinavia but virtually non-existent in Malaysia or Ecuador, which 
supports the role for an environmental trigger in disease (Compston et al 1998). The 
role of the environment is further supported by studies of migrant populations (Dean 
1967, Dean and Kurtzke 1971, Kurtzke et al 1979).
MS is generally diagnosed between the ages of 20 and 40, is twice as common in 
females as in males (National MS Society website) and can only be made upon 
demonstration of two or more attacks affecting two or more areas of the CNS, when 
all other neurological conditions have been ruled out (McDonald et al 2001). Tests 
for the diagnosis include head and spine magnetic resonance imaging (MRI; Ormerod 
et al 1987), neurological examination, and lumber puncture sampling for the 
determination of oligoclonal banding of CSF (Lowenthal et al 1960, Christenson et al 
1983).
1.9.1.1 Clinical MS
MS can present in a number of forms and as a result o f this symptoms of MS vary 
from individual to individual. Some common symptoms of MS include sensory 
problems, visual problems, fatigue, dizziness, pain, loss of muscle strength, problems
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with balance and coordination, bladder and bowel problems, cognitive problems and 
sexual problems. However, as with many other aspects of this multifactorial disease, 
MS can occur randomly and in an unpredictable manner. It is possible to classify MS 
disease in one of four major groups- Relapsing remitting MS, Secondary Progressive 
MS, Primary progressive MS and Primary relapsing MS.
Approximately 80% of patients diagnosed with MS present with symptoms of 
relapsing remitting MS (RRMS; Compston and Coles 2002). This stage o f disease is 
characterised by defined self-limited relapses or attacks which last for at least 24 
hours. Between relapses or attacks patients can make a full recovery and are found to 
be neurologically and symptomatically “normal” in a period termed remission. An 
attack or relapse is a period in which patients experience new symptoms or 
recurrence of old symptoms which vary in their intensity and duration and it is at this 
time in which inflammatory cells are thought to attack the nerve fibres o f the CNS. 
Secondary Progressive MS (SPMS) is characterised by the steady deterioration in 
neurological function as a result o f significant nerve fibre loss. This stage of disease 
can present in the presence or absence of isolated attacks. 50% of all MS patients 
diagnosed with RRMS are thought to progress to SPMS. In contrast Primary 
progressive MS (PPMS) presents as a disease with a steady decline in function from 
onset of disease without isolated attacks. Approximately 10% of all patients are 
diagnosed with this form of MS which predominantly affects the spinal cord. 
Progressive relapsing MS (PRMS) is the least common form o f MS and progressive 
from onset. Currently 90% of MS patients will progress to a progressive form of 
disease within 25 years o f diagnosis.
1.9 .2  Posterior U v eitis
Inflammation of the eye can be caused by a variety of diseases other than bacterial 
infection, many of which are sight-threatening. These include the group of 
intraocular immune-mediated diseases, known as uveitis, which is responsible for 
10% of all registered blind patients under the age of 65 years. Uveitis is the term
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given to any inflammatory condition affecting the uvea which is composed of the iris, 
ciliary body, and choroid. Causes of uveitis can include autoimmune disorders, 
infection, or exposure to toxins and the disease presents in many forms. The 
symptoms and signs of uveitis may be subtle, and vary considerably depending on the 
site and severity of the inflammation. However in many instances, the cause remains 
unknown.
1.9.2.1 Clinical uveitis
Uveitis is most commonly classified anatomically as anterior, intermediate, posterior, 
or diffuse, depending on which segment of the eye is affected. The most common 
form of uveitis is anterior uveitis (AU), which involves inflammation in the front part 
of the eye, usually isolated to the iris or the ciliary body. This condition is often 
called iritis and iridocyclitis and is generally the most symptomatic form of uveitis, 
generally presenting with pain and redness, photophobia and decreased vision. The 
inflammation may be associated with autoimmune diseases but in most cases occurs 
in healthy people and does not indicate an underlying disease. Most common in 
young and middle-aged people, AU does not generally lead to visual loss. 
Intermediate uveitis (IU), also called peripheral uveitis, affects the area immediately 
behind the iris and lens in the region of the ciliary body and pars plana, and may also 
be referred to as "cyclitis" and "pars planitis". IU is classically painless and presents 
with floaters and decreased vision. This form o f disease predominantly affects 
teenagers or sometimes young children. Symptoms present as visual blurring without 
pain or redness and usually affect both eyes.
Posterior uveitis (PU) signifies a number of forms of uveitis affecting the posterior 
segment of the eye. Inflammation presents in the choroid, retina or the blood vessels 
as choroiditis, retinitis, vasculitis or optic neuritis. Posterior uveitis is usually 
painless yet is far more likely to result in visual impairment, and is often associated 
with numerous other conditions including toxoplasmosis, Behcet’s Disease, 
sarcoidosis and MS. Drops or injections fail to reach the back of the eye and
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therefore treatment is generally administered systemically, which means the whole 
body is affected and may suffer side effects. Pan uveitis is the term given to 
inflammation involving all parts of the eye, including anterior, intermediate, and 
posterior structures. Endophthalmitis is a severe, acute, diffuse uveitis resulting from 
intraocular infection. Pan uveitis may produce any or if affects all o f the above- 
mentioned symptoms and signs. Complications of uveitis may result in profound and 
irreversible loss o f vision, especially when unrecognized or treated improperly with 
the most frequent complications including cataract; glaucoma; retinal detachment; 
neovascularization of the retina, optic nerve, or iris; and cystoid macular oedema. 
This thesis will concentrate upon those clinical forms o f uveitis characterised by the 
presence of cell infiltration of the retina which will be referred to as posterior uveitis.
1.9.2.2 Posterior uveitis pathology
Activated T cells play an important immunopathogenic role in the development of 
posterior uveitis (Deschennes et al 1988). Uveitis is characterised by the 
predominance of a CD4+ T cell infiltrate which are HLA DR positive (Charteris et al
1992). An upregulation of adhesion molecule expression is thought to occur which, 
in turn potentiates an increase in lymphocyte TEM (Whitcup et al 1992). An 
upregulation of HLA-DR upon ocular resident cells by has also been demonstrated 
during uveitis (Chan et al 1986, George et al 1997), which may contribute to 
increased antigen presentation to the infiltrating lymphocytes in order to perpetuate 
the inflammatory cycle.
1.10 Experimental models of CNS disease
1.10.1 Experimental Autoimmune Encephalomyelitis (EAE)
EAE is a CD4+ T cell-mediated autoimmune disease o f the CNS which is used 
extensively and from which much of our understanding of the basic mechanisms 
thought to occur during MS is derived (Wekerle et al 1994). Different EAE models 
facilitate investigation of different immunopathogenic aspects of autoimmune
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neuroinflammation which may have relevance for its human counterpart. EAE has 
been induced in a number of different animal species including mice, rats, guinea 
pigs, rabbits, macaques, rhesus monkeys and marmosets, following a protocol of 
active immunisation with encephalitogenic CNS-derived antigen peptides (Costa et al 
2003) or via the immunisation of activated encephalitogenic T cells which are able to 
confer disease in naive animals (Lublin, 1985).
There are two main models of EAE: acute EAE which is a monophasic disease 
induced upon immunisation with myelin basic protein in complete Freunds adjuvant 
(Paterson and Hanson 1969), and chronic relapsing EAE (crEAE). crEAE is 
characterised by the induction of an acute phase of EAE which is followed by a 
period of spontaneous remission and subsequent relapses. A more clinically relevant 
model for MS, crEAE can be induced by two immunisations of spinal cord 
homogenate in complete Freunds’ adjuvant containing Mycobacterium tuberculosis 
H37RA and Mycobacterium butyricum one week apart (Baker et al 1990, Brown and 
Moon 1998). A number of myelin components can be used to induce crEAE 
including MBP, myelin oligodendrocyte glycoprotein (MOG) and proteolipoprotein 
(PLP).
1.10.1.1 Induction of EAE
EAE can also be mediated by the active immunisation of the dominant 
encephalitogenic epitope of MOG35'55 peptide in C57BL/6 mice (Slavin et al 2001, 
Costa et al 2003). Immunisation of animals following this protocol was found to 
result in clinical onset of disease 10-15 days post immunisation with characteristic 
infiltration of inflammatory cells.
1.10.2 Experimental Autoimmune Uveoretinitis EAU
Posterior uveitis can be studied using an experimental model of disease called EAU 
which is a prototypic CD4+ T cell-mediated disease that targets the neural retina and 
related tissues (Caspi et al 1989, Gery et al 1985) and is therefore considered a good
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experimental model for investigating how T cells cross the BRB, induce retinal 
inflammation and uveitis. A number of experimental models of posterior uveitis have 
since been established using a variety of retinal antigens in a number o f animal 
species with models described in the rat, mouse, guinea pig, rabbit and monkey 
(Caspi 1997). O f note is that species-specific and strain-specific differences exist 
between different models of EAU and EAE.
1.10.2.1 Retinal Autoantigens
Wacker and Lipton in 1968 determined that the retina contained a number o f potent 
autoantigens and as a result EAU models in the rat and mouse have been developed 
in response to three main antigens: Retinal Soluble Antigen, Interphotoreceptor 
Retinoid Binding Protein and Rhodopsin. However it is known that EAU can be 
induced in response to recoverin, phosducin and even non-retinal antigens such as 
melanin associated protein and myelin basic protein. Most models of EAU have been 
established using bovine retinal antigens.
Retinal Soluble Antigen, SAg or Arrestin is a 48kD protein of the retina. Located 
within the rod outer segments, SAg is involved in the phototransduction cascade and 
responsible for binding photoactivated-phosphorylated rhodopsin. SAg from retinal 
rod photoreceptor cells induces a CD4+ T cell mediated autoimmune disease of the 
retina and uveal tract of the eye and the pineal gland (Chan et al 1985). Originally 
whole SAg was isolated from bovine eyes (Fong et al 1984). It has since been shown 
that synthetic peptides of SAg peptide can mediate EAU (Donoso et al 1990). SAg 
peptide-specific T cells derived from SAg peptide immunised animals have also been 
shown to be capable of mediating EAU in nai’ve animals (Fling et al 1991). 
Interphotoreceptor retinoid binding protein (IRBP) is a 148kD protein found within 
the photoreceptor matrix. IRBP is thought to transport vitamin A between the 
photoreceptor layer and the RPE. IRBP immunisation of Lewis rats induces severe 
autoimmune uveoretinitis and pinealitis (Dua et al 1992, Gery et al 1986). 
Rhodopsin and its illuminated form, opsin, is the rod cell visual pigment protein. The
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pathogenicity of this 40kD protein has been shown to be conformation-dependent 
(Schalken et al 1988).
1.10.2.2 Induction of EAU
SAg-induced uveitis in Lewis rats is a short acute disease (De Kozak et al 1981, 
Mochizuki et al 1985). A similar disease can also be induced by immunisation of 
synthetic peptides of retinal autoantigens such as SAg or IRBP in an antigenic 
adjuvant, such as Freunds’ adjuvant (Fling et al 1991, Hankey et al 2001). 
Immunisation with synthetic bovine SAg peptide 273-289 results in the development 
of EAU and the generation of uveitogenic T cells in vitro (Fling et al 1991). 
Uveitogenic or disease-mediating CD4+ T cells can be isolated from PLN from SAg 
immunised rats following a method described by Mochizuki et al (1986). Adoptive 
transfer of such recently activated uveitogenic CD4+ T cells expressing the molecules 
necessary for migration have been shown to mediate induction of EAU (Gregerson et 
al 1986, Mochizuki et al 1985).
1.11 Therapies for CNS diseases
1.11.1 Therapies for MS
The aims of therapy for MS are to prevent or postpone long-term disability and to 
alleviate symptoms of acute attack. At present, management of MS generally 
requires a multidisciplinary approach in order to accommodate the variety o f 
problems an MS sufferer may encounter such as physiotherapy and speech therapy. 
However a number of disease-modifying drug therapies for MS have been 
investigated in an attempt to modulate a number of immunological aspects of the 
disease. As a result, therapies trialled in the treatment of MS have included anti­
inflammatory, immunomodulatory and immunosuppressive agents.
Current management of MS is predominantly through the use o f glucocorticosteroids 
such as methylprednisolone and dexamethasone, which are highly potent
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immunomodulatory and anti-inflammatory drugs. Steroids have previously been 
shown to increase recovery speed as a result o f an MS relapse but have no impact 
upon the degree of recovery. Steroids are thought to alleviate symptoms of disease 
by the reduction of BBB abnormalities (Miller et al 1992), a reduction in levels of 
circulating CD3+ T cells (Dufour et al 1994) and decreased leukocyte adhesion 
molecule expression (Droogan et al 1998).
The most common therapy for MS at present is P-interferon (IFN-p). The initial 
rationale for the use of IFN-p in MS was the belief that the disease may be caused by 
a latent viral infection within the CNS (Jacobs and Johnson 1994). Various 
preparations of P-interferon (p-interferon-la and lb) have undergone clinical trials 
and have been shown to reduce relapse rate which is thought to be mediated by the 
suppression of Thl type cell generation (McRae et al 2000), although effects beyond 
the reduction in relapse rate are unknown.
Several other therapies have recently been investigated. Glatiramer Acetate (GA) 
also known as copolymer-1, was first found to inhibit EAE (Teitelbaum et al 1971). 
It has subsequently been shown to reduce relapse rate and disability progression in 
RRMS (Johnson et al 1995, Johnson et al 1998). It is thought to cause immune 
deviation from a Thl to a Th2 response, induce antigen-specific suppressor T cells, 
and inhibit antigen presentation (Neuhaus et al 2001). Side effects to GA therapy are 
mild but include transient chest pain and lymphadenopathy (Ziemssen et al 2001). 
Mitoxantrone, an immunosuppressive agent which inhibits T helper cell functions, 
has been shown to be beneficial in the treatment of disability progression, relapses 
and the formation of new lesions (Millefiorini et al 1997). However, it is thought 
from other studies investigating the effects of mitoxantrone in Hodgkin’s disease that 
therapy may result in severe side effects (Aviles et al 1993). The use of azathioprine 
and cyclophosphamide in the management of MS predate strict clinical trials and as 
such their clinical effects are undetermined. Both appear to exhibit high levels of 
toxicity and therefore serious consideration must be given prior to use. Most recent 
therapies for MS have involved the development of monoclonal antibodies which are
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able to disrupt specific stages of disease which include natalizumab, an antibody 
which recognises a4  integrins such as VLA-4, and thereby prevents leukocyte 
migration into the CNS (von Andrian and Engelhardt 2003); or Campath-1, marketed 
as alemtuzumab, which is a monoclonal antibody which recognises CD52 expressed 
by all leukocytes and results in leukocyte depletion. Both of these drugs have been 
subject to clinical trials in MS and have proved very effective (Tubridy et al 1999, 
Coles et al 1999) although side effects have been reported for Campath-1 (Coles et al
1999).
1.11.2 Therapies for Uveitis
The main aims of uveitis therapy are to relieve pain and discomfort, prevent sight loss 
due to the disease or possible complications and to treat the causes of disease. If 
inflammation is caused by viral or bacterial infection then treatment is with anti-virals 
or antibiotics. However, the cause of uveitis in the majority of cases remains 
undiagnosed. As a result of this, the immediate aim of treatment is to decrease 
inflammation and so alleviate symptoms of disease. This is achieved by means of 
steroids, immunosuppressants and mydriatics.
As with MS, glucocorticosteroids form the first line of defence for the treatment of 
non-infectious uveitis (Jabs et al 2000). This is due to their rapid ability to suppress 
inflammation through mimicking the function of cortisol (hydrocortisone). For the 
treatment of uveitis, steroids can be administered topically, systemically or in a peri­
ocular manner while in sight threatening cases it is possible to administer intravenous 
steroids if so required. Steroids used for the treatment of uveitis include prednisone. 
However, several side effects occur as a result of steroid therapy including nausea, 
weight gain, fluid retention, hypertension, diabetes and long term therapy has been 
shown to give rise to severe ocular complications such as cataract and glaucoma. 
Mydriatics and cycloplegics such as atropine or cyclopentolate are antimuscarinics 
which cause dilation of the pupil and paralysis of the ciliary muscle, and function to 
alleviate symptoms of pain and discomfort associated with AU. These drugs vary in
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potency and duration of their effects. The major group of compounds used in the 
treatment of uveitis are immunosuppressants these are often administered in 
combination with steroids to act in a steroid-sparing manner. Immunosuppressants 
which are currently used include antimetabolites such as azathioprine (Imuran), 
methotrexate (Rheumatrex) and mycophenolate mofetil (Cell cept). These have been 
shown to be effective in the treatment of uveitis and in some instances the treatment 
of steroid-resistant or steroid-intolerant uveitis (Holz et al 1992, Kilmartin et al 1998, 
Lau et al 2003, Baltatzis et al 2003). Although minor side effects have been reported, 
mycophenolate mofetil is reportedly successful in the treatment of uveitis with an 
acceptable profile of side effects (Larkin and Lightman 1999).
Cyclosporine (Sandimmune, Neoral, and SangCyA) an inhibitor of T cells functions 
by blockade of gene transcription and hence proliferation and cytokine production. 
It has previously been found to be highly effective in the treatment of a number of 
different forms of uveitis (Nussenblatt et al 1983) with success comparable to that of 
steroid therapy (Nussenblatt et al 1991). Cyclosporine therapy has highlighted side 
effects which include muscle cramps, nephrotoxicity and elevated blood pressure 
with a major side effect of suppression of the immune system resulting in an 
increased rate of infection. The majority of uveitis patients are children, and long 
term cyclosporine therapy has been shown to be highly detrimental for development 
(Ellis et al 1985). Tacrolimus (FK506; Prograf) is an antibiotic of the macrolide 
family which inhibits expression of early T cell activation genes and thus inhibits T 
cell mediated responses by mechanisms similar to cyclosporine (Suzuki et al 1997). 
Previously shown to be highly effective in the treatment of EAU (Kawashima et al 
1988) and endotoxin-induced uveitis (Whitcup et al 1998) it has shown efficacy in 
the treatment of refractory uveitis (Mochizuki et al 1993, Kilmartin et al 1998, Sloper 
et al 1999).
Rapamycin (RAPA or sirolimus) like tacrolimus, is an antibiotic of the macrolide 
family which inhibits the late phase of IL-2 receptor mediated T cell activation (Ikeda 
et al 1997). RAPA was found to be highly effective in the inhibition of EAU
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(Roberge et al 1993, Ikeda et al 1997). However a side effect of RAPA is 
hyperlipidaemia, including hypercholesterolemia and hypertriglyceridemia (Groth et 
al 1999). Current RAPA therapy may therefore be administered in conjunction with 
statins, which are inhibitors of the cholesterol synthesis pathway. As a last resort 
alkylating agents such as cyclophosphamide and chlorambucil have been used in the 
treatment of sight threatening disease despite severe side effects, which include 
sterility.
More recently treatment of uveitis has focused upon more specific targets including 
the use of biological therapies such as etanercept (Enbrel), a fusion protein comprised 
of the extracellular ligand binding portion of the human TNF-receptor and the Fc 
portion of human IgGl, which is capable of inhibiting the function of TNF-a and 
TNF-y. Conflicting evidence exists for the efficacy of etanercept at present (Reiff et 
al 2001, Reddy and Backhouse 2003). A second anti-TNF-a therapy includes 
infliximab (Remicade), a chimeric monoclonal antibody which binds to both 
membrane and soluble TNF-a (Scallon et al 1995) with exceptional efficacy 
documented in rheumatoid arthritis (Maini et al 1998, Lipsky et al 2000, Elliott et al 
1993, Elliott et al 1994). Infliximab therapy has shown to be successful in a number 
of forms of uveitis (El-Shabrawi and Herman, 2002, Sfikakis et al 2001, Joseph et al 
2003). A third TNF therapy investigating the ability of the p55 TNF receptor fusion 
protein (TNFr-Ig) has shown clinical efficacy in the treatment of posterior uveitis 
(Murphy et al 2004). Campath-1 or alemtuzumab is a monoclonal antibody directed 
against the CD52 antigen expressed by human lymphocytes. Antibody recognition of 
CD52+ leukocytes results in their death and therefore leukocyte depletion. The 
antibody is fully humanised and has previously been found to be effective in the 
treatment of MS, despite some side effects (Coles et al 1999). In addition, research 
has demonstrated clinical efficacy of Campath-1 in refractory ocular inflammatory 
disease (Isaacs et al 1996 and Dick et al 2000). Daclizumab (Zenapax) is a 
humanised monoclonal antibody, which recognises the alpha subunit of the IL-2 
receptor (p55 alpha, CD25 or Tac subunit) and inhibits binding o f IL-2 to its receptor. 
It functions by the suppression of IL-2-mediated activation of lymphocytes and has
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since been deemed safe for long term use in intermediate and posterior uveitis 
(Nussenblatt et al 1999, Nussenblatt et al 2003).
1.12 Potential therapies for CNS disease
It is widely accepted that numerous events are involved between predisposition to 
disease and expression of disease. It has previously been suggested that events 
including peripheral activation of CNS reactive T cells, migration of these activated T 
cells to the CNS, crossing of the BBB and perpetuation of the immune response once 
within the CNS, represent several stages at which therapeutic intervention may be 
targeted (Pender and Wolfe 2002).
1.12.1 Statins
Statins or HMG CoA reductase inhibitors are a group of compounds which were 
originally isolated from Penicillium species by Endo et al (1976) but may also be 
derived from Aspergillus and Monascus. The active compound “compactin’’ was 
found to lower cholesterol in normolipidemic and hyperlipidemic individuals. A 
number of compactin derivatives are now available and have clinical efficacy for the 
treatment of hyperlipidemia and atherosclerosis. Statins such as lovastatin, 
simvastatin, pravastatin, and mevastatin are type I statins or naturally occuring 
statins. Fluvastatin, atorvastatin, cerivastatin, rosuvastatin and pitavastatin are 
considered type II statins and are synthetic statins. Statin-mediated inhibition of 
cholesterol synthesis is achieved by the similarity in structure of statins and HMG- 
CoA. These compounds are based on a lactone ring structure and can exist in a pro­
drug form, which must be converted to the active acid form for its biological activity. 
Hydrolysis of lovastatin to lovastatic acid can produce between 4-6 metabolites.
Statins have been shown to inhibit the activity of HMG-CoA reductase in a 
competitive, specific and reversible manner. It has been demonstrated that statins 
inhibit de novo synthesis of cholesterol and also increase LDL receptor expression on
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the cell surface, which increases catabolism of cholesterol from the circulation and 
both result in a decrease in circulating cholesterol levels. Statins have also been 
shown to possess a higher affinity for HMG-CoA reductase (Ki=3.5-44nM) than 
HMG-CoA itself (Km=4pM; Holdgate et al 2003).
Statins can either be completely absorbed after oral administration or require 
metabolism from the pro-drug form to the active form by the liver. A number of 
statins have undergone extensive trials for the treatment o f hypercholesterolemia and 
few adverse effects have been reported including liver toxicity and myopathy.
1.12.2 Statin therapy
Atherosclerosis is known to be a multifactorial disease characterised by the complex 
interaction of lipid metabolism, mononuclear cells, coagulation proteins, cytokines, 
the extracellular matrix (ECM) and haemodynamic forces (Libby 2000) and as such 
is suggested to be a chronic inflammatory disease (Vaughan et al 1996, Ross 1999, 
Lusis 2000). The rapid effectiveness by which statins decrease coronary events 
suggested that statins are able to influence vascular biology independently of lowered 
plasma cholesterol. It has been suggested that statins influence the blood vessel wall, 
blood flow and constituents of blood (Vaughan et al 1996). However they have also 
been shown to exert a number of varied effects which include vasodilative, 
antithrombotic, antioxidant, antiproliferative, anti-inflammatory and plaque 
stabilising effects (Davingnon and Laaksonen 1999).
1.12.3 Statins in EAE
A number of recent studies have demonstrated the ability of statins to ameliorate 
EAE. These studies revealed that the effects of statins upon this multifactorial 
disease are numerous and those known, to date, include the suppression of pro- 
inflammatory cytokines decreased MHC expression and inhibtion of MMPs 
(Stanislaus et al 1999, Stanislaus et al 2001, Youssef et al 2002, Greenwood et al 
2003, Aktas et al 2003). Subsequent to these findings in EAE, clinical trials are
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underway in order to test statins in the treatement of MS and preliminary reports 
suggest a high degree of clinical efficacy (Vollmer et al 2004).
1.12.4 Statins in EAU
Given the reported success of statins the treatement of EAE and MS and that similar 
mechanisms are believed to play a role in the induction of EAU, we investigated 
whether statins were able to modulate clinical EAU. In subsequent chapters of this 
thesis, the effects of statins upon EAU will be described. As previously discussed 
RAPA is proposed to induce an increase in serum cholesterol, thus patients currently 
undergoing treatment for uveitis may receive statins in the treatment of RAPA- 
induced hyperlipidemia. It would therefore be extremely interesting to investigate the 
anti-inflammatory effects of statins in uveitis patients undergoing RAPA therapy.
1.13 AIMS
It has previously been shown that activated T lymphocytes are able to migrate across 
the BBB and BRB into the CNS and that BEC and REC play a role in the regulation 
of lymphocyte migration. Therefore I initially set about to investigate the 
immunoregulatory effects of CNS EC upon T cells as a result o f TEM in vitro.
Secondly given the role o f the EC in the regulation of lymphocyte trafficking into the 
CNS and the requirement of leukocyte trafficking into the CNS for the initiation of 
CNS mediated diseases such as uveitis and MS I investigated whether disruption of 
EC signalling pathways by statins is able to modulate lymphocyte migration into the 
CNS using both in vitro and in vivo models.
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Chapter 2
Materials and Methods
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2.1 Materials
Product Product Code Supplier
100 bp DNA ladder 15628-019 Invitrogen UK
2-Mercaptoethanol M6250 Sigma Laboratories UK
CFSE (CFDA tracker kit) V12883 Cambridge Bioscience UK
Chloroform C2432 Sigma Aldrich UK
Collagen Type I C8919 Sigma Aldrich UK
Collagenase C2674 Sigma Aldrich UK
Complete Freunds Adjuvant F5881 Sigma Aldrich UK
Concanavalin A C7275 Sigma Aldrich UK
Cytofix/Cytoperm Kit 554772 BD Bioscience UK
FasL PCR primers N/A Sigma Genosys, UK
Fluorescein (20%) N/A Moorfields Eye Hospital
Geneticin, G418 10131-019 Invitrogen UK
Gentamicin G1397 Sigma Aldrich UK
Glutamine 25030-024 Invitrogen UK
Hanks balanced salts solution HBSS 24020-091 Invitrogen UK
HBSS without Ca2+and Mg2+ 14170-088 Invitrogen UK
Heat inactivated Fetal Calf Serum 4-101-500 LabTech International UK
IL-2, recombinant, mouse 212-12 Peprotech UK
IL-2, recombinant, rat PRP09BZ Serotec UK
Infinity Cholesterol Assay Kit TR13421 ThermoTrace Australia
IRBP Peptide N/A A.B.C. UK
Live-dead viability assay kit L-3224 Cambridge Bioscience UK
Loading buffer blue/orange 6x G1881 Promega UK
Lovastatin 438185 Calbiochem UK
Lympholyte Rat CL5045 VH Bio UK
Methyl-3H thymidine [25Ci/mMol] TRK300 Amersham Bioscience UK
Methyl a-D-mannopyranoside M6882 Sigma Aldrich UK
Mevalonolactone M4667 Sigma Aldrich UK
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Mineral oil
MOG peptide
Mouse Fas ligand ELISA
Mouse IFN-y ELISA
Mouse IL-2 ELISA
Mouse IL-4 ELISA
Mouse IL-5 ELISA
Mouse IL-10 ELISA
Mouse IL-12 p70 ELISA
Mouse TGF-pi ELISA
Mouse TH1/TH2 CBA kit
Non essential amino acids
Nutrient mix F10 Ham
Penicillin and Streptomycin Solution
Perm/Wash Buffer
Phosphate buffered saline
RNeasy Extraction kit
RPMI 1640 with Glutamax
RPMI-1640 Dutch Modification
RPMI-1640 without L-Glutamine
SAg peptide
Sodium pyruvate
Squalene
Superscript Kit
Taq DNA polymerase
Trans wells 4pm Collagen Coated
Transwells 4pm Tissue culture treated
Trypsin EDTA solution
YoPro-1
P-actin PCR primers
M5904 Sigma Aldrich UK
N/A A.B.C. UK
MFL00 R&D systems UK
MIF00 R&D systems UK
M2000 R&D systems UK
M4000 R&D systems UK
M5000 R&D systems UK
Ml 000 R&D systems, UK
M1270 R&D systems, UK
MB 100 R&D systems, UK
551287 BD Bioscience UK
11140-035 Invitrogen UK
31550-023 Invitrogen UK
15070-063 Invitrogen UK
554723 Pharmingen BD UK
P4417 Sigma Aldrich UK
74104 Qiagen Ltd UK
72400-021 Invitrogen UK
22409-015 Invitrogen UK
31870-025 Invitrogen UK
N/A A.B.C. UK
11360-039 Invitrogen UK
S3626 Sigma UK
11904-018 Invitrogen UK
600 132-81 Stratagene UK
3496 Coming BV UK
3472 Coming BV UK
25300-062 Invitrogen UK
Y3603 Cambridge Bioscience UK
N/A Sigma Genosys UK
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2.2 Antibodies
Antibody Clone Host Isotype Source
Anti-rat CD5-RPE OX-19 Mouse IgGl Serotec
Anti-rat CD4-RPE W3/25 Mouse IgGl Serotec
Anti-rat CD8 RPE-Cy5 OX-8 Mouse IgGl Serotec
Anti-rat CD25-RPE OX-39 Mouse IgGl Serotec
Anti-mouse CD4-PerCP RM4-5 Rat IgG2a BD Bioscience
Anti-mouse CD25-PE PC615.3 Rat IgGl Caltag
Anti-mouse CD62L MEL-14 Rat IgG2a Caltag
Anti-mouse IL-4-PE 11B11 Rat IgGl BD Bioscience
Anti-mouse IFN-y-FITC XMG1.2 Rat IgGl BD Bioscience
Isotype control PerCP R35-95 Rat IgG2a BD Bioscience
Isotype control FITC R3-34 Rat IgGl BD Bioscience
Isotype control PE R3-34 Rat IgGl BD Bioscience
Isotype control RPE F8-11-13 Mouse IgGl Serotec
Isotype control RPE-Cy5 MCA1209C Mouse IgGl Serotec
Table 2.1 Directly conjugated primary antibodies used in these studies.
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Antibody Clone Species Isotype Source
Anti-rat CD45 OX-22 Mouse IgGl Serotec
Anti-human CD95 DX2 Mouse IgGl BD Bioscience
Anti-human FasL 4H9 Hamster IgG Beckman Coulter
Anti-human FasL 4A5 Hamster IgG Beckman Coulter
Anti-rat FasL (biotinylated) MFL4 Hamster IgG3 BD Bioscience
Anti-human FasL FSLOl Mouse IgM Biocarta
Anti-rat ICAM-1 1A29 Mouse IgGl Serotec
Anti-mouse MHC class II M5/114.15.2 Rat IgG2b e-bioscience
Table 2.2 Unconjugated primary antibodies used in these studies.
Secondary Reagents Host Specificity Source
Streptavidin-PE Biotin BD Bioscience
Anti-mouse RPE (rat preabsorbed) Goat Mouse IgG Serotec
Anti-hamster FITC Goat Mouse IgG Serotec
Anti-mouse FITC Donkey Mouse IgG 
H+L chain
Jackson
Laboratories
Anti-mouse FITC Rabbit Mouse IgM p 
chain specific
Rockland
Protein A/G-Horse Radish 
Peroxidase
Mouse Pierce
Streptavidin Texas Red Biotin Amersham
Bioscience
Table 2.3 Secondary antibodies and reagents used in these studies.
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2.3 Animals
Lewis rats, B10.RIII7INS mice and C57BL/6 mice were purchased from Harlan Olac 
(Bicester, UK). All animal studies were conducted in accordance with the 
institutional guidelines and UK Home Office regulations. All animals were provided 
with RM1(E) feed and water ad libitum and terminated using a schedule 1 method of 
killing.
2.4 Stock Solutions
A number of solutions were prepared, aliquoted and stored as described as follows. 
This was in order to prevent degradation of the reagents as a result o f multiple freeze 
thaw cycles and also to prevent contamination of stock solutions.
2.4.1 2-Mercaptoethanol
2-mercaptoethanol (2ME; molecular weight 78.13) was purchased as a 14.3M stock 
solution. 14.3M 2-ME was diluted in phosphate buffered saline [1/14.3 v/v] (PBS; 
see section 2.4.17). In aseptic conditions this was then sterilised by passing through a 
0.22pM filter and aliquoted in 500pl volumes and stored at -20°C until use. At this 
time 2-ME was thawed and further diluted [1/50000 v/v] in culture medium to give a 
final concentration of 2xlO'5M.
2.4.2 C3-transferase
C3-transferase (C3 exoenzyme from Clostridium Botulinum) was prepared as 
described by Adamson et al 1999.
2.4.3 Calcein AM
A working concentration of Calcein AM [0.2pM] was prepared by a 1/20000 dilution 
in PBS (see section 2.4.17).
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2.4.4 Collagen Solution Type I
In aseptic conditions Type I collagen solution was diluted 1 in 20 (v/v) in HBSS 
immediately prior to use in collagen coating of tissue culture wares.
2.4.5 Collagenase
In aseptic conditions, collagenase was resuspended at 1 mg/ml in sterile calcium and 
magnesium free HBSS. Collagenase was then aliquoted in 1ml volumes and stored at 
-20°C until required for use. Aliquots were then thawed and used immediately.
2.4.6 Concanavalin A (Con A)
In aseptic conditions lyophilised Concanavalin A was resuspended at 1 mg/ml in 
sterile RPMI-1640. Con A was then aliquoted in 1ml volumes and at stored at -20°C 
until required for use. Aliquots were then thawed and stored at 4°C for up to 3 days.
2.4.7 CNS EC medium
In aseptic conditions lOOmls of media was removed from a 500ml bottle of Nutrient 
mix Ham’s F-10. The media was then supplemented with FCS [20% v/v] and 
penicillin and streptomycin solution [lOOU/ml and 100pg/ml].
2.4.8 Ethidium Homodimer-1
A working concentration of Ethidium Homodimer-1 (EthDl [0.1 pM]) was prepared 
by a 1/20000 dilution in PBS (see section 2.4.17).
2.4.9 FCS
In aseptic conditions FCS was thawed in a 37°C water bath. After complete thawing 
FCS was either heat-inactivated at 56°C in a water bath for 45 min or if purchased 
already heat-inactivated, aliquoted in 50ml volumes. FCS was then stored at -20°C 
until required and thawed in a 37°C water bath when required for tissue culture 
purposes.
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2.4.10 Glutamine Solution
Glutamine solution [200mM] was thawed in a 37°C water bath and aliquoted in 5ml 
volumes. Aliquots were then refrozen and thawed as required in a 37°C water bath 
for tissue culture media. Glutamine was then further diluted in tissue culture media.
2.4.11 Lovastatin
Lovastatin was brought into suspension by dissolving in dimethyl sulfoxide (DMSO; 
100%). This solution was aliquoted, stored at -20°C and thawed as required.
2.4.12 Methyl 3H-thymidine
In aseptic conditions lmCi/ml methyl 3H-thymidine was diluted 1 in 10 in RPMI- 
1640 to give a lOOpCi/ml solution. lOpl or 5pi of diluted methyl 3H-thymidine was 
added as the equivalent of lpCi or 0.5pCi per 200pl/well of a 96-well assay plate, 
respectively.
2.4.13 Methyl-a-D-mannopyranoside
A 1M solution of methyl-a-D-mannopyranoside (molecular weight 194.2) was 
prepared by dissolving 1.942g methyl-a-D-mannopyranoside in 10ml o f RPMI 1640. 
This solution was prepared immediately prior to use and not stored.
2.4.14 Non CNS EC medium
In aseptic conditions 50ml o f media was removed from a 500ml bottle of RPMI- 
1640. The bottle was then supplemented with FCS [10% v/v], L-glutamine [2mM] 
and Penicillin and streptomycin solution [lOOU/ml and 100pg/ml].
2.4.15 Non-essential amino acids (NEAA) Solution
Sterile NEAA solution [lOOx stock] was aliquoted into 5ml volumes. Aliquots were 
then stored at 4°C and used as required.
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2.4.16 Normal Rat Serum (NRS)
Normal rat serum was obtained by cardiac puncture of specifc pathogen-free rats. 
Whole blood was stored in sodium heparin coated vacutainers at 4°C overnight. This 
was then centrifuged at 260g for 10 min, the serum removed and aliquoted into 2ml 
volumes. NRS was heat-inactivated by incubation in a 56°C water bath for 45 min. 
The serum was then stored at -20°C until required. At this time NRS was thawed in a 
37°C water bath and used for tissue culture media.
2.4.17 PBS
PBS was prepared following instructions provided by the manufacturer. Briefly one 
PBS tablet was dissolved in 200ml of 18Q water on a magnetic stirrer. Sterile PBS 
was prepared in aseptic conditions by sterilisation through a 0.22pM filter using a 
25ml syringe.
2.4.18 Penicillin and Streptomycin Solution
Sterile penicillin and streptomycin solution [lOOOOU/ml and lOOOOpg/ml] was 
thawed in a 37°C water bath. The solution was then aliquoted into 10ml volumes and 
re-frozen at -20°C until required. Aliquots were thawed as required for tissue culture 
media.
2.4.19 Permwash Buffer
Concentrated Permwash buffer was diluted lin 10 in 18Q water. This solution was 
used or stored for up to 7 days at 4°C.
2.4.20 Propidium Iodide
Propidium Iodide (PI) was resuspended at 1 mg/ml in 18Q water and aliquoted in 
lOOpl volumes into 500pl microfuge tubes. Aliquots were then stored at -20°C and 
thawed as required. Once thawed, PI solution was stored at 4°C.
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2.4.21 PLN T cell medium
This medium was prepared for PLN T cells to be used for the purpose o f adhesion 
assays. In aseptic conditions 65ml of media was removed from a 500ml bottle of 
RPMI 1640 with L-alanyl-L-glutamine. The bottle of media was then supplemented 
with FCS [10% v/v], penicillin and streptomycin solution [lOOunits and lOOpg/ml], 
sodium pyruvate solution [ImM], NEAA [ImM] and 2-ME [2x1 O'5]. This was then 
stored at 4°C until use.
2.4.22 Rat IL-2 (IL-2-containing supernatant)
Supernatant was harvested from the mouse IL-2 transfected C 127 mammary tumour 
cell line and sterilised through a 0.22pM filter under aseptic conditions. Supernatant 
was then aliquoted into 5ml volumes and stored at -20°C until required for assay or 
culture at which time it was thawed in a 37°C water bath and subsequently stored at 
4°C for up to 7days. However this will further be referred to as rat IL-2.
2.4.23 Serotec Rat IL-2
Rat recombinant IL-2 [5000U/ml] (Serotec) was aliquoted into 50p,l volumes and 
stored at -20°C. When required, aliquots were thawed and used by making a further 
dilution [1/50 v/v] in culture medium.
2.4.24 Sodium Pyruvate (SP) Solution
Sterile SP solution was aliquoted into 5ml volumes. Aliquots were then stored at 4°C 
and used as required.
2.4.25 Squalene
In aseptic conditions squalene was made into a 5mg/ml solution in ethanol.
2.4.26 T cell Medium
The following T cell medium was prepared for the culture o f rat and mouse 
splenocyte and PLN T cells for the establishment of T cell lines, T cell cytokine 
production or T cell proliferation. In aseptic conditions 65ml of media was removed
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from a 500ml bottle of RPMI 1640 buffered with 25mM HEPES and lg/L sodium 
bicarbonate. The media was then supplemented with FCS [10% v/v], L-Glutamine 
[2mM], gentamicin [50pg/ml], SP [ImM], NEAA [ImM] and 2-ME [2x1 O'5 M] and 
stored at 4°C.
2.4.27 T cell medium for antigenic restimulation
In aseptic conditions a 500ml bottle of RPMI- 1640 buffered with 25mM HEPES and 
lg/L sodium bicarbonate was supplemented with L-Glutamine [2mM] and 
gentamicin [50pg/ml]. 194mls of this was then transferred to a sterile tissue culture 
bottle and further supplemented with NRS [1% v/v], SP [ImM], NEAA [ImM] and 
2-ME [2x10‘5 M]. This was then stored at 4°C until use.
2.4.28 Wash Buffer
In aseptic conditions 25ml of media was removed from a 500ml bottle of RPMI-1640 
buffered with 25mM HEPES and lg/L sodium bicarbonate. This was then 
supplemented with FCS [5% v/v] and L-Glutamine [2mM].
2.4.29 YoPro-1
A working dilution of YoPro-1 [0.5pM] was prepared by a 1/2000 dilution in PBS 
(see section 2.4.17)
2.5 Tissue Culture
2.5.1 Thawing of Cells
Cells cultured from frozen stocks were defrosted quickly at 37°C in a water bath and 
washed in lOmls of respective warmed medium and centrifuged at 260g for 10 min in 
an MSE Harrier 18/80 centrifuge (Sanyo Gallenkamp PLC, UK). Cells were counted 
in a haemocytometer and viable cells, as determined by Trypan Blue exclusion, were 
set up at 2x105 cells/ml in respective media. After washing, endothelial cells were 
transferred directly to a T75cm2 vented tissue culture flask in the respective tissue
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culture media. All cells were then cultured at 37°C, 5% CO2 humidified incubator 
(Phillip Harris, UK).
2.5.2 Freezing of cells
Cells were set up at a known density in the respective media and 900jlx1 volumes were 
transferred to 1.8ml cryotubes. Cells were then incubated on ice for 10 min and 
supplemented with DMSO [10% v/v] added dropwise. Cryotubes were then wrapped 
in tissue and transferred to a polystyrene box within a -70°C freezer for up to 72h 
before transfer to liquid nitrogen (LN2) for long term storage.
2.5.3 Isolation of a single cell suspension
Single cell suspensions of rat splenic, cervical and mesenteric lymph node T cells and 
thymocytes were prepared from tissues isolated from 4-8 week old female Lewis rats. 
Single cells suspensions of splenic T cells and PLN T cells were also prepared 
following this protocol from Lewis Rats, BIO.RIII1^  and C57BL/6 mice at expected 
peak of disease. Cell suspensions were prepared by mechanical disruption of the 
tissue and passage through a 0.75pm sterile sieve using the plunger of a 5ml syringe. 
Cells were washed twice with 50ml of wash buffer and centrifugation at 260g for 10 
min. Lymphocytes were isolated and stored in wash buffer (see section 2.4.28) on ice 
until processing.
2.6 T lymphocytes
2.6.1 Thymocytes
Thymocytes were prepared (as described in section 2.5.3) and resuspended in a 
known volume of T cell medium. Cells were then irradiated with 2000rads on a 
Caesium137 source (GammaCell Irradiator, MDS Nordion, courtesy of the London 
School of Hygiene and Tropical Medicine, London UK). Irradiated cells were then 
added to T cells in culture at a 50:1 ratio of feeder cells to T cells (Sedgewick et al 
1989). Three days later dead feeder cells were removed from the culture by density
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centrifugation of cultures on Lympholyte Rat at 720g for 20 min (Figure 2.1). In this 
process dead cells precipitate at the bottom of the centrifuge tube whilst the live T 
cells form a layer above the Lympholyte.
2.6.2 IL-2 transfected C127 mammary tumor cells.
A mouse mammary tumour cell line transfected to constitutively secrete mouse IL-2 
kindly donated by Dr F. Melchers, Bern (Karasuyama and Melchers 1988), was 
cultured at a density of 2x105 cells/ml in T cell medium (see section 2.4.26). Cells 
were provided with fresh medium every 3-4 days. These hybridoma cells were G418 
resistant and regularly, IL-2 secreting cells were selected by culturing in the presence 
of Geneticin (G418) [1 mg/ml] then cultured for 3-4 days in the absence of G418 prior 
to culture at 4x l05 cells/ml for 2-3 days, after which time the supernatant was 
harvested. The supernatant was then sterile-filtered and stored at -20°C until 
required for assay or T cell culture. All batches of IL-2 containing supernatant were 
tested for their ability to stimulate T cell proliferation using an IL-2 dependent T cell 
line and the optimum concentration determined (see section 2.8.1). This source of 
IL-2 is further referred to as rat IL-2. Cell viability and growth was monitored using 
a haemocytometer and Trypan blue exclusion.
2.6.3 Mitogen specific T cell lines
Lewis rat splenocytes prepared as described (section 2.5.3) were then set up at 
lx l0 6cells/ml in T cell medium (see section 2.4.26) and stimulated with Con A 
[5pg/ml] (Zhao et al 1994). Cells were re-stimulated with autologous Lewis 
thymocytes (see section 2.6.1) and Con A [5pg/ml] every 7-10 days and maintained 
between re-stimulation every 3-4 days with rat IL-2 (see section 2.4.22). T cells were 
cultured and re-stimulated with mitogen and feeders for at least 3-4 passages, thus 
establishing a Con A driven T cell line prior to use in the subsequent experiments. 
Cell viability and growth was as described previously (see section 2.6.2).
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A
Centrifuge tube-
Rat T cells in 
T cell 
medium
Lympholyte Rat-
B
Rat T cell 
medium
Interface layer 
containing 
“live” T cells
Lympholyte
Rat
Dead cells 
and debris
Figure 2.1 The principles of density centrifugation.
Tube A shows the layering of the cell suspension to the Lympholyte Rat prior to 
centrifugation. Tube B shows the separation of the cells post centrifugation. The live 
cells are prevented from passage through the Lympholyte due to size exclusion and 
thus form an “interface layer or buffy coat” on top of the Lympholyte rat. Dead cells 
and debris pass freely through the density gradient and sediment at the bottom of the 
tube. The interface layer containing the live cells is then carefully aspirated and the 
cells washed thoroughly to remove any traces of Lympholyte.
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2.6.4 PLN T cells
PLN T cells were isolated and prepared as described in section 2.5.3. Cells for the 
purposes of adhesion assays were cultured at lx l0 6 cells/ml in rat PLN T cell medium 
(see section 2.4.21) and stimulated with Con A [5pg/ml] for at least 24h prior to use 
in assay (see section 2.8.6).
PLN T cells were also isolated from EAU and EAE mice for the purpose of cytokine 
detection. In this instance cells were set up at 2x l06 cells/ml in T cell medium (see 
section 2.4.26) in the presence or absence of antigen or mitogen (see section 2.13.19).
2.6.5 Soluble retinal antigen peptide specific T cell lines
Antigen specific T cell lines were established following a method originally 
described by Sedgewick et al (1989). Briefly, fore and hind leg, cervical and 
mesenteric PLN T cells were isolated from 4-6 week old female Lewis rats 
immunized in the hind foot pad with SAg peptide273-289 and maintained in wash 
buffer (see section 2.4.28) on ice until processing. Single cell suspensions were 
prepared as described (section 2.5.3) and cultured at 2x106 cells/ml in T cell medium 
for antigenic restimulation (see section 2.4.27) and stimulated between 7 and 10 days 
with SAg peptide " [10pg/ml]. Cells were re-stimulated with autologous
thymocytes (see section 2.6.1) and SAg peptide273-289 [lOpg/ml] every 7-10 days and 
maintained between re-stimulation every 3-4 days with rat T cell medium (see section
2.4.26) containing rat IL-2 (see section 2.4.22). T cells were cultured and re­
stimulated with antigen and feeders for 3-4 passages establishing a SAg peptide 
specific T cell line prior to use in the subsequent experiments. All migration studies 
(see section 2.8.2, 2.8.3, 2.8.8) were performed using T cells 4-5 days post-antigenic 
restimulation (3 days with peptide and feeder APC, 1-2 days post IL-2), whilst at 
their migratory peak (Pryce et al 1997). Cell viability and growth was monitored as 
described previously (see section 2.6.2).
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2.6.6 HT-2 Cell line
An IL-2 dependent murine helper T cell line HT-2 (Watson 1979) was cultured in 
order to assay for IL-2 activity in the C l27 cell supernatants. Cells were cultured at a 
density of 2x105 cells/ml in T cell medium (see section 2.4.26) in the presence of rat 
IL-2 (see section 2.4.22). Fresh medium was added every 3-4 days until required for 
IL-2 bioassay. Cell viability was determined as described for T lymphocytes.
2.6.7 L1210 cells
Parental L1210 (L121010, L1210') and human Fas-Fc transfected L I210 (L1210hl, 
L1210+,L 1210Fas) mouse lymphocytic leukaemic cell lines (Rouvier et al 1993) 
were cultured in vitro at a density of 2xl05 cells/ml in T cell medium (see section
2.4.26). Cells were provided with fresh medium every 3-4 days until required for 
functional Fas ligand assay. Cell viability was again determined as for T 
lymphocytes. These cells will further be referred to as L I210 and L1210Fas cells.
2.7 Endothelial Cells
2.7.1 Cell Dissociation
In preparation for dissociation of EC monolayers, culture medium was aspirated and 
the monolayers washed three times with calcium-and-magnesium-free (Ca2+ and 
Mg2+ free) HBSS to remove traces of serum and Ca2+ and Mg2+ essential for cell 
attachment. For routine tissue culture purposes, monolayers were then incubated 
with Trypsin/EDTA [IX] for 5 min at 37°C, 5% CO2 For cell dissociation prior to 
cell surface staining of EC for flow cytometry, monolayers were dissociated with 
collagenase [1 mg/ml] at 37°C 5%CC>2 until cells had detached. Detachment was 
confirmed by phase-contrast light microscopy and cells were collected into lOmls of 
their respective serum-containing medium. Cells were then centrifuged at 260g for 
10 min prior to replating or distribution into 1.5ml microfuge tubes required for 
staining purposes.
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2.7.2 Collagen Coating
Tissue culture plastics required for the culture of CNS derived EC (e.g. GP8/3.9 and 
JG2.1, LD7.4) were coated with a type I collagen (see section 2.4.4) for lh  at room 
temperature (RT). The solution was then aspirated and the collagen cross-linked by 
placing the flask/dish in an ammonia hydroxide vapour chamber for 20 min. 
Conversion of the collagen solution from yellow to pink was confirmed and the 
collagen-coated surface of the flask/dish was subsequently washed with HBSS until 
the phenol red of the HBSS remained red, indicating a neutral pH.
2.7.3 Central Nervous System-derived Endothelial Cells (CNS EC)
2.7.3.1 Brain microvascular EC
The SV40 “large T” immortalised Lewis rat brain endothelial cell line, GP8/3.9, 
representing the BBB was cultured in vitro on type I collagen-coated tissue culture 
flasks (Greenwood et al 1996). Cells were cultured in CNS EC medium (see section 
2.4.7), which was changed every 3-4 days until the formation of confluent 
monolayers (3-6 days). Cells were plated onto collagen-coated tissue culture plastic 
at a maximum split ratio of 1 in 5. All experiments were performed on EC 
monolayers between passages 15 and 20.
2.7.3.2 Retinal microvascular EC
The SV40 “large T” immortalised Lewis rat retinal endothelial cell line, JG2.1 
representing the vascular BRB was cultured in vitro on Type I collagen-coated tissue 
culture flasks (Greenwood et al 1996). Cells were cultured in CNS EC medium (see 
section 2.4.7). Culture medium was changed every 3-4 days until the formation of 
confluent monolayers (3-6 days). Cells were plated onto collagen-coated tissue 
culture plastic at a maximum split ratio of 1 in 5. All experiments were performed on 
EC monolayers between passages 15 and 20.
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2.7.3.3 Retinal pigment epithelial cells
The SV40 “large T” immortalised PVG (RT1C) rat retinal pigment epithelial cell line, 
LD7.4 representing the posterior BRB was cultured in vitro in CNS EC medium (see 
section 2.4.7; Greenwood et al 1996). Culture medium was changed every 3-4 days 
until the formation of confluent monolayers (3-6 days). Cells were plated directly 
into tissue culture flasks at a maximum split ratio of 1 in 5. All experiments were 
carried out on cells between passages 19 and 23.
2.7.4 Non-Central Nervous System-derived Endothelial Cells.
2.7.4.1 HEV
The high endothelial venule (HEV) endothelial cell line, a kind gift from A. Ager 
(NIMR, Mill Hill) was cultured in non-CNS EC medium (see section 2.4.14). 
Culture medium was again changed every 3-4 days until the formation o f confluent 
monolayers. Cells were plated directly into tissue culture wares at a maximum split 
ratio of 1 in 5. All experiments were carried out on cells between passages 15 and 
20.
2.8 Cellular Assays
2.8.1 IL-2 Bioassay
IL-2-containing supernatants were assayed for their ability to support T cell 
proliferation by means of the IL-2 bioassay (Zhao et al 1994).
Prior to setting up an IL-2 bioassay, the appropriate number of IL-2 dependent HT-2 
cells were washed twice in T cell medium (see section 2.4.26) by centrifugation at 
260g for 10 min in order to remove residual IL-2 that may be present within the 
culture. 2xl04 HT-2 cells in a volume of lOOpl of T cell medium were added to 39 
wells of a flat-bottomed 96 well plate per IL-2-containing sample to be assayed. HT- 
2 cells were then incubated in triplicate with no IL-2, or increasing concentrations of
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IL-2 supernatant [0-15%] (see Figure 2.2). Commercially available recombinant rat 
IL-2 (recombinant rat IL-2, see section 2.4.23) or a previously assayed rat IL-2 (see 
section 2.4.22) with known optimal activity was set up as a standard positive control. 
Each well was made up to a final volume of 200pl with T cell medium. Cells were 
cultured for 2-4 days at 37°C and 5% CO2 until HT-2 cells cultured in the absence of 
IL-2 appeared as resting non-proliferating cells at which time they were then pulsed 
with 0.5jaCi overnight or lpCi of methyl 3H-thymidine for 8 hours. Cells were 
adsorbed onto nitrocellulose filters using a Dynatech Cell harvester. The uptake of 
radiolabel by proliferating cells was measured by (3 scintillation counting using 
Packard Ultima Gold F scintillation fluid and a Canberra Packard 1600TR liquid 
scintillation analyser.
As illustrated in Figure 2.2 the optimum concentration of IL-2 for each supernatant 
was determined by the lowest concentration required to support maximal 
proliferation.
2.8.2 Non-contact EC assay
lx l 04 BEC and HEV EC were plated into collagen-coated and untreated wells of a 24 
well plate respectively. At confluence EC culture medium was aspirated and 
monolayers washed three times with 1ml HBSS. The media was then replaced with 
600pl of T cell medium (see section 2.4.26) containing rat IL-2 (see section 2.4.22). 
2 x 105 syngeneic Con A-activated T cell line cells in lOOpl o f T cell medium 
containing IL-2 were added to 0.4pm Costar transwell inserts (which do not permit T 
cell migration) and incubated for 24, 48 or 72h either alone or in the presence of EC 
cultured in the wells beneath the insert (Figure 2.3). Control T cells were incubated 
in T cell medium containing IL-2 for the duration o f the experiments to determine 
basal levels of apoptosis, to prevent IL-2 deprivation-induced apoptosis (Akbar et al 
1993). T cells were harvested from the transwell insert by washing twice with lOOpl 
of PBS. Cells were then stained for flow cytometric analysis as described in section 
2.9.2.
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Figure 2.2 Proliferation of HT2 cells as quantitated by methyl 3H-thymidine 
incorporation in response to increasing concentrations of rat ILr2.
The optimum concentration of IL-2 was determined as the lowest concentration to 
support maximal proliferation. In this instance the optimum final concentration of 
IL-2 was determined as 5% since at 5% IL-2, cells were observed to proliferate at 
levels comparable to that of 10% and 15% IL-2. Data is shown as the means of 
triplicate wells ± S.D.
80
Rachel Ann Harry Materials and Methods
°  o  °  O
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EC monolayer
Figure 2.3 showing the relationship of T cells to EC in the non-contact assay.
T cells are cultured for 24, 48 or 72h within inserts, above EC monolayers cultured in 
the wells beneath. During assay all cells were cultured in T cell medium containing 
rat IL-2. The 0.4pm inserts prevent contact of T cells with EC.
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2.8.3 Transmigration Assay
lxlO4 BEC and HEV EC were plated out into 3.0pm collagen-coated or tissue culture 
treated Costar transwell inserts respectively, and cultured in 24-well plates with 600pl 
of the respective EC media (see section 2.4.7 and 2.4.14) in the well beneath the 
insert. At confluence EC culture medium was aspirated from the lower chamber of 
the assay plate and washed with 1ml of HBSS and replaced with 600pl of T cell 
medium (see section 2.4.26) containing IL-2 (see section 2.4.22). Culture medium 
was carefully aspirated from the monolayers and the cells were washed three times 
with lOOpl of HBSS. 3 x 105 syngeneic Con A-activated T cell line cells (>passage 
3) in lOOpl of T cell medium containing IL-2 were added directly onto the EC 
monolayers and incubated for 24 or 48h. Non-migrated T cells were harvested by 
washing of the monolayers three times with lOOpl o f PBS (Figure 2.4). Migrated T 
cells were harvested by washing of the lower well with 600pl of PBS. Adherent T 
cells or T cells in the process of migrating through the EC monolayers were harvested 
by trypsin/EDTA dissociation of the monolayers and were then incorporated into the 
migrated T cell population. Control T cells were incubated in complete T cell 
medium containing IL-2 in the absence of EC to determine basal levels of apoptosis 
in the highly activated T cell populations. Cells were then stained for flow 
cytometric analysis as described in section 2.9.2.
2.8.4 Trucount Assay
The levels of cells which migrated through BEC and HEV monolayers were 
quantitated using the BD Trucount assay. The assay was performed according to the 
manufacturer’s instructions. Briefly migrated T cell populations (see Figure 2.4) 
were recovered from the lower chamber and incubated in BD Trucount tubes. Cells 
were then stained with anti rat-CD5-PE and then aquired on a BD FACScan 
cytometer.
Absolute cell numbers were determined by the number o f CD5+ cells divided by the 
number of beads multiplied by the bead concentration.
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Figure 2.4 showing the relationship between T cells and EC during the 
transmigration assay.
Panel A; EC monolayers were cultured within the insert and T cells added for 24, 48 
or 72h directly to confluent monolayers. During assay all cells were cultured in rat T 
cell medium in the presence of rat IL-2. The transwell inserts contain 3.0pm pores, 
which permit only active migration of T cells to the lower chamber. Panel B shows 
the T cell populations investigated in the transmigration assay. Non-adherent or 
loosely adherent T cells within the insert were harvested and comprised the “non­
migrated” T cell population. T cells in the well beneath were harvested and 
comprised the “migrated” T cell population. Firmly adherent T cells or those in the 
process of migration are obtained by trypsinisation of the EC monolayer and 
incorporated into the migrated T cell population.
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2.8.5 Functional FasL Bioassay
The mouse lymphocytic leukaemic L1210 and L1210Fas cell lines (kind gifts o f P. 
Golstein, Marseilles, France) were cultured in vitro in order to determine the function 
of FasL expressed by the EC lines. The close homology and subsequent cross­
reactivity of mouse to human Fas has been demonstrated (Brunner et al 1995). 
Therefore we investigated the functional cross reactivity of the transfected human 
Fas-Fc protein expressing L1210 cells against the rat FasL expressing BEC.
2xl06 target L I210 and L1210Fas cells were radiolabeled for 2h with 20pCi of 
methyl 3H-thymidine. Cells were then washed twice with 50ml of warm wash buffer 
to remove any excess non-incorporated methyl 3H-thymidine. lx l0 5 L1210 and 
L1210Fas cells were incubated in triplicate in lOOpl volumes with unstimulated or a 
range of cytokine treated BEC and HEV monolayers in a flat-bottomed 96 well plate 
at a range of target to effector cell ratios. L1210 cells were incubated alone as a 
negative control or with FasL expressing rat or mouse T cells or a human B cell 
lymphoma cell line (J-Y; Palmer and van Seventer 1997) as positive controls. Cells 
were incubated overnight at 37°C and 5% CO2. Cells were then harvested and 
incorporated methyl 3H-thymidine radiolabel levels quantitated by adsorption of 
intact radiolabeled cells to nitrocellulose filters using a Dynatech Cell Harvester and 
subsequent quantitation of radiolabel by p-scintillation spectroscopy.
L1210 and L1210Fas cells incubated alone were used as controls to determine 100% 
viability. Viability of LI 210 and L1210Fas cells incubated in the presence o f EC was 
expressed as a percentage of control viability. FasL mediated cytotoxicity was 
calculated as the loss of cell viability represented by a loss of radiolabeled L1210Fas 
cells using the following equation:
(cpm of control labelled cells) -  (cpm of labelled cells + EC)
-----------------------------------------------------------------  x 100
cpm of control labelled cells
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2.8.6 T cell viability
The viability and cell surface expression of the rat leukocyte surface antigen CD5 and 
ICAM-1 on T-lymphocytes and retinal EC respectively, in response to lovastatin 
treatment was determined by PI staining and flow cytometry. Viability was 
determined by PI exclusion (Pavlik et al 1985).
Lewis rat Con A T cell line cells were set up at lxlO6 cells/ml in T cell medium (see 
section 2.4.26) containing IL-2 (see section 2.4.22) in the absence or increasing 
concentrations of lovastatin [O.l-lOOpM] and cultured for up to 5 days. 1 x 1 0 6 T  cells 
were harvested at each timepoint into 1.5ml microfuge tubes. Cells were centrifuged 
at 336g for 5 min and the supernatant carefully removed. Cells were then agitated 
and incubated with 4pl of anti-CD5-RPE for 30 min on ice in the dark. Cells were 
then washed with 1ml of PBS and centrifuged at 336g for 5 min. The cells were 
again agitated and resuspended in 200pl of PBS. Samples were then transferred to 
FACS tubes for acquisition on the flow cytometer. Immediately prior to the 
acquisition of each sample, 2 pi of PI [1 mg/ml] was added to each sample tube and to 
the relevant controls. CD5 PE was detected within FL2 while PI emits at wavelength 
617 nm that was detectable within the FL3 channel of the FACScan.
EC monolayers either untreated or pretreated for 24h with increasing concentrations 
of lovastatin [O.l-lOOpM] or C3 transferase [lOpg/ml] were prepared for flow 
cytometric analysis as described in section 2.7.1. EC were then stained with 
50pl/tube of the 1A29 anti-rat ICAM-1 antibody [10pg/ml]. Cells were incubated on 
ice for 30 min in the dark. Cells were then washed with 1ml of PBS and centrifuged 
at 336g for 4 min. The supernatant was poured off and the pellet agitated. Cells were 
then incubated with 50pl of donkey anti-mouse IgG-FITC [1/50 v/v] in PBS for 30 
min on ice in the dark before washing with 1ml of PBS. Cells were centrifuged at 
336g for 4 min, the supernatant was poured off and the pellet agitated. The cells were 
then resuspended in 200pl of PBS and transferred to FACS tubes for acquisition. 
Prior to acquisition 2 pi o f PI [1 mg/ml] was added to each sample tube and the
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relevant controls. ICAM-1 FITC was detected within the FL1 channel while PI was 
detected in FL3.
For control purposes four samples of lx l06 T-lymphocytes or EC were permeabilised 
using a Cytofix/Cytoperm kit. 1 OOpl of cytofix/cytoperm was added to each sample 
tube and cells incubated on ice for 20 min in the dark. Cells were either unstained to 
determine the live population, single stained for CD5-PE, ICAM-1 FITC or PI and 
used to determine compensation and also to determine PI positive and negative cells 
or double stained for CD5 and PI or ICAM-1 and PI to confirm compensation 
settings. Cells were stained as for test samples however post permeabilisation with 
Cytofix/cytoperm, cells were washed with 1 ml of Perm/Wash. Control tubes were 
resuspended in 200pl of PBS and transferred to FACS tubes prior to acquisition. 2pl 
of PI [1 mg/ml] was added immediately prior to acquisition to the relevant controls.
Cells were acquired using CellQuest software (BD). Gates were set to exclude non- 
viable cells on forward scatter and side scatter plots, counting at least 10000 events 
within the gate. PI stained permeabilised cells were used to determine live and dead 
cells. Cells exhibiting a mean fluorescence intensity (MFI) of >103 were classified as 
PI positive and thus dead. Data was expressed as a percentage of untreated viable 
cells.
2.8.7 PLN-Lymphocyte Adhesion Assay
PLN T cells were prepared as described previously (see sections 2.5.3, 2.6.4), 
activated with ConA [5p,g/ml] for at least 24h prior to use in the following adhesion 
assay.
Con-A activated PLN cells were labelled with Calcein AM [1 jlxM ] at 5x106 cells/ml 
in PLN T cell medium for 30 min at 37°C. Cells were then washed with wash buffer 
and 1x10s fluorescently labelled cells in lOOpl PLN cell medium (see section 2.4.21) 
were added to duplicate plates of untreated, statin, mevalonolactone or squalene 
pretreated REC or RPE monolayers and incubated for 90 min at 37°C, 5% CO2. The
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wells of one plate were then washed 6 times to remove non adherent cells with 
warmed Ca2+and Mg2+ free HBSS and replaced with lOOpl PLN cell medium. The 
unwashed plate was used to determine total adhesion. Plates were then centrifuged at 
200g for 5 min at 20°C to collect cells at bottom of wells. Plates were then read on a 
Tecan Safire fluorescent plate reader taking an average o f 10 readings o f 9 points 
within each well. Readings were normalized by the subtraction of values for medium 
alone.
The percentage of cell adhesion was calculated as the ratio o f adhesion mediated 
fluorescence (washed plate) as a percentage of total fluorescence per well (unwashed 
plate). Percentage adhesion for treatment groups was expressed as a percentage of 
control. Twelve wells were assayed per condition per experiment. Each experiment 
was performed in triplicate.
2.8.8 Time-lapse video microscopy transmigration assay
The effect of lovastatin treatment of EC upon T cell migration was investigated using 
a method of time-lapse video microscopy previously developed within the laboratory 
(Pryce et al 1997, Adamson et al 1999).
REC and RPE cells were cultured in flat-bottomed 96 well plates until confluent. At 
confluence, cells were either untreated or pretreated with increasing concentrations of 
lovastatin [0-100jaM] in the presence or absence o f mevalonolactone or squalene. EC 
monolayers were washed three times with 200pl of HBSS and, at 10 min intervals, 
2xl04 SAg specific T cells in lOOpl of rat T cell medium (see section 2.4.26) 
containing rat IL-2 (see section 2.4.22) were added to the EC monolayers. Cells were 
allowed to settle and migrate over a 4h period at 37°C, 5% CO2. T cell migration was 
recorded using a Carl Zeiss inverted microscope linked to a Macintosh computer and 
Macintosh Openlab data acquisition software in a temperature and CO2 controlled 
environment. 30 images were captured at 10 second intervals and composite videos 
produced.
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Lymphocytes on the surface of the monolayer were identified by their highly 
refractive morphology (phase-bright) and rounded or slightly spread appearance. 
Migrated cells were phase-dark, highly attenuated, and were seen to probe under the 
EC in a distinctive manner (Greenwood and Calder, 1993; Greenwood et al, 1995; 
Pryce et al, 1997).
Control percentage migration was calculated from the percentage of migrated cells as 
a proportion of the total number of cells per field of view for untreated monolayers. 
Percentage migration for treatment groups was expressed as a percentage of control. 
Ten wells were assayed per condition per experiment. Each experiment was 
performed in triplicate.
2.9 Antibody based assays
Cells were stained to quantitate the percentages of apoptotic cells within differential 
T cell subsets using antibodies directed to specific T cell markers and cell viability 
was assessed using a Live, Dead viability assay (see below).
2.9.1 Live, Dead and apoptotic cell staining.
Live cells were characterised by their inherent ability to convert the non-fluorescent 
precursor Calcein AM to fluorescent Calcein through an intracellular esterase 
activity. Calcein is a polyanionic dye, which is retained within live cells and 
produces an intense green fluorescence in live cells, which has a fluorescence 
excitation wavelength of 495nm and emission at 515nm.
Dead cells were determined by nucleic acid staining with Ethidium homodimer-1, an 
ethidium bromide analogue, which is able to permeate the cell through the 
compromised leaky cell membrane. Ethidium homodimer-1 binds to nucleic acids of 
the dead cells resulting in a red fluorescence, which is excited at a wavelength of 
495nm and emits at 635nm.
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Apoptotic cells are characterised by the uptake of YoPro-1, a PI derivative (Idziorek 
et al 1995). Early apoptotic cells stain positively for YoPro-1, a monomeric cyanine 
nucleic acid stain that is capable o f penetrating the compromised membrane of an 
early apoptotic cell. Once inside the cell the dye binds to chromatin bundles 
characteristic of apoptosis and emits a green fluorescence at approximately 509nm. 
Early apoptotic cells were defined as cells stained positively for YoPro-1. Late 
apoptotic cells were defined as cells, which stained positively for both YoPro-1 and 
EthD-1, however for our purposes were considered to be dead.
The percentage of live, dead and apoptotic cells was quantitated as the percentage of 
cells positive for a given marker as a percentage o f the total T cell population. 
Subsequent analysis calculated the percentage change in apoptosis using the 
following equation
(% YoPro+ cells test population - % YoPro+ cells control population)
--------------------------------------------------------------------------------------------  x 100
% YoPro+ cells control population
2.9.2 Differential T cell subset staining
Differential T cell subsets were identified using a panel o f monoclonal antibodies 
directed at rat T cell surface antigens (see section 2.2). Mouse anti-rat CD5-RPE was 
used as a marker o f rat T cells. Anti-rat CD4-RPE and anti-rat CD8-RPE-Cy5 were 
used to identify CD4+ and CD8+ T cells respectively. Mouse anti-rat CD25-RPE 
specific for the CD25 antigen, the IL-2 receptor a-chain, was used to identify 
activated T cells. An unconjugated IgGl mouse anti-rat CD45RC (MRC-Ox22) 
antibody was used to detect the high molecular mass isoform of the CD45RC antigen 
(Spickett et al 1983). When unprimed, naive CD4+ T cells are stimulated by antigen, 
the expression of CD45RC changes from a high molecular mass isoform to a low 
molecular mass isoform. Thus the CD45RC high molecular mass isoform may also
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be used as a marker of resting memory T cells. OX-22 was used in conjunction with 
Star-76, a rat preabsorbed goat-anti mouse IgG-RPE as a secondary antibody.
2xl05 lymphocytes per tube in lOOpl PBS were stained with a variety of 
combinations of antibodies and dyes as shown in Table 2.4. Initially T cells were 
stained by incubation for 30 min in the dark with 2pl per 105 cells for anti-CD5, anti- 
CD4, and anti-CD25 antibodies and lp l per 105 cells for Star 76 and anti-CD8. Cells 
incubated with OX-22 were incubated for a further 30 min with Star-76, a rat 
preabsorbed goat-anti mouse IgG-RPE. Cells were then incubated with 50pl of 
Calcein AM [0.2pM] (see section 2.4.3), 50pl of EthD-1 [0.1 |^M] (see section 2.4.8) 
or 50p,l of YoPro-1 [0.5pM] (see section 2.4.29) for 10 min in the dark at 4°C. Cells 
were then washed twice with 1ml PBS and resuspended in 200jul of PBS for 
acquisition on a Becton Dickinson FACScan flow cytometer and subsequent analysis 
using CellQuest analysis software (BD). Gates were set to exclude non-viable cells 
on forward scatter and side scatter plots, counting at least 5000 events within the gate.
2.9.3 Direct immunofluorescent staining of cells for FasL.
Cell preparation
Both T cells and EC were stained for FasL. 2x105 per sample of rat con A T cell line 
cells were either unstimulated or stimulated with PMA [25ng/ml] and Ionomycin 
[lpg/ml] for 6 or 24h. EC were cultured in 6-well plates and either unstimulated or 
differentially stimulated with IFN-y [100 U/ml] or IFN-y [50U/ml] in the presence or 
absence of TNF-a [5-100U/ml] for 24, 48 or 72h.
To investigate the effects of matrix metalloproteinases upon FasL expression, both T 
cells and EC were cultured for the duration of the stimulation in the presence of 
increasing concentrations of KB8301 [0-1 OpM] an inhibitor of matrix
metalloproteinase 7 (a kind gift o f Professor Hideo Yagita, Tokyo; Kayagaki et al 
1995).
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FL1 FL2 FL3
YoPro-1* EthD-1* -
Calcein* EthD-1* -
YoPro -1 CD5-PE -
YoPro -1 CD4-PE -
YoPro -1 CD25-PE CD8-CY5
YoPro -1 Ox22-Star76 -
Table 2.4 Combinations of fluorescent-conjligations used for staining of T cell 
populations for cell viability and apoptosis on the differential T cell subsets.
*Denotes staining performed upon control T cell populations cultured in the presence 
of IL-2 but in the absence of EC.
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Cell surface staining
Cells were incubated with 40jLtl biotinylated hamster anti-mouse/rat FasL antibody 
MFL4 at a range of concentrations [1/10 -  1/400 dilution v/v) in PBS for 30 min on 
ice in the dark. Cells were then washed with 1ml o f PBS and centrifuged at 336g for 
4 min. The supernatant was poured off and the cells agitated. Cells were then 
incubated with 5 pi of undiluted streptavidin-PE (SA-PE) and incubated for 30 min on 
ice in the dark. Cells were again washed with 1ml of PBS and centrifuged at 336g for 
4 min. The supernatant was poured off and the cells agitated prior to resuspension in 
200pl of PBS and transfer to FACS tubes for acquisition on the BD FACScan flow 
cytometer. Control untreated EC were stained with 5 pi o f SA-PE alone to determine 
non-specific staining of the secondary antibody.
Cells were also double stained for FasL, using ICAM-1 expression as a positive 
control. Cells were incubated with 50pl of 1A29 anti-ICAM-1 antibody [lOpg/ml] 
for 30 min on ice in the dark and washed with 1ml of PBS prior to incubation with 
50pl of donkey anti-mouse IgG-FITC at a 1/100 dilution (v/v) for 30 min on ice in 
the dark. Control cells were incubated with donkey anti-mouse IgG-FITC alone to 
determine non-specific binding of the secondary antibody. Cells were then stained 
for FasL, as described previously, prior to acquisition for flow cytometry.
2.9.4 Intracellular cytokine staining.
In order to permeabilise the cells, cells were incubated with 1 OOpl cytofix/cytoperm 
for 20 min on ice in the dark. Cells were then washed with 1 ml of Permwash by 
centrifugation at 336g for 2 min. Permwash contains a detergent called saponin, 
which has the effect of maintaining the pores in cell membranes created by 
incubation with cytofix/ cytoperm solution. Subsequent steps were carried out in the 
presence of saponin. Cells were incubated with 40pl biotinylated anti-FasL MFL4 
antibody at a range of concentrations [1/10-1/400 dilution v/v] in PBS for 30 min on 
ice in the dark. The cells were then washed with 1 ml o f Permwash before incubation 
with 5pi of undiluted SA-PE for 30 min on ice in the dark. Cells were washed with 
lml of Permwash and centrifuged at 336g for 4 min. The supernatant was poured off
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and the cells resuspended in 200pl of PBS. Cells were transferred to FACS tubes for 
acquisition on a BD FAC Scan flow cytometer. Control cells were incubated with 
SA-PE alone to determine non-specific binding of the secondary antibody.
Cells stained for intracellular FasL were also stained for cell surface ICAM-1. In this 
situation cells were stained with 1A29 anti-ICAM-1 antibody and donkey anti-mouse 
IgG FITC as described for cell surface staining. Cells were then permeabilised and 
stained as described above.
T cells and EC were subsequently stained for cell surface and intracellular FasL using 
anti-human FasL FSLOl [1/25 dilution v/v] with 50pl o f rabbit anti-mouse IgM p 
chain [1/50 dilution v/v] as a secondary antibody and also anti-human FasL 4H9 
[lOpg/ml] and anti-human FasL 4A5 [lOpg/ml] in conjunction with goat anti hamster 
IgG FITC [1/50 dilution v/v]. The antibody concentrations used were recommended 
by the manufacturer.
Gates were set to exclude non-viable cells on forward scatter and side scatter plots, 
and at least 5000 events were analysed within the gate.
2.9.5 Immunocytochemistry and Confocal Microscopy
The anti-rat FasL antibody, MFL4 had not been previously tested for use in 
immunocytochemistry and confocal microscopy. Cells were stained following a 
protocol described by Bossi and Griffiths (1999) although a different cell type and 
antibody were to be used. Cells were stained with lOOpl of the MFL4 Ab [lOpg/ml] 
for 30 min at RT in the dark. Cells were then washed three times with 3ml of PBS. 
Cells were then stained with lOOpl of SA-Texas Red [1/100 dilution v/v] for 30 mins 
in the dark at RT and lOOpl of Hoescht [1/100 dilution v/v]. Cells were then washed 
three times with 3ml of PBS, prior to mounting of cells with MOWIOL. Cells were 
then analysed using a Zeiss LSM 510 confocal microscope and LSM 5 Image 
Browser software.
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2.10 Mouse soluble Fas ligand ELISA.
A commercially available mouse Fas ligand ELISA was tested to quantitate sFasL 
production by rat cells due to the 91% homology of mouse and rat FasL at the amino 
acid level. Rat sFasL concentrations were determined in cell supernatants of BEC and 
HEV monolayers which were either untreated or differentially stimulated with 
cytokines at a range of concentrations and combinations. Rat T lymphocyte 
supernatants stimulated with PMA [25ng/ml] and ionomycin [lpg/ml] for 6 or 24h 
were used as a positive control. Essentially the ELISA was performed as per the 
manufacturer’s instructions. Briefly, all reagents were brought to RT before starting 
the experiment. The assay employed a quantitative sandwich enzyme immunoassay, 
in which a monoclonal antibody specific for mouse FasL had been pre-coated onto 
the 96-well microplate. Standard curves were generated by 2-fold serial dilution of 
the supplied mouse Fas ligand standard solution ranging from 0-2000pg/ml. All 
samples and standards were assayed in duplicate in order to produce statistically 
significant data. Samples were incubated with the pre-coated plates for 2h whilst 
agitating at room temperature followed by washing 5 times with wash buffer 
(supplied). lOOpl FasL conjugate was added to each well for 2h. The plate was 
washed as before, in preparation for the addition of lOOpl o f substrate solution for 30 
min in the dark with gentle agitation to ensure thorough mixing. 1 OOpl Stop Solution, 
containg 4N NaOH was then added to each well and the optical densities determined 
using a SpectraCount microplate reader (Beckman). Triplicate readings of each well 
were taken at 450nm and 540nm to correct for optical imperfections in the plate and 
sFasL concentrations were normalized to the Opg/ml standard and calculated using 
the regression formula of the linearized standard curve. Mean concentrations were 
calculated from the duplicate wells. The mean lower limits of detection of this 
ELISA was 3.6pg/ml.
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2.11 Reverse transcriptase - polymerase chain reaction (RT-PCR)
2.11.1 RNA extraction
Total RNA was extracted from BEC and HEV monolayers using an RNeasy kit, 
(Qiagen, UK) according to the manufacturer’s instructions. After complete removal 
o f medium from the wells, cells were lysed by addition o f lysis buffer RLT 
containing p-mercaptoethanol (p-ME) [1% v/v]. Cell lysate was passed through a 
sterile (RNase-free) syringe and 20 gauge needle (0 .9  mm) 15 times in order to 
homogenize any high molecular weight DNA. RNA was extracted using the 
chloroform and ethanol method and air dried before being resuspended in 30pl 
diethylpyrocarbonate-treated distilled water (DEPC-H2O).
lpl of extracted RNA was diluted in 70pl DEPC-H2O in order to determine purity 
and concentration of RNA by spectrophotometric analysis, using the A26o^ A28o ratio 
to determine RNA purity, with an absorbance of 1 unit at 260nm corresponding to 
40pg RNA per ml. Total RNA was calculated using the following formula:
RNA yield [pg/ml] = A260x40x dilution factor
2.11.2 Complementary Deoxyribose Nuceleic Acid (cDNA) synthesis
2jug of RNA was then reverse transcribed to cDNA using the Superscript First-Strand 
Synthesis System for RT-PCR according to the manufacturer’s instructions. Briefly, 
cDNA synthesis was catalysed by superscript II reverse transcriptase using 
oligo(dT)i2-ig-primers to hybridise to 3’ poly (A) tails. 2 pg total RNA was denatured 
with 0.5 pg oligo(dT) at 65°C for 5 min and chilled on ice. The reaction mixture, 
consisting of 10 mM deoxynucleotide triphosphates (dNTP); mix; lOx PCR buffer; 
25mM MgC^; and lOmM DTT; was then added to the RNA/oligo(dT)i2-i8 primers to 
make a volume o f 19pl. This mixture was then warmed to 42°C for 5 min before 
addition of 1 pi Superscript II reverse transcriptase and incubated at 42°C for 50 min. 
Finally, heating at 70°C for 15 min terminated the reaction and the cDNA was stored 
at -20°C until use.
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2.11.3 PCR amplification
2pl aliquots o f each cDNA preparation were amplified by PCR. The rat specific 
primers used for p-actin and FasL were: p-actin (sense: 5’-
ATGAGGTAGTCTGTCAGGT-3’; antisense: 5’-ATGGATGACGATATCGCTG- 
3’) (Nudel et al 1983) and FasL (sense: 5’-CCCTCTAAAGAAGAAGG-3’; 
antisense: 5’-AAATGGTCAGCAACGGTAAG-3’), giving 591 and 589 base pair 
(bp) products respectively. A PCR reaction mixture containing 10 x RT-buffer; 
25mM MgC^; lOmM dNTP mix and 1U Taq DNA polymerase was added to the 
cDNA/primers to reach a final volume of 50pl and this was overlaid with one drop of 
mineral oil. PCR conditions optimized for rat p-actin primers were: denaturation at 
94°C for 1 min, annealing at 60°C for 1 min, and extension at 72°C for 1 min for 30 
cycles in a DNA thermal cycler. PCR conditions optimized for rat FasL primers were: 
denaturation at 94°C for 1 min, annealing at 57°C for 1 min, and extension at 72°C 
for 1 min for 40 cycles. CCI3 was added to each tube and 10pl of the aqueous phase 
removed (PCR product). 10pl of the PCR products were then mixed with 10pl 
loading buffer and resolved by 1.5% agarose gel electrophoresis visualized by 
ethidium bromide. A 1 OObp DNA ladder was used as a molecular weight marker and 
the size of all DNA products corresponded to that predicted. All experiments were 
performed using cDNA samples positive for rat p-actin. To confirm specificity o f the 
PCR reaction for rat FasL PCR, products from each amplification protocol were 
isolated and cycle-sequenced on an ABI PRISM automated DNA sequencer and the 
identity of the amplicon was confirmed using NCBI Genebank.
For quantification of relative band intensities, both FasL and P-actin were confirmed 
to be in the linear part o f the PCR scale by cDNA concentration titration for P-actin 
and cycle titration for FasL (not shown). Data was obtained using P-actin at a 1/400 
dilution of cDNA and FasL at 36 cycles. All positive bands were of the expected size. 
Relative band intensity was then quantitated using ScanAnalysis v2.50 software and 
the relative amounts of FasL mRNA expression were calculated as a proportion of the 
P-actin expression in each sample.
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2.12 Western blotting
2.12.1 Cellular lysates for Western blotting
To test whether the FSLOl, anti-human FasL antibody was able to recognise rat 
FasL, cellular lysates were prepared from unstimulated and stimulated rat T cell 
cultures as a positive control, lx l0 6 T cells were set up at 2x l05 cells/ml in T cell 
medium (see section 2.4.26) and either untreated or stimulated for 6 or 24h with PM A 
[25ng/ml] and ionomycin [lng/ml]. Cells were harvested by centrifugation and lysed 
at 4°C for 15 min in 500pl of ice cold lysis buffer containing HEPES [lOmM pH 
7.5], NP-40 [0.25% v/v], magnesium chloride [1.5mM], sodium chloride [50mM]), 
EGTA [0.5mM], (3-glycerophosphate [50mM], sodium orthovanadate [ImM], PMSF 
[0.5mM], leupeptin [lOpg/ml], aprotinin [lOpg/ml] and sodium fluoride [ImM]. The 
lysate was collected and centrifuged for 10 min at 4°C at 12000g. Protein 
concentrations were determined using a standard Bradford protein assay and then 
stored at -70°C.
2.12.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
20pg of protein in SDS sample buffer was added per lane of a 10% polyacrylamide 
gel. Cellular proteins were resolved by SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) under reducing conditions. Proteins were then transferred by semi-dry 
blotting to a nitrocellulose membrane.
2.12.3 Immunoblotting
Immunoblotting of FasL protein was attempted using the mouse-anti human FasL Ab 
clone FSLOl from Biocarta as it had previously been demonstrated to recognise FasL 
using this method. Although the FSLOl antibody is a mouse IgM antibody, upon 
speaking to the manufacturer we tested the cross reactivity of Protein A/G with this 
antibody using the method below.
Membranes were blocked with 5% Marvel-PBS (M-PBS) for lh  at RT. Membranes 
were then washed twice with Tween 20/PBS (PBST; 1% v/v). Immunoblotting for
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FasL was performed using the mouse anti-human FasL antibody FSL01 [1/25 
dilution v/v) in M-PBS for 2h with continuous agitation at RT. Membranes were 
then washed twice with PBST and incubated with Protein A/G-HRP [1/10000 
dilution v/v] in M-PBS. Membranes were washed for lh  and proteins were then 
visualised by enhanced chemiluminescence (ECL) and X-ray film.
2.13 In vivo assays
2.13.1 Induction of Rat EAU
Experimental Autoimmune Uveoretinitis (EAU) was induced using SAg peptide 
(PNSSLTKTLTLVPLLANNRE; Fling et al 1989). EAU was induced in 4-6 week 
old female Lewis rats by hind footpad (50pl) and base-of-tail immunisation
0*72  O C O(remainder) with 50-600pg soluble retinal Ag peptide ‘ [2mg/ml] emulsified 
complete Freunds Adjuvant (CFA) supplemented with Mycobacterium Tuberculosis 
(strain H37Ra, final concentration 2.5mg/ml). Animals were also inoculated with 
5xl09 Bordetella pertussis organisms in a lOOpl volume intraperitoneally.
2.13.2 Treatment of EAU
The effect of lovastatin on EAU was assessed by in vivo administration of lovastatin. 
Lovastatin was dissolved in DMSO: PBS [1:1 dilution v/v] prior to administration. 
All animals were anaesthetised with isofluorane prior to intraperitoneal delivery of 
therapeutics. EAU animals were either treated daily with DMSO:PBS to serve as a 
vehicle control or treated with lovastatin [20mg/kg/day]. A further group of animals 
induced with disease were also treated with lovastatin [20mg/kg/day] and twice daily 
doses of mevalonolactone [2mg/kg] according to previous work by Greenwood et al 
2003. Mevalonolactone was administered to determine whether addition of 
exogenous mevalonolactone, a metabolic product downstream of lovastatin action 
was able to modify the effects of lovastatin. Lovastatin therapy commenced day 6 
post-immunisation and continued daily until expected peak of disease (day 15). Non­
diseased non-immunised animals served as normal controls.
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2.13.3 Fluorescein Angiography (FA)
Clinical progress of control animals and those induced with EAU were visualised by 
FA. In order to do this, animals were anaesthetized with 0.2ml/100g o f a 
Domitor:Ketamine solution [25%:37.5% v/v]. Pupils were dilated using Tropicamide 
[1%] and Phenylephrine [2.5%]. Animals were restrained using a mouthpiece and 
200pl of Fluorescein [10%] was injected intraperitoneally and the left eye visualized 
using a scanning laser ophthalmoscope. Saline solution was administered to the 
cornea during visualization. Early angiograms were captured between 2 and 7 min 
and late angiograms were captured 8-15 min post fluorescein injection.
Post SLO/FA analysis animals were resuscitated with O.lml/lOOg o f Antisedan (20% 
v/v). Animals were monitored until recovery from anaesthesia. FA was performed in 
a blinded manner. Grading of vascular disease was performed following the criteria 
documented in Table 2.5.
2.13.4 Clinical grading of EAU
Experimental animals were graded for the severity of disease daily from day 5 to 
expected peak of disease and subsequent termination o f animals at day 15 or day 22. 
Clinical examination of eyes was performed by two observers. Table 2.6 details the 
criteria employed to determine severity o f disease induced.
2.13.5 Retinal histology
Animals for which eyes were required for histological analysis were terminally 
anaesthetized with 500pl of Euthatal. The thorax was opened at the base of the 
sternum and the diaphragm cut to expose the chest cavity and the lungs. Two 
incisions were made up the left and right hand side of the chest and then restrained 
using a clamp. The liver was lifted to reveal the descending aorta, which was 
subsequently clamped. The thin pericardium was removed from the heart and an 
incision made into the right atrium. A larger incision was made into the left ventricle 
just above the point of the heart. A small gavage needle attached to the perfusion
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Grade Fluorescein angiographic signs
0 Normal. No leakage.
1 Mild leakage: hazy but reasonable view of optic disc, optic cup and retinal
vessels entering the optic disc.
2 Moderate leakage: unable to identify optic disc and retinal vessels
entering the optic disc clearly.
3 Severe leakage: no view of optic disc, optic cup or retinal vessels entering
the optic disc.
Table 2.5 Criteria for the grading of vascular disease.
Scoring of severity of vascular disease was performed following the above criteria.
Fluorescein angiograms were scored in a blinded manner.
Clinical grade Clinical signs
0 Normal. Clear medium with good red reflex.
1 Minimal but clearly positive signs of inflammation with occasional
cells in Anterior chamber. Dilation of iris vessels.
2 Presence of anterior chamber cells with minimal hypopyon.
3 Diffuse exudates within AC and vitreous plus moderate hypopyon.
Dull red reflex. Synechiae.
4 Presence of large cellular and fibrinous exudates. (AC very
cloudy). Large hypopyon in AC. Loss of red reflex.
5 Presence of grade 4 with gross orbital oedema and proptosis of
globe.
Table 2.6 Criteria for the clinical scoring of EAU.
Clinical scoring of EAU was performed following the above criteria and animals
were scored in a blinded manner. Criteria adapted from Merryman et al (1991).
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pump was inserted into the hole in the ventricle and the needle was inserted high up 
towards the ascending aorta and clamped in place. The rat was then perfused with 
50mls PBS at 15ml/min. The vessels within the chest cavity were observed to ensure 
perfusion of blood. The animals were then fixed to maximise preservation of the 
ocular vessels with 35ml Kamovsky’s half strength solution pH 7.4 (1% 
paraformaldehyde and 3% glutaraldehyde in 0.1M sodium cacodylate-HCl). 
Stiffening of limbs was ensured prior to ceasing fixation. The eyes were enucleated 
and stored in Kamovsky’s fixative until subsequent processing for histological 
analysis.
Animals whereby tissues in addition to the eyes were required for further cellular 
analyses were not perfuse-fixed. Following schedule 1 killing, eyes were enucleated, 
pierced with a 21 gauge needle and immersion-fixed in Kamovsky’s fixative for at 
least 24h prior to processing.
2.13.6 Histological preparation of retinal sections.
Segments o f eyes perfuse-fixed with glutaraldehyde [3% w/v] and paraformaldehyde 
[1%] in sodium cacodylate-HCl buffer [0.08M, pH7.4] were rinsed (x3) in PBS and 
immersed in aqueous osmium tetroxide solution [1% w/v] for 2h at RT. Tissue was 
then rinsed in distilled water (x3), dehydrated by single 15 min incubations in 50%, 
70% and 90% 3 x 100% ethanol, 2 x 20 min changes o f propylene oxide and left 
overnight in a 1:1 mixture of propylene oxide:araldite to infiltrate. This was changed 
for full resin and left on a rotator for 6h before embedding and overnight 
polymerization at 60°C. Semithin sections for examination by light microscopy were 
cut using a Leica ultracut S microtome and diamond knife, stained with a mixture of 
borax [1%] and toluene blue [1%] in ethanol [50%] at 60°C, dried and mounted in 
DPX.
All stains and resins were supplied by Agar Scientific Ltd, Essex. All histological 
preparation was carried out by Dr Peter Munro, Institute o f Ophthalmology, UCL.
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2.13.7 Histological Analysis
Histological analysis was performed on retinal sections from normal, vehicle, 
lovastatin and lovastatin and mevalonolactone treated animals. Sections were graded 
using criteria (Table 2.7) adapted from those previously described by Merryman et al 
(1991). Light micrographs of toluene blue stained histological rat retinal semi-thin 
sections were taken using a Zeiss LSM 510 confocal microscope operating in 
transmission mode using a FITC configuration.
2.13.8 Splenocyte Proliferation Assays
Splenocytes were harvested from normal, vehicle, lovastatin treated and lovastatin 
and mevalonolactone treated rats. Cells were processed (as described in section 
2.5.3) and resuspended at 2xl06/ml in T cell medium (see section 2.4.26). 4x105 cells 
were added per well o f a flat bottomed 96-well plate and cells incubated in triplicate 
either unstimulated or stimulated with SAg peptide [5pg/ml or lOpg/ml] or Con A 
[5pg/ml] in the absence or presence of exogenous lovastatin [1-lOp.M]. Proliferation 
of the splenocytes was quantitated when unstimulated cells appeared as resting non­
proliferating T cells, by the addition of lpCi of methyl 3H-thymidine for a further 
18h. Cells were then adsorbed to nitrocellulose filters using a cell harvester. Methyl 
H-thymidine incorporation was then measured by p-scintillation counting.
2.13.9 Adoptive transfer of Rat Experimental Autoimmune Uveoretinitis
In order to determine whether Lewis rat SAg peptide273'289 primed PLN T cells were 
capable of inducing disease in naive animals i.e. uveitogenic, an adoptive transfer 
model was employed. PLN were isolated from SAg peptide immunised Lewis rats 
and processed as described previously (see section 2.5.3). T cell lines were 
established as described in section 2.6.5 and after 6 passages, lxlO6 or 5xl06 recently 
activated (24-48h) SAg peptide specific T cells were immunised via tail vein or 
intraperitoneally into 4-6 wk old Lewis rats. EAU disease was monitored by clinical 
scoring, SLO/FA and histological analysis as described previously (see sections 
2.13.3, 2.13.4, and 2.13.7).
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Grade Histological signs 
0 Normal
1 Minimal signs of inflammation. Occasional inflammatory cells in the 
vitreous base or scattered cells in the neuroretina or adjacent to the ciliary 
body. V. minor focal retinal detachment generally around optic nerve and 
occasional focal retinal folding.
2 Uniform inflammatory cell infiltration of the photoreceptor cell layer (PR), 
outer nuclear layer (ONL) and inner nuclear layers (INL) o f the retina and 
infiltration of the vitreous cortex. Some perivascular cuffing. Retinal 
damage < 20%
3 Infiltration of the PR layer, ONL and INL of the retina with some retinal 
detachment (20-50%). Moderate retinal folding, diffuse cellular infiltration 
of the vitreous, and moderate uveal involvement.
4 Full thickness involvement of the retina, serious retinal detachment and 
folding. Subretinal exudate. Necrosis and gliosis, substantial uveal 
involvement
5 Severe retinal damage with destruction of the photoreceptor layer. Large 
scale retinal folding and large subretinal exudate. Massive cellular 
infiltrate and loss of anatomical structure.
Table 2.7 Criteria for histological analysis of EAU.
Histological analysis was performed upon toluene blue stained sections by two 
independent observers following the above criteria adapted from Merryman et al 
1991.
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2.13.10 Induction of mouse EAU
Male B10.RIII (7INS) mice (5-7 weeks old; >19g body weight; Harlan Olac) were 
immunised bilaterally subcutaneously with 25ju.g o f human IRBP peptide161'180 
(SGIPYIISYLHPGNTILHVD), emulsified in incomplete Freund’s adjuvant 
supplemented with 60pg/ml Mycobacterium Tuberculosis, as previously described 
by Hankey et al (2001).
2.13.11 Treatment of EAU
The effect o f lovastatin and atorvastatin on EAU was assessed by in vivo 
administration o f statins. Lovastatin was dissolved in DMSO:PBS (1:1 v/v) prior to 
administration while atorvastatin was dissolved in PBS. Administration of lovastatin 
was via intraperitoneal injection while atorvastatin was administered by oral gavage. 
EAU animals were either immunised daily with DMSO:PBS to serve as a vehicle 
control for lovastatin treated animals, treated with lovastatin [20mg/kg/day], or 
following a loading dose of lovastatin [lOOmg/kg] animals were immunised twice 
daily with lovastatin [20mg/kg]. A further group of animals induced for disease were 
also treated with lovastatin [20mg/kg/day] and twice daily immunisations of 
mevalonolactone [2mg/kg] or squalene [2mg/kg/day]. Animals were also 
administered with PBS by oral gavage as a vehicle control for animals treated with 
atorvastatin [10mg/kg/day]. Statin therapy commenced 5 days post immunisation 
and continued until expected peak disease (day 12; Hankey et al 2001). Non­
diseased, non-immunised animals served as normal controls.
2.13.12 Fluorescein angiography
Fluorescein angiography (FA) of the right eye was performed using a method 
previously described (Hawes et al 1999). FA was on carried out on 3 normal control 
animals and, at day 10 post-immunisation, on 7 vehicle treated EAU animals, 6 EAU- 
induced animals treated with lovastatin [20mg/kg], 6 EAU-induced animals treated 
with lovastatin [20mg/kg] and twice daily mevalonolactone [2mg/kg] and 6 EAU- 
induced animals treated with lovastatin [20mg/kg/day] and squalene [2mg/kg/day]. 
Mice were injected intraperitoneally with sodium fluorescein [2% v/v] at a dose of
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0.1ml per 15grams body weight. Pupils were dilated using tropicamide [1%] 20 min 
prior to examination. Using a Kowa Genesis small animal fundus camera (Tokyo, 
Japan) photographs of the retina were taken as previously described. The imaging set­
up was used in combination with a Volk 90 dioptre condensing lens (Mentor, OH, 
USA) mounted between the camera and the eye. Images were captured at 3 min and 
at 5-8 min after the injection o f fluorescein on black and white film (Kodak TMAX 
P3200) in conscious mice.
The fluorescein angiograms were assessed blind by a trained clinician for signs of 
vascular leakage, hyperfluorescence, and abnormal vascular calibre. Vascular leakage 
at 3 min after the injection of fluorescein was graded as described in Table 2.5.
2.13.13 Mouse Splenocyte proliferation
Splenocytes were harvested from each of the experimental groups at peak disease 
(day 12) and prepared as described previously (see section 2.5.3). Cells were 
resuspended at 5xl06 cells/ml in T cell medium (see section 2.4.26) and lx l0 6 cells 
were added per well o f a flat bottomed 96-well plate in triplicate wells. Cells were 
either unstimulated or stimulated with IRBP161'180 peptide [5pg/ml or 20pg/ml] or 
Con A [5pg/ml] as a positive control in the absence or in the presence o f an anti- 
MHC class II blocking antibody [0.5pg/106 cells]. Proliferation of the splenocytes 
was assessed at 72h by the addition of 1 pCi of methyl 3H-thymidine for the final 18h 
of culture. Cells were then harvested onto nitrocellulose filter using a Dynatech Cell 
Harvester, and methyl 3H-thymidine incorporation measured by P-scintillation 
counting.
2.13.14 Mouse Splenocyte cytokine production
Splenocytes were harvested from each of the experimental groups at peak disease. 
Cells were processed as described previously (see section 2.5.3) and resuspended at 
5xl06/ml in T cell medium (see section 2.4.26). lx l 06 cells were added per well of a 
96-well plate per time point and were either unstimulated or stimulated with IRBP161' 
180 [20pg/ml] or with Con A [5pg/ml]. Cells were cultured for 24-120h when the
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cells were harvested and cell supernatants collected by centrifugation of cells at 336g 
for 4 min and stored at -70°C.
IL-2, 4, 5, IFN-y, and TNF-a concentrations in the culture supernatant were 
determined by Cytometric Bead Array analysis and ELISA while IL-10, IL-12, and 
TGF-pi were assayed by ELISA alone.
2.13.15 Cytokine ELISAs
ELISAs were carried out following the manufacturers instructions, essentially 
following the protocol described in section 2 .10.
The lower limits of detection for each of the ELISAs were as follows; IL-2, 3pg/ml; 
IL-4, 2pg/ml; IL-5, 7pg/ml; IL-10, 4pg/ml; IFN-y, 2pg/ml; TNF-a, 5.1pg/ml and 
TGF-p, 2.89pg/ml.
2.13.16 Cytometric Bead Array (CBA)
The mouse Thl/Th2 cytometric bead array was used to quantitate IL-2, IL-4, IL-5, 
IFN-y and TNF-a secretion by normal, vehicle, lovastatin and atorvastatin-treated 
splenocytes. The CBA assay was carried out following manufacturer’s instructions. 
Briefly 50pl o f capture beads labelled with discrete fluorescence intensities for each 
of the different cytokines were incubated with splenocyte supernatants (unknowns), 
recombinant mouse cytokine standards and a negative control. Standard curves were 
generated over the concentration range of 0-5000pg/ml. 50pl of mouse Thl/Th2-PE 
detection reagent was added to each of the assay tubes and then incubated for 2h in 
the dark at RT. Samples were then washed with 1ml o f wash buffer (supplied) by 
centrifugation at 200g for 5 min. The supernatant was then aspirated and 300pl of 
fresh wash buffer added to each sample tube. Samples were then acquired 
immediately using a BD FACScan flow cytometer. Acquisition was performed 
following the manufacturers instructions and analysis was performed using BD 
CellQuest and BD CBA software.
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The lower limits of detection for each of the cytokines using this assay were as 
follows: IL-2, 5pg/ml; IL-4, 5pg/ml; IL-5, 5pg/ml; IFN-y, 2.5pg/ml and TNF-a, 
6.3pg/ml.
2.13.17 Determination of serum cholesterol
Serum samples were prepared from peripheral blood isolated from EAU mice at peak 
disease (day 12) by cardiac puncture. Serum samples were stored at -20°C until 
required for assay when total serum cholesterol was determined 
spectrophotometrically using the Infinity™ cholesterol liquid stable reagent 
following manufacturer’s instructions.
2.13.18 Determination of statin concentration
Plasma was prepared from peripheral blood isolated from EAU and EAE (see section 
2.13.22) mice at peak disease (day 12) by cardiac puncture and stored at -70°C until 
assay. Supernatants were also harvested from statin-treated EC monolayers and 
stored at -70°C until required for assay. Active atorvastatin acid and lovastatin 
hydroxy acid levels were determined in plasma and cell supernatants using liquid 
chromatography tandem mass spectrometry (LC/MS/MS) by HFL Contract Research 
(UK). Briefly atorvastatin acid or lovastatin hydroxy acid was extracted using a 
liquid-liquid extraction procedure followed by chromatographic separation using a 
reversed phase Phenomenex (Luna C l8, 50 x 2.0mm, 5p) analytical column. The 
analyte was ionised using an electrospray interface operating in negative ion mode 
and detection was via tandem mass spectrometry (MS/MS) in the multiple reaction- 
monitoring (MRM) mode. Simvastatin hydroxy acid was used as the internal 
standard for both analytes. The bioanalytical assays were sensitive over the 
concentration range of 0.5-500ng/ml for atorvastatin acid and l-1000ng/ml for 
lovastatin hydroxyacid.
2.13.19 Determination of Regulatory T cells
PLN cells were isolated from normal, vehicle or statin treated mice as described in 
section 2.5.3 and stained for cell surface markers of CD4, CD25 and CD62L (Fisson
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et al 2003). lx l0 6 cells were placed in a 1.5ml centrifuge tube and centrifuged at 
336g for 5 min. Cells were then agitated and stained in the dark on ice for 30 min 
with 50pl of anti-mouse CD25-PE [4pg/ml], 50pl of anti-mouse CD62L-FITC 
[2pg/ml] and 50pl of anti-mouse CD4-PerCP [20pg/ml]. After washing twice in PBS 
cells were acquired for flow cytometric analysis. Regulatory T cells were defined as 
CD62Lhl CD25+CD4+ cells and the percentage of regulatory T cells was determined 
as a percentage of the total CD4+ T cell population.
2.13.20 Detection of functional regulatory T cells
PLN cells prepared as previously described (see section 2.5.3) from a vehicle treated 
animal were labelled with CFSE following the method of Angulo and Fulcher (1998). 
Briefly cells were labelled with CFSE [lOpM] by incubation for 10 min in a 37°C 
waterbath. The labelling reaction was terminated by adding 1ml of cold RPMI 
containing FCS [10%]. Cells were then centrifuged at 336g for 5 min and 
resuspended in 1ml of RPMI-1640 supplemented with FCS [10%]. The CFSE 
labelled cells were allowed to equilibrate for 30 min at RT, recounted and then 
resuspended at lxlO6 cells/ml in T cell medium (see section 2.4.26). 1x10s CFSE 
labelled responder cells were then added per well to a flat bottomed 96 well plate. 
Cells were incubated in triplicate either alone to determine constitutive proliferation, 
in the presence of ConA [5pg/ml] as a positive control or with IRBP peptide 
[20pg/ml] to determine antigen specific proliferation. Cells incubated in the presence 
of IRBP peptide were also incubated with increasing concentrations (lx lO 3 to 2x105) 
of PLN cells isolated from vehicle, lovastatin treated or atorvastatin treated mice. 
Antigen-specific proliferation was assessed 5 days post stimulation. Cells were 
transferred to FACS tubes and immediately prior to acquisition on the flow cytometer 
labelled with 2pl of PI [1 mg/ml]. Subsequent analysis was performed upon CFSE+ 
PI' negative cells.
Data was also analysed following the method of Angulo and Fulcher (1998) where 
the percentage of blasts cells was calculated as the number o f blast T cells as a 
proportion of the total T cell population, as defined using forward scatter and side
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scatter. The percentage of divided cells was calculated as the total number of T blasts 
cells, which displayed less CFSE than the initial undivided CFSE+ T cell population 
or baseline fluorescence. The mitotic activity was then calculated to account for the 
loss of fluorescence, which is possible when considering that two cells o f a given 
CFSE intensity arose from a single mitosis of a cell possessing a CFSE intensity 
immediately greater therefore allowing the number of cell divisions that had taken 
place to be estimated relative to the starting cell number. The division index was 
calculated as 100 -  mitotic activity divided by the mitotic activity and the weighted 
division index, a measure of the total number of divisions, was calculated as the 
division index multiplied by the percentage of divided cells.
2.13.21 Intracellular Cytokine Analysis
PLN cells were isolated at peak disease from normal, vehicle or statin treated 
animals. PLN cells were prepared as described previously (see section 2.5.3) and set 
up at 2x l06/ml. 4x l05 cells plated out per well of a flat bottomed 96 well plate. Cells 
were either unstimulated or stimulated with IRBP161'180 [20pg/ml] or MOG35-55 
[20pg/ml] peptide for 96h, with Brefeldin A (BFA; [10pg/ml]) added for the final 
18h of culture. Cells were permeabilised and stained as described previously (see 
section 2.9.4) with rat anti-mouse IL-4-PE [0.5pg/106 cells] and rat anti-mouse IFN- 
y-FITC [0.5pg/106 cells]. Cells were subsequently analysed by flow cytometry.
The IL-4:IFN-y ratio was calculated as the percentage of IL-4+ cells as a percentage 
of the IFN-y+ cells
2.13.22 Induction of mouse EAE
EAE was induced in 8-12 week old female C57BL/6 mice by subcutaneous 
immunisation with 1 OOpg myelin oligodendrocyte glycoprotein peptide 35-55 (MOG35- 
55) emulsified in complete Freund’s adjuvant supplemented with Mycobacterium 
tuberculosis H37Ra [4mg/ml]. Animals were also injected with lOOng Bordetella 
pertussis toxin on the day of immunisation and 48h later (Youssef et al 2002).
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2.13.23 Treatment of EAE
The effect of atorvastatin therapy upon EAE was assessed by in vivo administration 
of atorvastatin. Atorvastatin was dissolved in PBS prior to administration. EAE 
animals were treated daily with PBS as vehicle control or with lOmg/kg/day 
atorvastatin administered by oral gavage. Treatment commenced within one day of 
clinical signs of disease being observed (Youssef et al 2002) until expected peak of 
disease at day 17.
2.13.24 Clinical grading of EAE
Mice induced with EAE were examined daily for clinical signs o f EAE. Grading was 
performed following the criteria (Table 2.8) described by Youssef et al (2002).
2.13.25 Splenocyte proliferation for EAE
Splenocytes were isolated and prepared as described for EAU animals. Proliferation 
of splenocytes in response to MOG35'55 peptide [20pg/ml] was assessed as previously 
described (section 2.13.13).
2.13.26 Splenocyte cytokine production of EAE
Splenocytes were isolated and prepared as described for EAU animals. Cytokine 
production o f splenocytes was assessed in response to MOG35'55 [20pg/ml] as 
previously described (section 2.13.14)
2.13.27 Statin Plasma concentrations
Statin plasma concentration was determined in plasma samples obtained from EAE 
induced animals as described in section 2.13.18.
2.14 Statistical analysis
Statistical analysis was performed using the Mann-Whitney U test for non-parametric 
analysis and the Students T test for analysis of parametric data. A p value of <0.05 
was considered significant while a p value of <0.01 was considered highly 
significant.
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Clinical Grade Clinical symptoms
0 No disease
1 Limp tail
2 Impaired righting reflex
3 Partial hindlimb paralysis
4 Complete hindlimb paralysis
5 Moribund or dead
Table 2.8 Criteria for the grading of clinical EAE.
Clinical EAE was graded following the criteria described above (Youssef et al 2002).
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Chapter 3
Induction of T cell apoptosis by CNS EC
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Introduction
Apoptosis or programmed cell death is essential for normal development, 
maintenance of homeostasis and for the elimination of autoreactive T cells. A 
genetically controlled cell suicide programme (Ellis and Horvitz, 1986, Vaux et al 
1988), it can be induced by a number o f signals both extracellularly and 
intracellularly. Evidence suggests that death-inducing signals may all be elicited via 
a common death effector pathway (Vaux and Strasser, 1996). A family of proteins 
called caspases mediate apoptosis of a cell. Apoptosis can be induced by stimulation 
of those members of the TNF receptor family which have a death domain (e.g. 
CD95), or by a broad range of stimuli including growth factor withdrawal. These 
pathways to effector caspase activation are distinct. Caspase-8 mediated activation of 
the pro-apoptotic BH3-only protein Bid may provide a link between these pathways 
in some cell types.
Morphological changes occur during apoptosis, which are characteristic o f this 
specialised form of cell death. During apoptosis nuclear chromatin condenses and 
cytoplasmic shrinkage and plasma membrane blebbing occurs. Apoptotic cells can 
be detected by a number of means including terminal dUTP nick end labelling: 
TUNEL which detects DNA breaks (Gavrieli et al 1991); Annexin V detects cell 
surface exposed phosphatidyl serine (Koopman et al 1994); and fluorescent dyes 
which bind to chromatin bundles e.g. YoPro (Idziorek et al 1995).
T cell effector functions include proliferation in response to antigen. In the absence 
of control mechanisms, continuous proliferation in response to antigen would result 
in expansion of the immune system. However this is not generally observed which 
suggests that mechanisms exist to maintain immune system homeostasis. Apoptosis 
is key to the regulation of T cell homeostasis by means o f three main processes. 
These are activation induced cell death (AICD), cytokine deprivation induced 
apoptosis and stromal cell mediated rescue of cytokine deprivation induced apoptosis. 
Optimal antigenic stimulation of T cells results in proliferation, whereas 
overstimulation o f T cells results in the death of the T cell by the process of AICD.
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AICD is thought to occur to protect against excessive immune stimulation and is 
therefore triggered as a result of the re-ligation of the T cell receptor (TCR) upon 
activated T cells. This form of cell death is generally encountered in the presence of 
large numbers of T cells and large quantities o f antigen (Abbas, 1996) and is known 
to be Fas-FasL dependent. Interferon-a has been shown to increase AICD through 
the upregulation of Fas and Fas Ligand (FasL; Kaser et al 1999).
In addition to being sensitive to levels of antigen, activated T cells are highly 
sensitive to cytokines. Activated T cells require IL-2 for continuous proliferation. 
Omission o f IL-2 from T cell cultures in vitro results in the phenomenon o f IL-2 
deprivation induced apoptosis, which can be rescued by reintroduction of IL-2 (Akbar 
et al 1996). IL-2 has been shown to be essential for the prevention of apoptosis in T 
cell cultures by the up-regulation of apoptosis inhibitory proteins such as Bcl-2 
(Akbar et al 1993). In addition to IL-2, cytokines such as IL-4, IL-7 and IL-15, 
which signal through the y-chain of the IL-2 receptor (IL-2R) are thought to rescue T 
cells from cytokine deprivation induced apoptosis in vitro (Akbar et al 1996).
In the absence o f IL-2R y chain interaction, activated T cells are able to survive as a 
result o f interaction with fibroblasts, epithelial and endothelial cells. These cells are 
able to prevent apoptosis in a process called stromal-cell-mediated rescue (Akbar et 
al 1993). Although this was shown to rescue T cells from apoptosis it was thought 
that T cells persisted in a quiescent state. It has since been proposed that inhibition of 
apoptosis by the stromal cell microenvironment is in part responsible for the 
enhanced survival o f inflammatory cells within the joint resulting in chronic 
inflammation such as rheumatoid arthritis (Salmon et al 1997). Subsequent research 
has shown that this is mediated by synovial fibroblast and macrophage production of 
type I interferons such as IFN-a and IFN-p and the upregulation o f B c 1 -x l in the 
rescued cell (Pilling et al 1999). In addition to the role o f the synovium in the 
persistence of inflammatory cells, chemokine production within the local 
environment is thought to contribute to the inappropriate retention o f T cells within 
the rheumatoid joint (Buckely et al 2000). Stromal derived TGF-p has been shown to
114
Rachel Ann Harry Induction o f f  cell apoptosis
result in the sustained expression of CXCR4 once within the synovial environment 
which, upon interaction with SDF-1, in turn facilitates a strong integrin-mediated 
adhesion and thus retention within the rheumatoid joint.
In addition to T cell regulation by cell death T cells can also be rendered in a state of 
anergy or unresponsiveness (reviewed by Jenkins, 1992), which is achieved by the 
partial or inappropriate activation of T cells upon presentation with antigen by non­
professional APC. This occurs due to a failure to present antigen with costimulation 
by co-stimulatory molecules such as B7-1 and B7-2 (Slavik et al 1999) resulting in 
cells which are alive but are unable to produce IL-2 and fail to respond to optimal 
antigenic stimulation (James et al 2003).
EC lining the microvasculature o f the CNS form the highly active interface between 
the CNS and the immune system. This interface is the BBB or BRB. Initially 
thought to prevent immune cell entry to the CNS, it has been shown that activated 
lymphocytes are able to migrate across the BBB and BRB (Hickey et al 1991, 
Greenwood and Calder 1993, Greenwood et al 1995). CNS EC have since been 
shown to play an active role in the regulation of immune cell entry to the CNS 
through the regulated expression of cell adhesion molecules (Male et al 1990, Pryce 
et al 1991, Greenwood et al 1995).
Under normal physiological conditions the central nervous system (CNS) and the 
retina are “immune privileged” sites. Numerous mechanisms are implicated in the 
maintenance of immune privilege including the generation o f an immunosuppressive 
microenvironment by the local production of cytokines and neuropeptides (Streilein 
1995). However it has been shown that T cells which enter the CNS do not leave but 
die via apoptosis, and that this process may contribute to the subsidence of disease 
(Pender et al 1992). Previously it has been shown that brain microvessel EC are 
capable of regulating T cell function by the induction o f anergy (Bourdoulous et al 
1995) and RPE of the posterior BRB have the ability to induce T cell apoptosis 
(Jorgenssen et al 1998). Astrocytes and microglia o f the CNS have also been
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implicated in the induction of apoptosis of infiltrating inflammatory cells (Weber et al 
1994, Ford et al 1996). Given the increasing understanding of the role of BEC in the 
regulation of T cell infiltration into the CNS we set about to investigate the role o f 
BEC in the immunoregulation of T cell function.
Aims
To investigate the effects o f transmigration across BEC upon the regulation o f T 
lymphocytes.
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Results
T cell viability is maintained for up to 72h.
Initially, experiments were carried out to determine basal viability of the T cells used 
in each of the assays for the duration of the assay. Control T cell populations were 
cultured in the presence of IL-2 for 24-72h and stained with combinations o f calcein 
AM, EthDl and YoPro-1 for the determination of cell viability, death or apoptosis, as 
described in chapter 2 (section 2.9.1 and 2.9.2). Live cells were determined as 
calcein+ EthDl', dead cells were determined as cells which stained positively for 
EthDl, while apoptotic cells were determined to be YoPro-1+ EthDl' cells. YoPro-1+ 
EthDl+ cells were determined to be late apoptotic and for the purposes of this study 
were classified as dead cells. Our results clearly show that T cell viability of a highly 
activated T cell line could be maintained for the duration of the assay with greater 
than 94% viability at all timepoints investigated (Figure 3.1). Less than 10% of dead 
and apoptotic cells were quantitated at each of the timepoints investigated (Figure 
3.1).
Percentage recovery of viable CD5+ T cells is greater from HEV EC cultures 
than BEC cultures.
Given our previous finding we investigated the effects o f TEM upon T cell viability. 
The BD Trucount assay was used to quantitate the recovery o f viable CD5+ T cells, 
which migrated across BEC and HEV monolayers (see chapter 2, section 2.8.4). 
3xl05 T cells were added to both BEC and HEV monolayers cultured upon transwell 
inserts with pores o f 3.0pM. Significantly greater numbers o f viable CD5+ T cells 
were recovered from HEV cultures as compared with BEC cultures at both 24 and 
48h (p<0.01; Figure 3.2). This data suggests that T cell viability post TEM is 
supported by HEV cells but to a lesser degree by BEC monolayers.
CD4+ T cell viability is significantly decreased as a result of migration across 
BEC monolayers.
Our data suggested that viability of CD5+ T cells is modulated as a result of TEM 
through BEC monolayers as compared to HEV monolayers. We therefore decided to
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Figure 3.1 Percentages of live, dead and apoptotic cells as a percentage of the 
total T cell population in control T cell cultures.
T cells were cultured in the presence o f IL-2 for up to 72h. Cell viability was then 
determined by staining of cells with calcein AM as a marker of live cells; ethidium 
homodimer-1 (EthDl) as a marker of dead cells and YoPro-1 as a marker of apoptotic 
cells. Results are shown as the means of three independent experiments ± S.D.
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Figure 3.2 Percentage recovery of viable migrated T cells as a percentage of the 
total number of T cells at the onset of the assay.
T cells were added to EC monolayers and the percentage o f viable migrated T cells 
recovered from the lower assay chamber was quantitated using the BD TruCount 
assay. Data is shown as the means o f four samples ± SEM, except for BEC at 48h 
which is the means of three samples ± S.D. Statistical analysis was performed using 
the students T test. *p<0.01.
119
Rachel Ann Harry Induction o fT  cell apoptosis
further investigate the effects of TEM upon CD4+ and CD8+ T cells (see section 2.8.3 
and 2.9.2).
3x105 syngeneic T cells were added to BEC and HEV monolayers and at increasing 
timepoints T cell viability in the CD4+ and CD8+ migrated T cell population was 
determined. The total percentage o f the different subsets was similar in each o f the T 
cell populations: 85.1 ± 2.1% were CD4+ and 7.8 ± 0.6% were CD8+ (mean ± SEM of 
7 exp; data not shown). Dual staining of T cells for YoPro-1 as a marker of apoptosis 
and anti-CD4 or anti-CD8 antibodies revealed an intriguing difference in the levels of 
YoPro-1' i.e. live cells (Figure 3.3A). Control CD4+ and CD8+ T cells showed no 
significant difference in the levels of YoPro-F cells at each of the timepoints 
investigated. However a significant decrease in the levels of YoPro-1' CD4+ T cells 
(p<0.05) was observed in T cell populations which had migrated through BEC 
monolayers by 24h (Figure 3.3B). No significant differences were observed in the 
levels of YoPro-1' CD8+ T cells which had migrated through BEC monolayers or in 
the CD4+ and CD8+ T cell population which had migrated through HEV monolayers 
by 24h. Similarly no significant difference in the level o f YoPro-1' cells was 
detectable in either the CD4+ or CD8+ T cell population which had migrated through 
BEC or HEV monolayers by 48h.
TEM across BEC but not HEV monolayers results in a significant increase in 
CD4+ and CD8+ T cell apoptosis.
As a result o f these findings, we continued to investigate the changes in the levels of 
apoptosis as compared to controls in these populations as described in chapter 2 
(section 2.9.1). Due to the inherent variation between biological assays, the 
percentage change in apoptosis was calculated relative to the control in each 
experiment. Apoptosis of the control CD4+ T cell population was found to be 14.0 ± 
3.7% and 12.5 ± 2.2% at 24 and 48h respectively while levels o f apoptosis within the 
CD8+ T cell population was found to be 4.0 ± 1.0% and 4.4 ± 1.0%. CD4+ T cells 
which migrated through BEC monolayers by 24h exhibited a significant increase in 
the levels of apoptosis (p<0.01; Figure 3.4), while CD8+ T cells which migrated
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Figure 3.3. showing the percentage of viable T cells in control T cell and 
migrated T cell populations at 24 and 48h.
Cell viability was determined as the percentage of YoPro' CD4+ or CD8+ cells as a 
percentage of the total T cell population in A) control T cells and B) migrated T cells. 
Values are expressed as the means ± SEM of 7 independent experiments. Statistical 
analysis was performed using the Students T test *p<0.05.
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through BEC monolayers by 48h showed a smaller but significant increase in 
apoptosis (p<0.05; Figure 3.4). In contrast to this is the observation that both CD4+ 
and CD8+ T cells which migrated through HEV monolayers exhibited a decrease in 
the levels of apoptosis as compared to controls, although these values failed to reach 
significance (Figure 3.4).
BEC monolayer induced apoptosis is cell contact dependent.
The previous experiments clearly demonstrate that T cells cultured in the presence of
BEC exhibit a significant increase in the level o f apoptosis as compared to control T 
cells. However from this data we were unable to deduce the mechanism by which 
this induction of apoptosis occurs. We therefore set about to determine whether this 
induction of apoptosis was as a result of direct cell-cell contact or mediated via a 
soluble factor. In order to investigate this, T cells were cultured in the presence of 
both BEC and HEV monolayers in the absence of cell-cell contact using a transwell 
insert system with 0.4pM pores thereby preventing migration o f the T cells to the 
lower chamber. In these cultures T cells and EC share the same culture medium 
whilst remaining spatially isolated to determine whether direct cell-cell contact is 
required for the induction of apoptosis. CD5+ T cells cultured in the presence of BEC 
monolayers for up to 72h showed no significant change in the levels of apoptosis as 
compared with controls. Interestingly CD5+ T cells cultured in the presence o f HEV 
monolayers exhibited a significant decrease in the levels o f apoptosis observed at 24 
and 48h (p<0.01 and p<0.001 respectively; Figure 3.5). A decrease in apoptosis was 
also observed at 72h but did not achieve significance. This data is consistent with 
that o f the transmigration experiments, in that T cells co-cultured with HEV 
monolayers exhibit a decrease in the levels o f apoptosis of CD4+ and CD8+ T cells 
(Figure 3.4). This data also supports the ability o f HEV EC to protect T cells from 
apoptosis, by means of a soluble factor. In addition, this data suggests that the 
increased levels of apoptosis observed in CD4+ and CD8+ T cells which migrate 
through BEC monolayers as determined by our transmigration experiments is 
mediated by direct cell-cell contact.
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Figure 3.4 Percentage change in the levels of apoptosis of migrated CD4+ and 
CD8+ T cells.
Levels of apoptosis were determined by YoPro-1 staining. Due to the inherent 
variation between biological assays, the percentage change in apoptosis was 
calculated relative to the control in each experiment. A significant increase in 
apoptosis was observed in CD4+ and CD8+ T cells which migrated through BEC 
monolayers at 24 and 48h respectively. Values are expressed as the mean ± SEM of 
at least 4 independent experiments. Statistical analysis was performed using the 
Students T Test. * p<0.01 and ** p<0.05).
123
Rachel Ann Harry Induction o fT  cell apoptosis
300 n
250
200 -
2 150
100
W
too
Q.Oo.(0
c
oo>c(0£o
a>o>
5c
<DOi_(UQ.
50
-50
-100
% — ■ BEC □ HEV
-150
-200
24h 48h 72h
Figure 3.5 showing the change in apoptosis of CD5+ T cells in the absence of cell­
cell contact.
Levels of apoptosis were determined by staining with YoPro-1. Due to the inherent 
variation between biological assays, the percentage change in apoptosis was 
calculated relative to the control in each experiment. A small but significant reduction 
in the levels of apoptosis were observed in CD5+ T cell populations cultured in the 
presence of HEV monolayers for 24 and 48h. Results are shown as the means of 
three independent experiments ± S.D. Statistical anlaysis was performed using the 
Students T Test. *p<0.01, **p<0.001.
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Discussion
The CNS is known to be an immune privileged site which is protected from the 
harmful effects of the immune system by the presence of highly specialised 
mechanisms such as immune privilege. Initially it was thought that the CNS was 
devoid of lymphocyte traffic. However, it has since been reported that surveillance 
o f the CNS occurs by activated T cells (Hickey et al 1991, Greenwood and Calder
1993).
I therefore investigated the effect of TEM upon T cell viability following migration 
across BEC monolayers as compared to HEV monolayers. T cells which migrated 
through HEV monolayers showed significantly greater levels of viability as compared 
with T cells which migrated through BEC monolayers at each o f the timepoints 
investigated, suggesting that HEV EC maintain T cell viability as a result of TEM. In 
addition the results observed suggest these effects are as a direct consequence of 
culture with BEC and HEV monolayers, given that control T cell viability is 
maintained for up to 72h under similar conditions.
We continued by investigating the effects of TEM upon CD4+ and CD8+ T cells. Our 
data showed that a significant reduction in CD4+ T cell viability occurred as a result 
of migration through BEC monolayers. Subsequently we were able to demonstrate 
that this decrease in viability was associated with a corresponding increase in 
apoptosis. A significant increase in apoptosis was also detectable in CD8+ T cells, 
which were found to have migrated across BEC monolayers by 48h. The increase in 
CD8+ T cell apoptosis did not appear to be associated with a corresponding decrease 
in CD8+ T cell viability; however this may be a limitation of the assay given the small 
proportion o f CD8+ T cells within the T cell population and the variation between 
experiments.
As a result o f our findings mechanisms by which the induction of apoptosis occurred 
was investigated. Complementary experiments were set up to determine whether T
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cells exposed to BEC and HEV monolayers in the absence of direct cell-cell contact 
were susceptible to apoptosis. These experiments revealed that direct cell-cell 
contact is required for BEC induced T cell apoptosis. This data also revealed that T 
cells cultured in the presence of HEV monolayers were protected from apoptosis in 
the absence o f direct cell-cell contact and thus supports the role for soluble factors in 
this process.
This data complements that described previously for the functional role o f HEV EC 
and BEC. HEV EC function to maximise lymphocyte migration into the peripheral 
lymph node (PLN; Girard and Springer 1995) while endothelia of the CNS are 
adapted to minimise leukocyte trafficking through the low level expression of the 
requisite molecules for the purpose of migration (Male et al 1990, Pryce et al 1991, 
Fabry et al 1994).
Our findings presented here are extremely interesting given the role o f T cells in 
immune mediated diseases of the CNS such as multiple sclerosis (MS) and uveitis. 
This data suggests that BEC may play a role in the regulation o f T cell function 
within the CNS by the induction of apoptosis of both CD4+ and CD8+ T cells as a 
result of TEM. The temporal separation observed in the induction of apoptosis o f 
CD4+ and CD8+ T cells may reflect the ability of each T cell subset to synthesise and 
correctly display the requisite molecules upon their surface in order to mediate TEM, 
although our present studies are unable to confirm this. Alternatively it may be 
possible that the duration required in order for a CD8+ T cell to be recognised as 
apoptotic by YoPro-1 is greater than that of CD4+ T cells, hence we observed levels 
of apoptosis at 48h in CD8+ T cells. This data is suggestive of a greater susceptibility 
of CD4+ T cells to apoptosis than CD8+ T cells. However since CD4+ T cells are 
thought to be the initial cells found at MS lesions, this data may reflect in vivo 
findings whereby CD8+ migration may occur post CD4+ migration into the CNS. The 
significant induction of apoptosis in both CD4+ and CD8+ T cells may, in part, aid in 
the maintenance of immune privilege within the CNS.
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Evidence exists to suggest that the retinal pigment epithelium (RPE) which forms the 
posterior BRB is capable of inducing apoptosis in T cells (Jorgenssen et al 1998) and 
lymphocytes which enter the mouse eye have been shown to undergo apoptosis 
(Griffith et al 1995). It is therefore plausible to suggest that a similar mechanism may 
exist at the level of the BBB. Previous studies have demonstrated that brain 
microvessel endothelial cells are capable o f inducing anergy in syngeneic T cells 
(Bourdoulous et al 1995).
In contrast to BEC, HEV EC do not appear to induce apoptosis in either CD4+ or 
CD8+ T cells when cultured in the absence or presence of direct cell-cell contact at 
the timepoints investigated. Interestingly it would appear that HEV EC may protect 
T cells from apoptosis. As mentioned previously this may be due to the functional 
role of HEV, to maximise lymphocyte migration into the PLN. This data is also 
consistent with that previously described by Borthwick et al (2003) in which 
transmigration across HUVEC monolayers and HUVEC conditioned supernatants 
conferred protection against apoptosis. It has also been shown that HUVEC 
monolayers suppressed T cell proliferation but did not render T cells unresponsive 
(Marelli-Berg et al 1999).
Apoptosis of T lymphocytes is known to occur during EAE (Pender et al 1992, 
Schmied et al 1993) which is in contrast to inflammatory disorders of the skin where 
less apoptosis is observed (Schneider et al 1996). It is reported that MS disease 
activity correlates with enhanced T cell expression of survivin, an anti-apoptotic 
protein (Sharief et al 2002) and that recovery o f EAE is associated with a decrease in 
the survival of encephalitogenic T cells (Chang et al 2003). One current therapy for 
the treatment o f MS, IFN-p, is thought to mediate induction of apoptosis o f peripheral 
immune cells (Gniadek et al 2003). It has been proposed that astrocytes (Weber et al
1994) and microglia (Ford et al 1996) of the CNS, acting as non-professional antigen 
presenting cells (APC’s), prime invading T cells for an apoptotic stimulus from the 
local microenvironment. Given the immune privilege nature o f the CNS, this may be 
due to the presence o f local immunosuppressive cytokines or neuropeptides.
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Previous findings within our laboratory demonstrate that primary rat BEC and REC 
fail to support T cell proliferation (Wang et al 1995), it is possible therefore that BEC 
may also function to prime T cells for additional apoptotic signals. However the 
effects observed within our co-culture would suggest that BEC are capable o f 
inducing apoptosis of T cells in the absence of non-BEC derived environmental 
stimuli.
Pro-inflammatory cytokines play a critical role in the pathogenesis of MS and EAE. 
It is known that highly activated T cells secrete such pro-inflammatory cytokines and 
that BEC respond to such stimuli by the upregulation of cellular adhesion molecules. 
Therefore it would be extremely interesting to investigate the modulation o f T cells as 
a result o f migration across an activated endothelium.
In keeping with the growing understanding of the role of CNS EC in leukocyte TEM, 
this data supports a role for specialised mechanisms at the BBB, and provides further 
evidence that endothelia from different vascular beds exhibit specialised properties 
dependent upon their location (Oh et al 2004). This therefore highlights one reason 
why caution should be taken to apply principles determined for one type of 
endothelium and bestow such principles upon other endothelia.
The necessity for cell-cell contact suggests close communication between T and EC 
cells thus suggesting a role for a cell surface mediator o f apoptosis. Apoptosis has 
previously been shown to play a role in the preservation of immune privilege o f the 
eye by the downregulation of T cells (Griffiths et al 1995). Apoptosis can be induced 
by a number of means but due to the dependency o f cell-cell contact this suggests 
mediation o f apoptosis occurs via a cell surface initiator of apoptosis and expression 
of the reciprocal death receptor upon the apoptosis susceptible cell. Activated T cells 
are known to express Fas which, upon ligation with its ligand (FasL), results in the 
death of the Fas expressing cell. Considering the aforementioned role for the Fas- 
FasL interaction in immune privilege (Griffiths et al 1995) and in normal T cell 
homeostasis it seems plausible that this interaction may indeed play a role in T cell
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regulation at the level of the BBB. It is also recognised that the BRB and BBB share 
numerous similarities. We therefore propose that FasL expression by BEC may 
induce apoptosis o f infiltrating inflammatory cells and aid in the maintenance o f 
immune privilege.
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Chapter 4
Expression of FasL
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Introduction
FS7-associated surface antigen or Fas (APO-1/CD95), first discovered due to its 
cytocidal properties (Trauth et al 1989, Yonehara et al 1989), is a 45kD cell surface 
molecule which is a member o f the Tumor necrosis factor-receptor (TNF-R) 
superfamily (Itoh et al 1991). This type I membrane protein is composed of an 
extracellular domain of three cysteine rich domains, a transmembrane domain and a 
death inducing cytoplasmic domain which bears significant homology to TNF-R 1 
(Itoh et al 1991, Oehm et al 1992). Triggering of the apoptotic pathway requires 
crosslinking of Fas with either antibodies to Fas, cells expressing FasL or purified 
FasL (Nagata and Golstein, 1995). It has also been shown that protection against 
Fas-mediated apoptosis can occur by means of a soluble Fas molecule (Cheng et al
1994).
Activation of Fas results in the aggregation of the intracellular death domain, the 
recruitment o f FADD (Fas associating death domain protein/MORT-1) and 
subsequent crosslinking via its death domain (Boldin et al 1995, Chinnaiyan et al
1995) which then results in the recruitment of caspase 8 (FLICE/MACH-1/Mch5) 
(Boldin et al 1996, Fernandes-Alnemri et al 1996, Muzio et al 1996) via its N- 
terminal death effector domain. Crosslinking of these two key regulatory proteins to 
Fas forms the death inducing signalling complex (DISC; Kischkel et al 1995; Figure 
4.1). Induction of apoptosis via Fas can occur by two main pathways (Scaffidi et al 
1998; Figure 4.1) and cells can be classified by means of the Fas induced apoptotic 
pathways used, all of which is determined by caspase kinetics. Caspase activation in 
Type I cells is rapid and mitochondria independent, whilst the delayed caspase 
activation o f Type II cells is a mitochondria dependent mechanism.
Binding of Fas to its ligand, FasLigand (FasL/CD95L) results in the generation o f a 
death-inducing signal in the Fas bearing cell. FasL is a 40kD type II membrane 
glycoprotein (Suda and Nagata, 1994), which is dependent upon ligation with its 
receptor, Fas in order to mediate Ca2+ independent cytotoxicity (Rouvier et al 1993).
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Figure 4.1 Model of the two CD95 signalling pathways.
(A) In type I cells CD95 triggering leads to strong caspase-8 activation at the DISC 
which bypasses mitochondria directly leading to activation of other caspases and 
subsequent apoptosis. (B) In type II cells a little DISC is formed leading to the 
activation of mitochondria, which results in caspase cleavage downstream of the 
mitochondria. Red box, death domain; blue box, death effector domain. Adapted 
from Scaffidi et al 1998.
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Expression of FasL is known to be restricted to activated T cells (Anel et al 1994, 
Suda et al 1995, Vignaux et al 1995) and immune privileged sites (Streilein 1995). 
This is in contrast to the broader distribution of Fas, which has been demonstrated 
upon numerous cell types including activated mature lymphocytes (Trauth et al 
1989), tumour cells and in the mouse thymus, liver, heart, lung, kidney and ovary 
(Watanabe-Fukunaga et al 1992).
The importance of Fas and its ligand has been demonstrated in vivo in spontaneous 
mutant mice. Ipr (lymphoproliferation) mice are defective for Fas due to a truncated 
gene (Andrews et al 1978) and gld  mice (generalised lymphoproliferative disease) 
suffer a point mutation within the FasL gene, which results in an amino acid 
substitution close to the C-terminus and are thus defective for FasL (Roths et al 
1984). Although these appear as two distinct diseases both can be characterised by 
excessive lymphoproliferation and lymph node splenomegaly as a result of the 
accumulation of lymphocytes. This therefore supports a role for Fas and FasL in the 
regulation of T cells during the process o f selection within the thymus (Kishimoto et 
al 1998) and a specific role in the induction of apoptosis during AICD or the deletion 
of peripheral T cells (Alderson et al 1995). Rat FasL cDNA was cloned first (Suda et 
al 1993) followed by that of human and mouse (Takahashi et al 1994) and all three 
have since been shown to share a high degree of amino acid homology (Figure 4.2). 
Mouse and rat FasL share a 91% amino acid homology while human and rat FasL 
share 84% homology at the amino acid level. FasL has been implicated in the 
maintenance of immune privilege, as demonstrated by the necessity of FasL for the 
control o f invading lymphocytes, which have been shown to remain viable and exert 
local tissue damage in gld  mice (Griffith et al 1995) where it was observed that FasL 
is located at areas of the BRB, on RPE cells and photoreceptor cells (Figure 4.2).
Expression of FasL has been documented at the cell surface and also in intracellular 
lysosomal type vesicles within epithelial cells (Ragnarsson et al 2000) and tumour 
cells (Hyer et al 2000) which is proposed to be a mechanism to prevent apoptosis. It
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Figure 4.2 Localisation of FasL in the eye.
FasL is expressed in several strategic locations, including the cornea, retina, iris and 
ciliary body. FasL is located near areas that comprise the blood-ocular barrier and at 
locations where there is an opportunity for interaction between ocular tissue and 
inflammatory cells. In the retina, FasL is expressed on the retinal pigment epithelial 
cells, which comprise the outermost layer of the retina, and FasL is prominently 
expressed on the photoreceptors (rods and cones) where it might have a protective 
function in vision. FasL on the iris and ciliary body can contact and kill cells that 
enter from the vessels that are prominent in this tissue. In the cornea, FasL is 
expressed on the endothelium and epithelium, where it can control inflammatory cells 
that enter from the conjunctiva or anterior chamber. Taken from Green and Ferguson 
(2001)
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1 MQQPVNYPCPQIYWVDSSATSPWAPPGSVFSCPSSGPRGPGQRRPPPPPPPPSPLPPPSQ 
*  *  *  *  * * * * * * *  * * * * * * * *  * * * * * * * *  *  *  *  * * * * *  * * * * * * * * * *  * * * * * * * *
61 PLPLPPLTPLKKKDHNTNLWLPWFFMVLVALVGMGLGMYQLFHLQKELAELREFTNQSL 
61 PPPLPPLSPLKKKD-NIELWLPVIFFKVLVALVGMGLGMYQLFHLQKELAELREFTNHSL 
*  * * * * *  * * * * * *  *  * * * * *  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  * *
121 KVSSFEKQIANPSTPSEKKEPRSVAHLTGNPHSRSIPLEWEDTYGTALISGVKYKKGGLV 
120 RVSSFEKQIANPSTPSETKKPRSVAHLTGNPRSRSIPLEWEDTYGTALISGVKYKKGGLV
181 INETGLYFVYSKVYFRGQSCNNQPLNHKVYMRNSKYPEDLVLMEEKRLNYCTTGQIWAHS 
180 INEAGLYFVYSKVYFRGQSCNSQPLSHKVYMRNFKYPGDLVLMEEKKLNYCTTGQIWAHS
241 SYLGAVFNLTSADHLYVNISQLSLINFEESKTFFGLYKL 
240 SYLGAVFNLTVADHLYVNISQLSLINFEESKTFFGLYKL
Figure 4.3: Alignment of rat and mouse FasL amino acid sequences showing 
91% homology.
From: http://ca.expasv.org
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has also been shown that CD4+ T cells, CD8+ T cells and natural killer cells contain 
intracellular stores of FasL which are released via secretory lysosomes (Bossi and 
Griffiths 1999). Cell surface FasL can also be cleaved to a 26kD soluble form termed 
soluble FasL (sFasL; Tanaka et al 1995, Kayagaki et al 1995). Human sFasL has 
been shown to induce apoptosis in Fas expressing cells whereas mouse sFasL is 
unable to induce apoptosis (Suda et al 1996). Production of sFasL is thought to be 
mediated by the action of matrix metalloproteinase-7 or matrilysin (Powell et al 
1999, Mitsiades et al 2001, Vargo-Gogola et al 2002) and is proposed to be a 
downregulatory mechanism of FasL induced apoptosis (Suda et al 1997, Schneider et 
al 1998).
FasL is known to play a role in human disease as it is thought that tumour cells are 
able to evade the immune system by the loss o f Fas and the induction of FasL 
expression (Strand et al 1996, Kim et al 2004). Elevated levels of sFasL are observed 
in ocular fluid during ocular inflammation (Sotozono et al 2000, Sugita et al 2000) 
and in tear fluid as a result of photorefractive keratectomy (Tuominen et al 1999), 
which suggests less membrane bound FasL. It is also extremely interesting, given the 
role of Fas and FasL in immune privilege within the eye (Griffith et al 1995), within 
the CNS (Streilein 1995, Bechmann et al 1999) and in the testis (Bellgrau et al 1995) 
that treatment of EAU with matrix metalloproteinase inhibitor BB-1101, an inhibitor 
of MMP-7, has been shown to prevent EAU, thus implicating the loss o f membrane 
bound FasL in the pathogenesis o f EAU (Wallace et al 1999). Fas and FasL have 
both been shown to contribute to the pathogenesis of EAE (Dittel 2000).
It has previously been shown that human macrovascular EC are able to induce 
apoptosis (Imanishi et al 2001) and that HUVECs express FasL (Walsh and Sata 
1999) although expression at this site has been implicated in the facilitation of 
leukocyte extravasation (Walsh and Sata 1999). Expression of FasL by HUVECs has 
been shown to be downregulated in response to TNF-a (Walsh and Sata 1999). 
However IFN-y has been shown to upregulate FasL upon Schwann cells in vitro and 
astrocytes upregulate FasL in response to IFN-y and TNF-a (Choi et al 1999)
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suggesting that the role for FasL may vary dependent upon the sites or tissues 
involved.
Aims
Having observed an increase in CD4+ T cell apoptosis as a result of TEM across BEC 
monolayers, the aim of this chapter is to determine whether FasL is a candidate 
molecule for the induction of T cell apoptosis in this system. This will be 
investigated using a number of techniques in order to demonstrate FasL protein 
expression and functional FasL.
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Results
Detection of FasL by immunocytochemistry
Initially experiments to investigate cell surface FasL expression by BEC were 
performed using a commercially available antibody and flow cytometry. Due to the 
reported low level expression of FasL upon cells not transfected to overexpress FasL 
we decided to use an indirect staining protocol using the biotinylated anti-rat FasL 
primary antibody MFL4 and amplification of any signal by the use of streptavidin-PE 
as a secondary antibody.
Given the reported effects of pro-inflammatory cytokines upon FasL expression in 
Schwann cells (Wohlleben et al 2000) and astrocytes (Choi et al 1999), in an attempt 
to maximise expression we investigated the effects of pro-inflammatory cytokines 
upon BEC FasL expression. Using the MFL4 antibody we investigated FasL 
expression by BEC at differing degrees of confluence, using increasing 
concentrations o f antibody and increasing timeperiods in response to exposure to pro- 
inflammatory cytokines such as IFN-y and TNF-a. However, we were unable to 
determine FasL expression under the conditions investigated (data not shown). We 
also investigated whether BEC contained intracellular stores of FasL, as a result of 
saponin-permeabilisation of cells, and the effects of pro-inflammatory cytokines upon 
levels of expression. However at each of the timepoints and conditions investigated, 
FasL expression by BEC was not observed above that of the non-specific binding of 
control, streptavidin-PE alone (data not shown). To determine whether our inability 
to confirm FasL expression was due to the detachment of the BEC from the culture 
flask FasL expression was investigated using confocal microscopy following a 
method previously described for staining of FasL upon T cells (Bossi and Griffiths 
1999). However we were again unable to determine FasL expression above the levels 
of control (data not shown). Another possibility was that FasL expression by BEC 
was transient, we addressed this question by means o f a matrix metalloproteinase 
inhibitor KB8301, (a kind gift o f Professor Hideo Yagita of Juntendo University, 
Japan) which is an inhibitor of MMP-7 which is thought to play a role in the 
generation of sFasL. We therefore investigated the effects of KB8301 at varying
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concentrations [0-20pM] upon cell surface and intracellular FasL, in unstimulated 
and cytokine stimulated BEC cultures. No FasL expression was detectable above that 
o f control. O f interest during this study was that FasL expression by PMA and 
ionomycin stimulated T cells, a known positive control, was investigated in parallel, 
and under each o f the conditions investigated no FasL expression was detectable.
As we were unable to determine FasL expression by any of the means investigated 
we set about to confirm using a different antibody or an alternative protocol, whether 
our inability to detect FasL was due to a lack of FasL expression by BEC or due to a 
limitation of the antibody employed in these studies. Given the close homology of rat 
FasL to human and mouse FasL we subsequently investigated a number of anti­
human FasL antibodies in order to determine whether cross reactivity was observed 
by carrying out experiments as performed for the MFL4 antibody. Antibodies tested 
for this purpose included three anti-human FasL antibodies; 4H9 and 4A5, which 
were kind gifts of Beckman Coulter and an anti-human FasL antibody FSLOl which 
was reported to exhibit cross reactivity with rat FasL as determined by western 
blotting. Staining of PMA and ionomycin and PHA stimulated human T cells 
resulted in FasL expression as determined using the 4A5 and 4H9 antibodies (data 
not shown). However, staining of PMA and ionomycin stimulated and Con A 
stimulated rat T cells with the 4A5 and 4H9 antibodies did not reveal FasL expression 
(data not shown). FSLOl, not previously tested for the purpose of flow cytometry 
failed to identify FasL expression upon human T cells using this method.
Soluble FasL was determined in BEC supernatants
In an attempt to confirm whether BEC express FasL, we set out to investigate 
whether sFasL was detectable in BEC culture supernatants as detectable using a 
commercially available mouse sFasL ELISA. sFasL was detectable in unstimulated 
and cytokine stimulated BEC cultures after 24h (Table 4.1) whilst levels in HEV 
cultures were found to below the sensitivity of the assay. Increasing concentrations
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Supernatant Soluble FasL (pg/ml)
BEC, Untreated 1563 ±32.4
BEC, lOOU/ml IFN-y 1093 ±226.0
BEC, 50U/ml IFN-y 315 ±44.8
BEC, 50U/ml IFN-y + 5U TNF-a 942 ± 782.8
BEC, 50U/ml IFN-y + 10U TNF-a 908 ± 1204.1
BEC, 50U/ml IFN-y + 100U TNF-a 1322 ± 235.4
Activated T cell Control 1383 ±304.1
Control supplied with kit 217 ±40.9
Table 4.1 sFasL levels in BEC and T cell culture supernatants.
sFasL levels were detected in BEC culture supernatants in unstimulated and cytokine 
stimulated monolayers at 24h using a commercially available mouse FasL ELISA 
(R&D Systems). sFasL levels were detectable in each of the conditions investigated. 
Data is expressed as the means of duplicate wells ± S.D.
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of IFN-y resulted in a decrease in sFasL levels as compared to unstimulated controls 
whilst treatment of BEC monolayers with IFN-y and increasing concentrations of 
TNF-a resulted in a dose dependent increase in sFasL levels.
FasL expression detectable in activated T cells by Western blotting
Given the promising results obtained by ELISA that BEC are capable of producing
sFasL we investigated whether we could detect FasL using the anti-human FSLOl 
antibody which was reported to detect FasL by Western blotting (see chapter 2, 
section 2.12). Western blot analysis of unstimulated and PMA/ionomycin stimulated 
rat T cells using the FSLOl antibody resulted in the detection of a band of 
approximately 30kD, in the T cell lysate of PMA/ionomycin stimulated cells (Figure 
4.4). Given that we were able to detect an activation dependent protein of 
approximately the predicted weight for FasL using an anti-human FasL antibody we 
would predict this to be FasL although subsequent protein analysis would be required 
in order to confirm this. Due to antibody and time constraints we were unable to 
investigate FasL expression upon BEC, although this data would suggest that this 
antibody may be suitable for the detection of rat FasL in BEC by western blotting.
BEC express FasL mRNA
In parallel to my studies, work within the laboratory carried out by Zoe Walters set 
about to investigate FasL expression by PCR. Some preliminary data has been 
generated which is extremely interesting and highly pertinent given our previous 
studies. Analysis o f FasL using RT-PCR has shown that confluent BEC 
constitutively express FasL mRNA, however HEV express FasL mRNA at a much 
lower intensity (Figure 4.5A). The effects of the pro-inflammatory cytokines, IFN-y 
and TNF-a upon FasL mRNA expression have also been studied. Despite an 
apparent increase in intensity o f FasL mRNA an increase in P-actin was also detected 
and as a result semi-quantitative PCR analysis revealed that treatment of confluent 
monolayers with IFN-y and TNF-a for 24h results in a downregulation of FasL 
mRNA relative to untreated BEC monolayers (Figure 4.5B). IFN-y would appear to 
be more effective in the downregulation of FasL mRNA expression than TNF-a,
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Figure 4.4 Western blot analysis of FasL in unstimulated and stimulated T cells.
Western blot analysis of unstimulated and PMA and ionomycin stimulated rat T cells 
using the FSLOl antibody revealed a protein band of approximately 30kD.
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Figure 4.5 FasL mRNA analysis of confluent unstimulated BEC and HEV 
monolayers and expression in response to IFN-y and TNF-a.
Panel A shows FasL mRNA expression by unstimulated BEC and HEV monolayers. 
Lane A: HEV; lane B: BEC; lane C: negative control and lane D: T cell control. 
Semi-quantitative PCR analysis revealed a low level expression of FasL mRNA in 
HEV monolayers as compared with a band of high intensity in BEC monolayers. 
Panel B shows quantification of FasL relative band intensities from BEC monolayers 
stimulated with IFN-y [50U/ml], TNF-a [lOOU/ml] or with IFN-y [50U/ml] and TNF- 
a [lOOU/ml] for 24h. All positive bands were of the expected size. Relative band 
intensity was then measured using ScanAnalysis v2.50. The relative amounts of FasL 
mRNA expression were calculated as a proportion of the P-actin expression in each 
sample.
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whilst treatment o f BEC monolayers with both IFN-y and TNFa results in a 
downregulation comparable to that of IFN-y alone.
Demonstration of functional FasL
Having detected FasL mRNA and sFasL in BEC cultures and the lack o f a suitable 
antibody to determine membrane FasL we set about to investigate whether it would 
be possible to demonstrate functional FasL so as to indirectly determine FasL 
expression by BEC. It has previously been reported that a mouse cell line transfected 
with human Fas was susceptible to apoptosis mediated by mouse FasL (Brunner et al 
1995, Griffith et al 1995). We therefore investigated whether rat BEC were able to 
induce Fas mediated cytotoxicity in the susceptible cells (see chapter 2 section 2.8.5). 
However, despite numerous attempts we were unable to detect Fas mediated 
cytotoxicity induced by BEC.
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Discussion
Our previous findings demonstrate that BEC but not HEV cells induce T cell 
apoptosis in CD4+ T cells, following TEM across an in vitro model of the BBB 
(Chapter 3). It is recognized that EC forming the BBB are specialised for this 
function. The CNS is known to be an immune privilege site and FasL has previously 
been reported to play a role in the induction of apoptosis as a mechanism of immune 
privilege within the eye (Griffith et al 1995). We therefore hypothesized that the 
induction of apoptosis by BEC may be an additional specialized property of BEC of 
the BBB and therefore decided to investigate whether FasL may be a candidate for 
this role in our model system.
Initially experiments set out to determine cellular expression o f FasL by BEC. 
However, using a panel of antibodies, we were unable to determine FasL expression 
at the cell surface, intracellularly, in the presence of a matrix metalloproteinase 
inhibitor or in response to pro-inflammatory cytokines. It has previously been 
reported that FasL expression may be transient or relatively low in cells, which are 
not induced to overexpress FasL (BD Bioscience). Given that we were able to 
determine FasL expression upon human T cells using anti-human FasL antibodies, 
but not upon rat T cells would suggest a low degree of species cross reactivity of the 
antibody, despite a high degree of homology between human and rat FasL at the 
amino acid level. However FasL expression has been documented in the normal rat 
brain by means of immunohistochemical techniques (Bechmann et al 1999). 
Therefore it would be intriguing to investigate whether antibodies for this purpose 
may be able to detect FasL upon BEC.
Despite our inability to determine FasL expression within the cell we were able to 
determine sFasL in BEC culture supernatants and levels o f sFasL were modulated in 
response to pro-inflammatory cytokines. This data indicates that BEC are capable of 
synthesising and expressing FasL, even if only transiently. IFN-y appears to down 
regulate FasL production, and increasing concentrations o f TNF-a in the presence of
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IFN-y appear to inhibit IFN-y induced downregulation o f sFasL production. Also of 
interest was that sFasL in culture supernatant harvested from HEV monolayers was 
below the sensitivity o f detection. This data is consistent with that presented in 
Chapter 3 whereby BEC but not HEV monolayers are able to induce T cell apoptosis. 
Therefore it is a possibility that the induction of apoptosis is a specialised function of 
BEC. This data also provides an insight into the functional nature o f rat sFasL. 
Given that sFasL was detectable in culture supernatant after 24h we would expect 
BEC to secrete sFasL during the course of our co-culture assays (up to 72h), however 
no significant increase in T cell apoptosis was detectable at each o f the timepoints 
investigated in our non-contact assay (see chapter 3), thus it would suggest that rat 
BEC-derived sFasL is biologically inactive or that it may act to prevent T cell 
apoptosis. This data complements that of the functional activity o f murine sFasL 
(Suda et al 1996) and as such may be considered as a mechanism of FasL 
downregulation (Suda et al 1997). Human EC have been shown to produce sFasL in 
response to hypoxia (Mogi et al 2001), this data therefore supports a role for rat BEC 
and rat T cells in the production of sFasL.
We therefore decided to investigate FasL protein expression by Western blotting and 
can report that rat T cells stimulated with PMA and ionomycin for 6h express a T cell 
activation dependent protein of the approximate molecular weight using the FSLOl 
anti-human FasL antibody. This data is in keeping with the reported expression of 
FasL upon activated T cells (Anel et al 1994, Suda et al 1995, Vignaux et al 1995). 
Unfortunately our present studies were unable to extend to determine FasL 
expression upon BEC by Western blotting. However, this promising data would 
suggest that this antibody may be suitable for the detection of FasL in BEC. This 
data, unlike that of the flow cytometry studies, supports a role for inter-species cross 
reactivity. This is most likely due to the different antibody employed or as a result of 
conformational changes to rat FasL which may make it more amenable to recognition 
by an anti-human FasL antibody.
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Given our conflicting findings, studies were undertaken in order to investigate FasL 
mRNA expression by RT-PCR. Preliminary results suggest that BEC constitutively 
express FasL to a greater level than HEV monolayers and semi-quantitative PCR 
analysis also revealed that IFN-y and TNF-a down regulated FasL mRNA expression 
as compared to unstimulated cells. This is in contrast to the role of IFN-y in the 
upregulation o f FasL upon Schwann cells of the peripheral nervous system (PNS; 
Wohlleben et al 2002) and upregulation of FasL upon human astrocytes in response to 
both IFN-y and TNF-a (Choi et al 1999). Our data is consistent with the effects of 
TNF-a upon a non CNS vascular endothelium (Sata and Walsh 1998, Walsh and Sata 
1999) suggesting that BEC are capable of FasL gene transcription. In order to 
conclusively state that BEC express FasL, confirmation of protein expression of FasL 
is necessary. In light of the PCR data it would suggest that in our attempts to 
maximize FasL expression by treatment with cytokines we were, in fact, inhibiting 
FasL expression. It would therefore be extremely interesting to reinvestigate FasL 
protein expression by BEC in the absence of IFN-y and TNF-a and possibly in the 
presence of interferon-a which has been shown to upregulate FasL mRNA expression 
upon peripheral blood mononuclear cells (Kaser et al 1999).
Our data supports the hypothesis that BEC are capable o f expressing FasL, despite 
our inability to confirm cell surface expression, which we feel may be due to the lack 
of a reliable antibody. However, as we have shown in chapter 3, EC induced T cell 
apoptosis is cell-contact dependent. This therefore supports a role for a cell surface 
molecule. It is also a possibility that the apoptosis observed is not due to FasL, and 
that a role for an alternative cell surface mediator could exist. It would also be 
interesting to investigate whether it would be possible to demonstrate the presence of 
functional FasL using our in vitro transmigration system. Given the PCR data 
demonstrating IFN-y downmodulation of FasL mRNA, experiments to investigate 
whether pre-treatment o f BEC monolayers with IFN-y prior to assay are currently 
being carried out, to assess whether an inhibition of CD4+ T cell apoptosis is 
observed. In addition the inhibition of FasL expression by treatment with vitamin E 
is also being investigated (Li-Weber et al 2002). Vitamin E has been reported to
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inhibit FasL mRNA expression in other systems and it will be interesting to 
investigate whether the effects observed at the gene level are evident at the protein 
level.
Rachel Ann Harry Immunomodulation by statins in vitro
Chapter 5
Immunomodulation by statins in vitro
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Introduction
The ICAM-l-LFA-1 interaction is known to play a major role in the multistep 
process of leukocyte migration at the vascular endothelium. EC ICAM-1 has further 
been shown to play an essential role in leukocyte extravasation within the CNS 
(Greenwood et al 1995, Pryce et al 1997, Reiss et al 1998) and also in the peripheral 
vascular system (Oppenheimer-Marks et al 1991, Shimizu et al 1992).
ICAM-1 has previously been shown to interact with a number of intracellular proteins 
including a-actinin, the actin binding protein and the microtubule associated p- 
tubulin (Federici et al 1996) thus suggesting an association of ICAM-1 with the EC 
cytoskeleton (Amos et al 2001). It is proposed that ICAM-1 forms a homodimer 
(Casasnovas et al 1998) upon which an EC signalling molecule is generated 
(Hubbard and Rothlein 2000). ICAM-1 cross linking mediated by antibody or 
lymphocyte adhesion has shown to result in the tyrosine phosphorylation o f a number 
of cytoskeletal proteins including focal adhesion kinase (FAK), paxillin and pl30Cas 
(Etienne et al 1998) in addition to the induction of cytoskeletal arrangements 
(Adamson et al 1999), calcium signalling (Clayton et al 1998) and the regulation o f 
TJ in epithelia (Nusrat et al 1995). The role for ICAM-1 in actin cytoskeleton 
reorganisation is supported by the inhibition of lymphocyte transmigration as a result 
of cytochalasin D treatment (Adamson et al 1999). In vitro studies have revealed that 
intracellular ICAM-1 (Amos et al 2001, Lyck et al 2003, Greenwood et al 2003b) 
and ICAM-1 mediated cytoskeletal modifications are associated with increased levels 
of activated Rho and that lymphocyte migration across BEC is a Rho-dependent 
pathway (Adamson et al 1999).
Rho proteins are a family o f small guanosine triphosphate (GTP) binding proteins of 
the Ras superfamily and are so-called because of their homology with Ras (Ras 
homologous). This family of 20-30kD monomeric proteins are thought to act as 
molecular switches to regulate numerous cellular processes, by cycling through an 
active GTP bound state and an inactive GDP bound state (Mackay and Hall 1998).
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These proteins have previously been described to play a role in cytoskeleton 
organisation (Paterson et al 1990, Ridley and Hall 1992), gene transcription (Coso et 
al 1995, Minden et al 1995), phagocytosis (Caron and Hall 1998) and pinocytosis 
(Ridley 1997). The most interesting role of which, given our present study, includes 
the role of Rho proteins in cell migration (Nobes and Hall 1999). These proteins are 
also thought to regulate tight junctions (Hall 1998) and work within the laboratory 
has shown that Rho proteins play a role in the regulation of lymphocyte TEM via 
ICAM-1 signalling (Adamson et al 1999).
Rho proteins cycle between an active GTP bound state and an inactive guanosine 
diphosphate (GDP) bound state (Boguski and McCormick 1993; Figure 5.1). This 
activation cycle is regulated by three main means; guanine nucleotide dissociation 
inhibitors (GDI’s), guanine nucleotide exchange factors (GEF’s) and GTPase- 
activation proteins (GAP’s). GDI’s are thought to bind to inactive RhoGDP proteins 
and result in their stabilisation. Dissociation of the GDI is thought to allow 
nucleotide exchange and activation mediated by GEFs. GAPs are responsible for the 
hydrolysis of Rho GTP to RhoGDP, which is subsequently sequestered by Rho-GDI. 
Active RhoGTPases are thought to interact with 30 or more potential effector proteins 
(reviewed by Bishop and Hall 2000) in order to initiate coordinated cellular 
responses.
A number of proteins of the Ras superfamily including the RhoGTPases contain a 
carboxyl terminal CAAX sequence, where C represents a cysteine, A represents an 
aliphatic amino acid and X represents any amino acid. This amino acid sequence is 
known to be a signal for three types of post-translational modification including 
prenylation, proteolysis and carboxyl group methylation (Hancock et al 1991). It has 
since been reported that Rho proteins undergo prenylation (Adamson et al 1992) 
which occurs via the C-terminal addition of C15 (famesyl; Casey et al 1989; Hancock 
et al 1989) or C20 (geranylgeranyl; Epstein et al 1990, Farnsworth et al 1990, Rilling 
et al 1990) isoprenoid structures. RhoA and RhoC are thought to undergo geranyl-
151
Rachel Ann Harry Immunomodulation by statins in vitro
RhoGDI
Rho
GDP GTP
GAP GEF
RhoGDI
Rho
GTP GDP
dD
cytoskeletal effects ?  gene transcription
Figure 5.1 The Rho GTPase cycle.
Rho GTPases are thought to exist in an inactive GDP-bound state complexed to one 
of the three known Rho-GDIs. In response to an incoming signal such as bradykinin, 
Rho-GDI dissociates, and a GEF catalyses nucleotide exchange and activation. It is 
thought that this is likely to occur at or close to the plasma membrane, because it is 
unlikely that isoprenylated GTPases will exist free in the cytosol. In its active state, 
the GTPase interacts with cellular targets or effectors (El-x) to generate a cellular 
response. Currently around eight potential targets are known for each of the three 
GTPases, Rho, Rac, and Cdc42, but there is no reason to believe that this list is 
complete. Most of the targets are ubiquitously expressed, and it is unknown how a 
GTPase "chooses" its target under a particular set of circumstances. Finally, one of 
around 10 known Rho GAPs will interact with the GTPase-target complex and 
catalyse GTP hydrolysis. The GDP-bound form of the GTPase is then "extracted" 
from the membrane by Rho-GDI, and the cycle is complete. The exact role of Rho­
GDI is unclear, and the rate-determining step in the cycle has not been determined. 
What is clear, however, is that Rho GTPases can, in their GTP-bound state, interact 
with numerous target proteins to induce coordinated signals. Taken from Mackay 
and Hall 1998.
152
Rachel Ann Harry Immunomodulation by statins in vitro
geranyl prenylation while RhoB exists in both a famesyl and geranylgeranyl 
prenylated form (Adamson et al 1992). The process of protein prenylation is known 
to influence biological activity, in that non-prenylated Rho proteins localize to the 
cytosol of the cell and are functionally inactive, while post-translational modification 
and activation permits interaction with cell membranes (Philips et al 1993, Boivin 
and Beliveau 1995). Previous experiments from within the laboratory have 
demonstrated that myristolation of Rho results in the generation of functional Rho 
and thus permits lymphocyte migration across BEC (Greenwood et al 2003). One 
known inhibitor of Rho function is C3 transferase from Clostridium botulinum, which 
was shown to inhibit Rho protein function through ADP ribosylation (Aktories et al 
1989) and has subsequently been shown to inhibit lymphocyte TEM.
More recently a group of compounds have been identified which are able to indirectly 
modulate Rho protein function. These compounds act as inhibitors of 3-hydroxy-3 - 
methylglutaryl co enzyme A reductase (HMG CoA reductase) and are more 
commonly known as statins. Statins are widely used in the clinical setting for the 
treatment of hypercholesterolemia (The Scandinavian Simvastatin Survival Study 
Group, 1994 and Shepard et al 1995). HMG-CoA reductase is the enzyme which 
regulates the rate-limiting step of cholesterol synthesis.
Statins function to inhibit the conversion of 3-hydroxy-3-methylglutaryl Co enzyme 
A (HMG CoA) to mevalonate through the inhibition o f HMG CoA reductase 
function. Inhibition of HMG CoA reductase results in the inhibition of cholesterol 
synthesis. Figure 5.2 is a schematic diagram of the cholesterol synthesis pathway in 
mammals. In addition to this, inhibition of mevalonate production results in the 
inhibition of subsequent intermediates of the cholesterol synthesis pathway which act 
as donors of isoprenoid pyrophosphate substrates such as the 15-carbon famesyl or 
20-carbon geranylgeranyl pyrophosphates (FPP, GGPP) which are essential for a 
number of cellular processes. Depletion of mevalonate by HMG-CoA reductase 
inhibition has been shown to result in the accumulation of unmodified proteins as a 
result o f limited FPP and GGPP availability (Schafer et al 1989, Leonard et al 1990).
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Figure 5.2 The Isoprenoid biosynthetic pathway.
Arrows indicate the site of action targeted by a number of inhibitors o f the isoprenoid 
biosynthetic pathway. The action of HMG-CoA reductase inhibitors or statins is 
represented as target l. Adapted from Holstein et al 2002.
154
Rachel Ann Harry Immunomodulation by statins in vitro
Isoprenoid pyrophosphate substrates are essential for the generation of functional Rho 
proteins (Zhang and Casey 1996). Statins, through the inhibition of isoprenoid 
donating compounds therefore inhibit the generation of functional Rho. Since 
functional Rho is essential for ICAM-1 mediated TEM across CNS derived 
monolayers (Adamson et al 1999), statins are likely to inhibit this process.
It has previously been demonstrated that protein prenyl transferase inhibitors prevent 
TEM as in vitro using BEC and also in vivo in EAE (Walters et al 2002) thus 
supporting the requirement of functional Rho for lymphocyte migration. Statins have 
previously been demonstrated to inhibit TEM in vitro using BEC (Greenwood et al 
2003) and also lymphocyte traffic in vivo in EAE (Youssef et al 2002, Greenwood et 
al 2003). Given that the BBB and BRB share numerous properties it was decided to 
investigate whether statins may influence TEM in an in vitro model of the BRB using 
REC.
Aims
The previous chapters document a role for CNS EC in the modulation o f T 
lymphocyte function as a result of TEM. In this chapter we aim to investigate 
whether statins are able to modulate the effects of CNS EC upon T lymphocyte 
function.
More specifically this chapter aims to investigate the effects of lovastatin upon 
lymphocyte adhesion to and migration across REC and RPE monolayers as in vitro 
models of the BRB and to investigate the role of ICAM-1 and its intracellular 
signalling pathway in this process.
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Results
Lovastatin affects T cell viability in a time- and dose-dependent manner
An initial study was conducted to investigate the effects of increasing concentrations
of lovastatin on T cell function, in particular T cell viability. Viability was 
determined by PI exclusion. T cells were either untreated or incubated with 
increasing concentrations of lovastatin [1-lOOpM] for up to 120h (Table 5.1). All 
incubations were carried out in the presence of IL-2. Results are expressed as the 
means of three independent experiments ± SD calculated as a percentage of the 
positive control without lovastatin.
Lovastatin suppressed T cell viability in a dose- and time-dependent manner. Of 
importance for the purposes of our immediate study is that at 4h (the maximum 
exposure of T cells to lovastatin for the duration of the migration assay) lovastatin 
showed no significant effect upon T cell viability except upon T cells cultured in the 
presence of lOOpM lovastatin (p<0.05; Table 5.1).
Lovastatin does not influence REC viability
Previous results from within the laboratory have determined optimal depletion of 
functional Rho within BEC to occur as a result o f treatment of EC monolayers with 
C3 transferase for 24h (Adamson et al 1992). We therefore investigated the effects 
of increasing concentrations of lovastatin upon EC viability at this time. REC 
monolayers as an in vitro model of the BRB were pretreated with increasing 
concentrations of lovastatin [0-100pM] and also C3 transferase [lOpg/ml] for 24h 
and cell viability determined by PI exclusion. Lovastatin showed no significant 
effect upon EC viability at 24h at each of the concentrations investigated. C3 
transferase elicited no significant effect upon EC viability at 24h (Figure 5.3) as 
compared to untreated controls.
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[Lovastatin] pM
Hours
00
0 0.1 1 10 50 100
1 100.0 ± 
0.0
100.2 ± 
3.7
100.5 ± 
0.9
99.6 ±0 .6 93.0 ±3.4* 74.9 ± 22.9
2 107.3 ± 
6.5
105.4 ± 
7.6
107.6 ± 
8.1
107.7 ± 
4 .I f
97.8 ± 11.4 72.5 ± 27.4
4 105.0 ± 
7.0
104.3 ± 
10.6
106.8 ± 
4.6
103.9 ± 
6.1
96.1 ±11.2 42.1 ± 
25.1*
6 100.1 ± 
10.2
100.0 ± 
10.0
99.2 ± 5.9 97.3 ±3.8 92.0 ± 15.6 27.7 ± 
22.0**
24 95.2 ± 
21.0
90.5 ± 
14.9
89.1 ± 
15.4
74.6 ± 7.7 52.5 ± 4.9* 5.8 ± 
1.7*ff
48 89.5 ± 
33.2
88.0 ± 
38.2
64.4 ± 
21.Of
5.4 ± 
4 .0*ff
5.4 ± 
6.6*ff
0.0 * f f
120 57.0 ± 
31.1
51.5 ± 
33.2
11.2 ± 
8 .3 ft
0.1 ±
0 .2*ff
0.1 ± 
0.1 **ff
0.0*ff
Table 5.1 Lovastatin exerts a time- and dose-dependent effect upon T cell 
viability in vitro.
Table shows the mean percentage viability o f Con A line T cells treated with 
increasing concentrations of lovastatin [0-100pM] for increasing periods as a 
percentage of control untreated cells. Cell viability was assessed by PI exclusion and 
flow cytometry. Values are expressed as a percentage o f control viability. Values 
represent the means of three independent experiments ± S.D. Statistical analysis was 
performed using the Students T Test. * p<0.05 compared with untreated control of 
same concentration, ** p<0.01 compared with untreated control of same 
concentration, t  p<0.05 as compared with respective lh  timepoint of control, t f  
p<0.01 as compared with respective lh timepoint of control.
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Figure 5.3 Increasing concentrations of lovastatin for 24h does not affect REC 
viability.
Percentage viability of REC populations was determined in populations pretreated for 
24h with increasing concentrations of lovastatin [0-100pM] or 16h with C3 
transferase [10pg/ml]. Cell viability was determined by PI exclusion and flow 
cytometry. Values are expressed as a percentage of untreated control viability. Bars 
represent the means of three independent experiments ±S.D. Statistical analysis was 
performed using the Students T Test.
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Treatment with lovastatin for 4h does not affect lymphocyte adhesion or 
migration
Subsequent experiments set out to determine the effect of lovastatin treatment on 
PLN adhesion to and antigen-specific T cell migration across REC monolayers. 
Mean basal migration of antigen-specific T cells across untreated monolayers was 
found to be 36.8 ± 6.8% while mean basal adhesion to REC monolayers was found to 
be 13.6 ± 2.6% (data not shown).
Previous studies determined that pretreatment of EC for 4h with statins has no effect 
upon T cell adhesion or migration using an in vitro model of the BBB (Greenwood et 
al 2003). Initially we investigated the effects of REC exposure to lovastatin for 4h. 
No significant difference in the level of PLN adhesion or antigen-specific T cell 
migration was detectable between lovastatin-treated and untreated monolayers 
(Figure 5.4).
Pre-treatment of REC with lovastatin for 24h inhibits lymphocyte migration
Given our previous findings that exposure of BEC monolayers to lovastatin for 24h
has been shown to result in the depletion of intracellular stores of isoprenyl groups 
thereby inhibiting TEM whilst having no detectable effect upon leukocyte adhesion 
(Greenwood et al 2003), we decided to investigate the effects of increasing 
concentrations of lovastatin on PLN adhesion and antigen-specific T cell migration 
upon REC after 24h pre-treatment (Figure 5.5). Small but significant decreases in 
PLN adhesion to lovastatin treated monolayers were detectable in a dose dependent 
manner in cultures pretreated with lovastatin [l-100pM] (100pM; 83.4 ± 1.9% as 
compared to untreated control; 100 ± 1.8%; p<0.05 and p<0.001) whilst a small but 
significant increase in PLN adhesion to C3 transferase treated monolayers was 
observed as compared to untreated controls (110.9 ± 3.9%; p<0.01; Figure 5.5). In 
contrast pretreatment with increasing concentrations o f lovastatin resulted in highly 
significant decreases in the level of TEM at all concentrations investigated (p<0.001). 
Using a known inhibitor o f TEM, levels of lymphocyte migration across C3 
transferase-treated monolayers were comparable with that observed for REC 
monolayers pretreated with 1 pM lovastatin.
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Figure 5.4 Exposure of REC and T cells to 10p,M lovastatin for 4h showed no 
significant effect upon T cell migration or adhesion to REC.
REC were cultured in the presence of lOpM prior to and during the assay for a 
maximum of 4h. Means are expressed as a percentage o f control adhesion or 
migration. Ten (migration) or twelve (adhesion) wells were assayed per condition 
per experiment. Each experiment was performed in triplicate. Results are expressed 
as the means ± SEM. Statistical analysis was performed using the Student's T-test.
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Figure 5.5 pretreatment of REC with lovastatin results in a significant inhibition 
of lymphocyte migration and a small but significant effect upon T cell adhesion.
REC monolayers were pre-treated with increasing concentrations of lovastatin [0- 
100pM] for 24h or 16h with C3 transferase [10pg/ml]. Means are expressed as a 
percentage of control adhesion or migration. Ten (migration) or twelve (adhesion) 
wells were assayed per condition per experiment. Each experiment was performed in 
triplicate. Results are expressed as the means ± SEM. Statistical analysis was 
performed using the Student's T-test. *p < 0.001, **p <0.01, ***p < 0.05 compared 
with untreated control.
161
Rachel Ann Harry Immunomodulation by statins in vitro
Lovastatin treatment does not affect ICAM-1 cell surface expression
To establish whether lovastatin altered REC expression of ICAM-1 and therefore
REC capacity for T cell adhesion and migration we set about to determine REC 
ICAM-1 expression in response to increasing concentrations of lovastatin. For this 
purpose REC monolayers were again pretreated with lovastatin [0-100pM] and the 
level of cell surface ICAM-1 expression determined by flow cytometry. Our data 
suggests that lovastatin does not affect REC cell surface expression o f ICAM-1 
(Figure 5.6).
Supplementation with mevalonolactone but not squalene restores lymphocyte 
TEM across lovastatin treated REC
Given our hypothesis that statins disrupt the ICAM-1 signalling pathway by the 
specific inactivation of Rho proteins, we set about to demonstrate that lovastatin 
inhibited migration as a result o f the inhibition of isoprenoid pyrophosphate 
intermediates, which are essential for the generation o f functional Rho and not as a 
result of the inhibition of the cholesterol synthesis pathway. Experiments were 
carried out in order to determine whether supplementation o f lovastatin treated 
monolayers with exogenous squalene, a precursor of cholesterol, or mevalonolactone, 
a precursor of isoprenoid donating compounds, could rescue the inhibitory effects of 
lovastatin. Given our hypothesis, we would predict that addition of exogenous 
mevalonolactone but not squalene, could restore lymphocyte TEM. In order to 
investigate this, REC monolayers were either untreated or pretreated with lovastatin 
[lOpM], mevalonolactone [5mM] or squalene [lOjaM] alone or with lovastatin in the 
presence of mevalonolactone or squalene (Figure 5.7).
Pretreatment with lovastatin or lovastatin and squalene resulted in a small but 
significant decrease in PLN adhesion; 93.5 ± 2.1% (p<0.05) and 91.5 ± 2.6% 
(p<0.05) respectively, as compared to control (100 ± 2.1%) while adhesion of PLN
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Figure 5.6 REC ICAM-1 expression is unaffected by lovastatin.
REC monolayers were pretreated with increasing concentrations of lovastatin [0- 
lOOpM] or C3 transferase [lOpg/ml] for 24h and 16h respectively. Levels of ICAM- 
1 expression were determined using the 1A29 antibody by flow cytometry. Bars 
represent mean percentage of ICAM-1 positive cells as a percentage of control 
ICAM-1 expression. Bars represent means ± S.D. o f three independent experiments.
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Figure 5.7 Concomitant administration of mevalonolactone but not squalene 
with lovastatin is able to reverse lovastatin-induced inhibition of lymphcoyte 
migration.
REC monolayers were pretreated for 24h with lovastatin, mevalonolactone or 
squalene alone or lovastatin in the presence of mevalonolactone or squalene. Means 
are expressed as a percentage of control adhesion or migration. Ten (migration) or 
twelve (adhesion) wells were assayed per condition per experiment. Each experiment 
was performed in triplicate. Results are expressed as the means ± SEM. Statistical 
analysis was performed using the Student's T-test. * p< 0.001, **p< 0.05 as 
compared with controls.
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to squalene treated monolayers was significantly increased to 105.7 ± 1.3% of control 
(p<0.05). Levels of adhesion of PLN to REC monolayers treated with 
mevalonolactone alone and lovastatin in the presence of mevalonolactone did not 
differ from that of control. Pretreatment o f REC monolayers with lovastatin resulted 
in a significant inhibition of antigen-specific migration as compared to control 
(p<0.001) while antigen-specific T cell migration across mevalonolactone, squalene 
and lovastatin and mevalonolactone treated monolayers showed levels of migration 
comparable with that of control. However, monolayers pretreated with lovastatin and 
squalene exhibited a significant inhibition in lymphocyte TEM (44.6 ± 4.9%; 
pO.OOl) as compared to controls.
Lovastatin inhibits lymphocyte migration across RPE monolayers
It is proposed that the BRB comprises of two barriers, the anterior BRB formed by
the REC of the retinal vasculature and also the posterior BRB formed by the RPE of 
the choroid. It was therefore decided to investigate the effect of lovastatin upon 
lymphocyte TEM across an in vitro model using the previously characterised LD7.4 
RPE cell line (Greenwood et al 1996). A mean level o f migration across LD7.4 
monolayers under control conditions was 31 ± 2.0% whilst mean adhesion to LD7.4 
monolayers was 26.3 ± 2.3% (data not shown; Figure 5.8).
Lovastatin elicited a small but significant inhibition of PLN adhesion to RPE 
monolayers as compared with control (92.8 ± 3.0% vs 100 ± 2.0%; p<0.05) while 
inhibition of antigen-specific T cell migration was comparable with that of the 
inhibition observed across lovastatin treated REC (23.9 ± 2.1% vs 100 ± 5.3%;
p<0.001).
Determination of active lovastatin
In our experiments inactive lovastatin was added to cultures and, due to the dose- 
dependent effects observed in vitro, it was important to quantitate the levels of active 
lovastatin hydroxy acid present within the cultures. The concentrations of lovastatin 
hydroxy acid were determined as described in chapter 2 (section 2.13.18).
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Figure 5.8 Pretreatment of RPE monolayers with lovastatin [lOpM] for 24h 
results in significant inhibition of lymphocyte TEM and a small but significant 
effect upon lymphocyte adhesion.
RPE cells were pretreated with lovastatin [10pM] for 24h and PLN adhesion to and 
antigen specific TEM across the RPE cell line was assessed. Means are expressed as 
a percentage of control adhesion or migration. Ten (migration) or twelve (adhesion) 
wells were assayed per condition per experiment. Each experiment was performed in 
triplicate. Results are expressed as the means ± SEM. Statistical analysis was 
performed using the Student's T-test. *p<0.001, **p<0.05.
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Results revealed that approximately 50% of total lovastatin added to each culture was 
present after 24h in the active lovastatin acid form (Table 5.2). This data would 
suggest that significant inhibition of lymphocyte TEM is achieved with 0.07pM 
lovastatin hydroxyacid.
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Concentration of Lovastatin [pM] Concentration of Lovastatin Acid [pM] ± SEM
0 0
0.1 0.07 ± 0.0
1 0.72 ±0.01
10 6.43 ± 0.24
50 28.13 ±2.01
100 51.30 ± 10.19
Table 5.2 approximately 50% of total lovastatin added to REC cultures is in the 
active lovastatin hydroxyacid form after 24h.
REC monolayers were pretreated with increasing concentrations o f lovastatin [0- 
lOOpM] for 24h after which time supernatants were harvested and assayed for 
lovastatin hydroxy acid concentrations by means of LC/MS/MS (see chapter 2). 
Results are shown as the means of triplicate samples ± S.D.
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Discussion
Given previous findings within the laboratory that statins were able to inhibit 
lymphocyte transmigration across the BBB we set about to determine whether similar 
mechanisms were employed at the BRB. Our data clearly demonstrates that 
lovastatin significantly inhibits lymphocyte TEM across both REC and RPE 
monolayers in vitro. This data also demonstrates that this inhibition o f TEM is not as 
a result o f the inhibition of the cholesterol synthesis pathway, but due to the specific 
inhibition of isoprenoid pyrophosphate intermediates and therefore the inhibition of 
active prenylated Rho and subsequent ICAM-1 signalling, which is known to be 
essential for migration across the BBB (Adamson et al 1999). It has previously been 
shown that another statin, pravastatin, inhibits neutrophil and monocyte migration 
across HUVECs in vitro in a mevalonate-dependent manner, which potentially 
supports a role for Rho dependent migration across HUVECs (Dunzendorfer et al 
1997).
REC pre-treatment for 24h with increasing concentrations of lovastatin resulted in a 
highly significant inhibition o f antigen-specific T cell TEM in a dose-dependent 
manner with similar effects previously described for lovastatin upon BEC 
(Greenwood et al 2003). From this data it was decided to investigate the effects of 
lOpM lovastatin as this showed significant inhibition o f antigen-specific lymphocyte 
TEM without a significant loss of T cell or EC viability, thereby suggesting the 
inhibitory effects observed are as a result of the direct effects of lovastatin upon EC 
intracellular signalling pathways and not simply due to a loss in cell viability. 
Previous reports have suggested statin treatment to be both anti- (Tanaka et al 2004) 
and pro-apoptotic (Kaneta et al 2003, Erl et al 2003). In our present study we 
investigated cell viability as determined by PI exclusion and therefore did not 
investigate apoptosis per se. The concentration o f lovastatin used in these studies has 
previously been used in the investigation of the effects of lovastatin upon TEM in an 
in vitro model of the BBB (Greenwood et al 2003).
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Exposure of both EC and T cells to lovastatin during the period of a 90min adhesion 
assay or 4h migration assay showed no significant differences in the levels o f PLN 
cell adhesion or antigen-specific T cell migration. This lack o f inhibition of TEM at 
4h suggests that a sufficient intracellular store of isoprenyl groups remains which 
must be utilized prior to the effects of lovastatin becoming evident (Adamson et al 
1999). Given that migration and adhesion assays were carried out in the presence of 
lovastatin our data would suggest that lovastatin does not inhibit the ICAM-1-LFA-1 
interaction as has previously been suggested. It has been suggested that statins may 
mediate their anti-inflammatory effect by binding directly to LFA-1 (Weitz-Schmidt 
et al 2001). The effects reported here for REC and RPE are consistent with the 
effects o f lovastatin upon BEC monolayers (Greenwood et al 2003) and also for the 
duration required in order to achieve sufficient depletion of intracellular stores of 
isoprenoid groups (Adamson et al 1999).
A significant inhibition of antigen-specific T cell migration was found as a result of 
EC treatment with statins for 24h. We predict these effects are due to the inhibition 
of isoprenyl groups required for the generation of functional Rho and a subequent 
inhibtion of REC and RPE ICAM-1 signalling pathways. Here we show that cell 
surface expression of REC ICAM-1 is not affected by lovastatin, which is consistent 
with ICAM-1 expression by BEC in response to lovastatin treatment (Greenwood et 
al unpublished data) and that pre-treatment of both REC and RPE monolayers with 
lovastatin for 24h results in comparable levels of TEM inhibition. This data therefore 
supports a role for lovastatin in the inhibition of T cell migration through RPE 
monolayers and thus migration at the level of the posterior BRB. Our results also 
suggest that similar mechanisms may be employed in T cell migration across RPE 
and REC monolayers, both o f which demonstrate a crucial role for ICAM-1 and 
intracellular ICAM-1 signalling.
Inhibition of TEM by C3 transferase, a known specific inhibitor of Rho proteins, was 
comparable with that of the inhibition achieved with pre-treatment of REC
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monolayers with lovastatin [lpM ]. This data supports a role for Rho proteins in the 
inhibition of T cell migration by lovastatin at the BRB.
Given our hypothesis, we set about to demonstrate that lovastatin specifically inhibits 
lymphocyte TEM as a result of the inhibition of isoprenoid pyrophosphates, 
intermediates of the cholesterol synthesis pathway, and not as a result o f inhibition of 
cholesterol synthesis. Experiments were performed to determine the effects of 
exogenous mevalonolactone, a precursor o f isoprenoid donating compounds and 
squalene, an intermediate of the cholesterol synthesis pathway downstream of the 
isoprenyl donating compounds at concentrations previously used with effects 
observed in vitro for mevalonolactone (Greenwood et al 2003) and squalene (Fisher 
et al 1999).
We found that inhibition of lymphocyte TEM by lovastatin was reversed by the 
addition of exogenous mevalonolactone but not as a result of the addition of 
exogenous squalene. This data supports our hypothesis that lovastatin-mediated 
inhibition of migration is not due to an inhibition of the cholesterol synthesis 
pathway, but is more specifically due to the inhibition of isoprenoid pyrophosphate 
donating compounds such as GPP and FPP, which are restored by the addition of 
exogenous mevalonolactone. This data is consistent with that previously reported for 
BEC (Greenwood et al 2003) and therefore suggests that similar mechanisms may be 
involved in lymphocyte migration across the BBB and BRB.
Pretreatment of EC for 24h with increasing concentrations of lovastatin shows small 
but statistically significant differences in the levels of PLN adhesion to REC 
monolayers. The biological significance of this reduction however, is undetermined. 
It is possible that the small reduction in adhesion is of functional relevance and that 
lovastatin treatment may elicit effects upon EC expression o f cell adhesion molecules 
essential for PLN adhesion such as selectins and the Ig superfamily. However, as 
our studies demonstrate, lovastatin does not affect REC expression of ICAM-1. This 
may therefore suggest that lovastatin affects PLN adhesion to REC independently of
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ICAM-1-mediated adhesion and, as such, may modulate the expression of molecules 
such as VCAM-1, known to play a role in lymphocyte adhesion to the vascular 
endothelium.
Previous findings within the laboratory showed that lovastatin is able to inhibit 
lymphocyte TEM across BEC in vitro and reduce lymphocyte traffic into the CNS in 
an experimental model o f CNS inflammation, namely EAE (Greenwood et al 2003). 
Given that lovastatin is specifically able to inhibit lymphocyte TEM across REC and 
RPE in vitro and that similar mechanisms are involved in lymphocyte migration at 
the BRB and BBB, we therefore decided to investigate whether lovastatin is able to 
inhibit lymphocyte trafficking across the BRB in vivo. For this we used EAU as a 
model of human posterior uveitis.
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Chapter 6
Immunomodulation of EAU by statins in vivo.
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Introduction
As a result of the findings presented in chapter 5, that lovastatin treatment of REC in 
vitro could prevent or inhibit lymphocyte transmigration across the BRB, it was 
decided to test whether lovastatin could modulate lymphocyte trafficking in vivo.
Statins have previously been shown to modulate inflammatory cell infiltration into 
the CNS during EAE (Stanislaus et al 1999, Stanislaus et at 2001, Youssef et al 2002, 
Greenwood et al 2003, Aktas et al 2003). It was therefore decided to test whether 
statins were able to influence clinical progress of a CD4+ T cell-mediated 
autoimmune inflammatory disease o f the retina. It has previously been suggested that 
statins mediate the amelioration of clinical EAE by the induction of Th2 type or anti­
inflammatory cytokines (Stanislaus et al 2001, Youssef et al 2002, Aktas et al 2003, 
Nath et al 2004). Studies from within our laboratory have provided evidence to 
suggest that statins may also alleviate disease through the inhibition of leukocyte 
migration (Greenwood et al 2003). Independent research also supports these findings, 
since it has been found that statins inhibit leukocyte migration into the CNS through 
the suppression of matrix metalloproteinase-9 (MMP-9; Neuhaus et al 2002, Wong et 
al 2001), known to be essential for the transmigration o f leukocytes through the basal 
lamina (Goetzl et al 1996). Statin treatment has also been shown to inhibit the 
expression of both MHC class II antigen and co-stimulatory molecules on APC that 
are essential for stimulating autoimmune T-cells (Youssef et al 2002).
EAU is a well-characterised model for T cell-mediated retinal disease, which has 
been used for the characterisation of events involved in T cell infiltration across the 
BRB and into the retina. We therefore set out to test our hypothesis that lovastatin 
inhibits T cell trafficking across the BRB in vivo using the Lewis rat model of SAg 
peptide induced uveitis (Fling et al 1991). However, we were unable to induce 
reliable disease using this model and therefore decided to use a mouse model of 
EAU.
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IRBP peptide161' 180 induced EAU in the B10.RIII mouse, previously characterised by 
Hankey et al (2001) is a reliable model of retinal disease which results in a high 
incidence and severity of disease (Silver et al 1995). Further characterisation o f this 
model has revealed timepoints for the onset of lymphocyte infiltration and for the 
expected peak of disease thereby providing us with an extremely well characterised 
acute model of EAU, suitable for the assessment of immunomodulation of disease.
Aims
Having demonstrated that lovastatin is able to inhibt lymphocyte TEM in vitro (as 
presented in chapter 5) we set out to investigate whether lovastatin and another statin, 
atorvastatin, were able to modulate lymphocyte trafficking in vivo, using a mouse 
model of EAU.
Given the known pleiotropic effects of statins upon clinical disease including EAE 
we also investigated whether previously reported effects of statins including the 
induction of Th2 type cytokines and suppression of MHC class II expression were 
observed as a result of statin treatment of EAU.
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Results
Effect of Lovastatin upon Lewis rat EAU
Initially we investigated the effects of lovastatin using a rat in vitro model of the BRB 
we therefore set out to investigate the effects o f lovastatin upon Lewis rat SAg 
peptide induced EAU. SAg peptide induced EAU [75pg] was induced following the 
method of Fling et al (1991), and lovastatin therapy was initiated prior to the 
expected onset of lymphocyte infiltration at day 6 post immunisation. Eyes were 
assessed for clinical signs of disease daily by two independent observers from the 
onset o f lovastatin therapy until the predicted peak of disease, day 15 post 
immunisation. However no detectable clinical disease was observed in the eyes of 
vehicle treated animals. To confirm our findings, we continued by investigating 
vascular disease of these animals by FA (day 12; Figure 6.1 A-C, see chapter 2 
section 2.13.3) and also retinal disease (see chapter 2, section 2.13.7) by toluene blue 
staining of semi-thin sections of retina post enucleation at peak disease (Figure 6.1 D- 
F). Using these two parameters no clinical disease was determined in vehicle treated 
animals (Figure 6.1 B and E). Subsequent experiments set about to determine the 
effects of increasing amounts of peptide [0-600pg] upon the induction o f EAU 
however no clinical, vascular or retinal disease was detectable at each of the doses 
investigated. As we were unable to induce disease by means of active immunisation 
with peptide we attempted to adoptively transfer EAU using uveitogenic T cells from 
actively immunised animals.
4-6wk old female Lewis rats were actively immunised with SAg peptide [75 pg] and 
10 days post immunisation PLN T cells were isolated and cultured in the presence of 
SAg peptide following the method of Sedgewick et al (1989; see chapter 2 section 
2.6.5) in order to establish uveitogenic SAg peptide T cell lines. 48h prior to 
adoptive transfer of antigen-specific T cell line cells, cells were restimulated with 
antigen and feeders (see chapter 2, section 2.13.9). Naive 4-6wk old female Lewis 
rats were then immunised with either lxlO6 or 5x106 activated SAg peptide specific T
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Figure 6.1 SAg peptide induced EAU in the Lewis Rat.
Panels A-C show vascular caliber of a normal control, vehicle treated and lovastatin 
treated retina respectively 12 days post immunization as determined by fluorescein 
angiography using a scanning laser ophthalmoscope. Panels D-F are representative 
light micrographs of toluidine blue stained histological semi-thin sections taken using 
a LSM 510 confocal microscope operating in transmission mode using a FITC 
configuration. A normal control (D), vehicle treated (E) and lovastatin treated (F) 
retina are shown. No signs of vascular leakage were detected as a result of 
fluorescein angiography, and no sign of disease was assessed daily from transfer of T 
cells to expected peak disease between day 13 and 15. Clinical grading of retinal 
disease was evident as determined by classical histology. Bar represents lOOpM.
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cells. Animals were then monitored daily for signs o f adoptively transferred ocular 
inflammation. Clinical disease was assessed daily from transfer of T cells to 
expected peak disease between day 13 and 15. Clinical grading o f disease was 
performed by two independent observers, however no clinical signs of disease were 
evident. To confirm these findings, vascular disease was assessed by FA and retinal 
disease determined by histology as described previously. No evidence of 
inflammation was detectable using either FA or classical histology. As these 
experiments were carried out following established protocols but no clinical disease 
was detected, we suspect that modifications to the peptide may have occurred during 
preparation, which may have altered the uveitogenic nature of the peptide.
Given our desire to test our hypothesis in vivo, that statins are able to modulate 
lymphocyte trafficking through the specific inhibition o f ICAM-1 signalling, we 
decided to investigate the effects of lovastatin and atorvastatin in the B 10.RIII mouse 
model of EAU in order to determine whether variations exist in the efficacy of 
different statins. For this purpose EAU was induced in 5-7 week old B10.RIII male 
mice by subcutaneous injection of 25pg of human IRJBP peptide in incomplete 
freunds adjuvant supplemented with 60pg/ml Mycobacterium Tuberculosis (Hankey 
et al 2001). Daily treatment regimens (see chapter 2 section 2.13.11) were applied to 
each clinical group 5 days post immunisation until the expected peak of disease at 
day 12. Lovastatin treatment was given by intraperitoneal injection while atorvastatin 
was administered by oral gavage. Intraperitoneal injection o f DMSO:PBS vehicle 
served as a control for lovastatin-treated animals while oral administration of PBS 
served as a control for atorvastatin-treated animals. Clinical disease was assessed 
daily from day 5 onwards with FA used to determine vascular disease at day 10 post 
immunisation. Retinal disease, as quantitated by classical histology, was graded at 
expected peak of disease (day 12). All subsequent experiments were carried out 
using this mouse model.
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Lovastatin but not atorvastatin treatment of EAU ameliorates signs of ocular 
clinical disease
Clinical scoring of each treatment group was assessed daily until the predicted onset 
of peak disease. Mean clinical score of each treatment group was calculated at peak 
disease as the mean of both eyes. Normal animals presented with bright eyes with a 
good red reflex. Vehicle-treated animals in contrast showed signs of inflammation 
from day 9 which increased in severity to day 12. Signs of inflammation included 
clouding of the eye and a poor red reflex (Figure 6.2 A and C). Lovastatin-treated 
EAU induced animals presented with minimal signs o f inflammation and generally 
exhibited a good red reflex (Figure 6.2 B and D). Lovastatin and mevalonolactone- 
treated animals showed signs of inflammation comparable with that of vehicle-treated 
controls whilst lovastatin and squalene-treated animals showed minimal signs of 
inflammation, which was comparable with that of lovastatin-treated animals.
Clinical grading of animals by two independent observers revealed that lovastatin 
treatment at both concentrations resulted in a significant reduction in disease 
incidence (p<0.001), mean group score (p<0.001) and mean EAU score (p<0.01) as 
compared to vehicle-treated animals (Table 6.1). Lovastatin and mevalonolactone 
treatment of EAU animals showed a small but significant decrease in mean group 
score (p<0.05) and also mean EAU score (p<0.01) as compared with vehicle-treated 
animals, however incidence of disease (p<0.01) and mean group scores (p<0.01) were 
found to be significantly greater than that of lovastatin-treated animals (Table 6.1). 
Lovastatin and squalene-treated animals showed a significant reduction in disease 
incidence (p<0.001) and mean group score (p<0.001) as compared to vehicle-treated 
animals, whilst no significance was detectable as compared to lovastatin-treated 
animals (Table 6.1).
In contrast atorvastatin treated animals showed no significant difference in disease 
incidence or disease severity as compared to vehicle gavage controls (Table 6.1).
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Vehicle treated Lovastatin treated
(grade 3) (graded)
Figure 6.2 Clinical EAU.
Clinical symptoms of disease were graded following criteria previously described 
(Chapter 2). Panels A and C show a vehicle treated animal with grade 3 disease. 
Panels B and D show an animal treated with lovastatin [20mg/kg/day].
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Treatment No.
EAU/total
Mean Group 
Score
Mean EAU 
Score
Normal 0/12 0.0 ± 0.0 0.0 ±0.0
Vehicle treated (i.p) 23/26 2.88 ±0.31 3.26 ±0.25
Lovastatin [20 mg/kg/day] 8/27*** 0.59 ±0.20*** 2.00 ±0.33**
Lovastatin [2 x 20 mg/kg/day] 0/5*** 0*** 0
Lovastatin + mevalonolactone 11/1355 1.54 ±0.35*55 1.82 ±0.35**
Lovastatin + squalene 0/6*** Q *** 0
Vehicle treated (gavage) 7/8 3.38 ±0.56 3.86 ±0.34
Atorvastatin [ 10 mg/kg/day] 13/18 2.22 ±0.40 3.08 ±0.31
Table 6.1 Mean clinical score of EAU day 12 post immunisation.
Clinical disease was graded following criteria described in chapter 2. Incidence o f 
EAU is calculated as the number of animals, which display clinical signs of disease 
as a proportion of the total number of animals within the experimental group. The 
mean group score is calculated as the mean disease score of all animals within the 
experimental group, while the mean EAU score is determined as the mean of all 
animals, which showed signs of clinical disease. Data from vehicle and lovastatin- 
treated mice are means from four separate experiments. Data from lovastatin and 
mevalonolactone-treated and atorvastatin-treated mice are from two separate 
experiments. Data from lovastatin [2 x 20 mg/kg/day], lovastatin and squalene are 
from one experiment. Statistical analysis was performed using the Mann-Whitney 
test. * p<0.05 compared to vehicle control, **p<0.01 compared to vehicle control, 
***p<0.001 compared to vehicle control and 55 p<0.01 compared to lovastatin.
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Lovastatin but not atorvastatin treatment of EAU ameliorates signs of retinal 
vascular disease
Vascular disease was assessed by means of FA and a fundus camera (see chapter 2 
section 2.13.12). Photographs of the retina were captured 3 min (early angiograms) 
and 5-8 min (late angiograms) post intraperitoneal injection of sodium fluorescein 
[2%]. Fluorescein angiograms were scored blind by Hadi Zambarakji. Control 
animals showed no signs of vascular leakage (Figure 6.3A). Early and late 
angiograms of vehicle-treated animals show significant levels of hyperfluorescence at 
the optic disc and dilation of blood vessels (Figure 6.3 B and C). Lovastatin-treated 
animals showed no signs of vascular dilation or hyperfluorescence in both early and 
late angiograms (Figure 6.3 D and E). Lovastatin and mevalonolactone-treated 
animals showed signs of vascular dilation and hyperfluoresence (Figure 6.3 F). 
Minimal signs of vascular dilation and hyperfluorescence were observed in the 
lovastatin and squalene-treated group. Fluorescein angiograms o f atorvastatin and 
vehicle (gavage) treated animals revealed marked vascular dilation and 
hyperfluorescence (data not shown).
Clinical grading of the fluorescein angiograms revealed that lovastatin treatment of 
EAU resulted in a significant reduction in disease incidence (p<0.01) and also mean 
group score (p<0.001) as compared to vehicle-treated animals (Table 6.2). Lovastatin 
and mevalonolactone-treated animals presented with clinical disease comparable with 
that of vehicle-treated animals, however disease incidence (p<0.01) and mean group 
score (p<0.01) were found to be significantly greater than that of lovastatin-treated 
animals (Table 6.2). Lovastatin and squalene-treated animals showed a significant 
difference in mean group score (p<0.05) as compared with vehicle control, however 
the reduction in disease incidence in this group did not achieve significance. No 
significant differences were detectable as compared with lovastatin-treated animals 
(Table 6.2).
Atorvastatin-treated animals showed no significant differences as compared to 
vehicle-treated animals by each of the three parameters assessed (Table 6.2).
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Figure 6.3 Representative images of retinal vessels during FA of normal, vehicle 
and lovastatin treated animals.
Clinical disease as determined by vascular leakage was graded following criteria 
previously described (Chapter 2). Panel A shows an early angiogram from a normal 
control animal. Panel B and C show an early and late angiogram of a vehicle (i.p.) 
treated animal respectively. This animal was determined to have grade 3 disease. 
Panels D and E show early and late angiograms from a lovastatin treated animal. 
This animal was given grade 0. Panel F shows an early angiogram from a lovastatin 
and mevalonolactone treated animal. This animal was scored with grade 3 disease.
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Treatment No.
EAU/total
Mean Group 
Score
Mean EAU 
score
Normal animals 0/3 0 0
Vehicle treated 9/13 1.38 ±0.33 2.00 ±0.33
Lovastatin [20 mg/kg/day] 1/10** 0.10 ± 0.10*** 1.00 ±0.00
Lovastatin + mevalono lactone 5/«& 1.33 ± 0 .4 2 ^ 1.60 ±0.40
Lovastatin + squalene 2/6 0.33 ±0.21* 1.00 ±0.00
Atorvastatin [10 mg/kg/day] 4/6 0.67 ±0.21 1.00 ±0.00
Table 6.2 Mean vascular leakage scores as determine by FA.
FA was performed at day 10 post immunisation. Vascular leakage was graded 
following criteria described previously (Chapter 2). Incidence of leakage is 
calculated as the number of animals which display vascular leakage of disease as a 
proportion of the total number of animals within the experimental group assessed by 
FA. The mean group score is calculated as the mean score of the animals assessed 
within the experimental group, while the mean EAU score is determined as the mean 
of all animals which showed signs of vascular leakage. Data from vehicle and 
lovastatin-treated mice are means from four separate experiments. Data from 
lovastatin and mevalonolactone-treated and atorvastatin-treated mice are from two 
separate experiments. Data from lovastatin [2 x 20 mg/kg/day], lovastatin and 
squalene are from one experiment. Statistical analysis was performed using the 
Mann-Whitney test. *p<0.05 compared to vehicle control, *** p<0.001 compared to 
vehicle control, ££ p<0.01 compared to lovastatin.
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Control
Grade 1
Grade 2
Grade 3
Grade 4
Figure 6.4 Representative images of EAU histology.
Eyes were enucleated at peak disease and histological disease was graded following 
criteria described in chapter 2. Panel A shows a normal retina grade 0, panel B shows 
a retina isolated from a lovastatin treated animal, grade 1. Panel C shows a retina 
isolated from a lovastatin and mevalonolactone treated animal, while panels D and E 
show retinae from vehicle treated animals of grade 3 and 4 respectively.
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Treatment No.
EAU/total
Mean Group Score Mean EAU Score
Normal 0/12 0.0 ± 0.0 0.0 ± 0.0
Vehicle treated (i.p) 25/26 3.42 ±0.31 3.56 ±0.29
Lovastatin [20 mg/kg/day] 15/27** 1.44 ±0.31*** 2.60 ± 0.32*
Lovastatin [2 x 20 mg/kg/day] 2/5* 0.40 ±0.24*** 1.00 ±0.00
Lovastatin + mevalonolactone 13/13^ 2.54 ± 0.39*2, 2.54 ±0.39*
Lovastatin + squalene 1/6** 0.33 ±0.33 *** 2.00 ± 0.00
Vehicle (gavage) 8/8 4.25 ± 0.49 4.25 ± 0.49
Atorvastatin [10 mg/kg/day] 18/18 3.44 ±0.32 3.44 ±0.32
Table 6.3 Mean histological score of retinal disease.
Eyes were enucleated and immersion fixed in Kamovsky’s fixative. Histological 
disease was graded following criteria described (Chapter 2). Incidence o f EAU is 
calculated as the number of animals which display clinical signs of disease as a 
proportion of the total number of animals within the experimental group. The mean 
group score is calculated as the mean disease score of all animals within the 
experimental group, while the mean EAU score is determined as the mean of all 
animals which showed signs of clinical disease. Data from vehicle and lovastatin- 
treated mice are means from four separate experiments. Data from lovastatin and 
mevalonolactone-treated and atorvastatin-treated mice are from two separate 
experiments. Data from lovastatin [2 x 20 mg/kg/day] and lovastatin and squalene is 
from one experiment. Statistical analysis was performed using the Mann-Whitney 
test. * p<0.05 compared to vehicle control, ** p<0.01 compared to vehicle control, 
*** p<0.001 compared to vehicle control, £, p<0.05 compared to Lovastatin, ££ 
p<0.01 compared to Lovastatin.
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Statin treatment does not affect serum cholesterol concentration
We next investigated the effects of our dosing regimen upon serum cholesterol
concentration in the different experimental groups. Lovastatin treatment of EAU did 
not significantly affect serum cholesterol levels as compared to vehicle-treated 
animals or normal controls (Figure 6.5). However lovastatin and squalene-treated 
animals were found to exhibit a small but significant increase in serum cholesterol as 
compared with vehicle-treated controls (p<0.05), while atorvastatin-treated animals 
showed a significant increase in serum cholesterol as compared with normal controls 
(p<0.05; Figure 6.5).
Lovastatin but not atorvastatin treatment reduced total splenocyte number
Data presented here clearly supports a role for statin therapy in the amelioration of
EAU. Given our in vitro findings outlined in chapter 5 and the results presented here, 
we hypothesise that amelioration of disease is due to the inhibition of ICAM-1 
signalling, and therefore an inhibition of lymphocyte trafficking into the CNS. This 
theory is strongly supported by the rescue of inhibition of T cell migration both in 
vivo and in vitro (chapter 5) by the addition of exogenous mevalonolactone but not 
squalene. Previous reports have suggested that statins may influence T cells directly 
(Youssef et al 2002, Stanislaus et al 2002, Neuhaus et al 2002, Hillyard et al 2002, 
Aktas et al 2003, Leung et al 2003, Nath et al 2004) by the modulation of T cell 
effector mechanisms. We therefore investigated the effects of statins upon T cells in 
our system.
Our first observation was that lovastatin treatment of EAU induced animals resulted 
in a significant reduction in total splenocyte number (p<0.01) as compared with 
vehicle-treated controls (Figure 6.6 A). Both once and twice daily treatment with 
lovastatin resulted in a highly significant reduction in splenocyte number as 
compared with vehicle-treated animals (p<0.001 and p<0.01 respectively; Figure 6.6 
A). Lovastatin and mevalonolactone treatment resulted in a significant decrease in 
cell numbers as compared with vehicle-treated animals (p<0.05), while lovastatin and 
squalene therapy resulted in a significant increase in cell numbers (p<0.05) as 
compared with lovastatin treatment alone.
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200 n
Control Vehicle Lovastatin Lovastatin + Atorvastatin
squalene
Figure 6.5 Histogram of mean serum cholesterol levels in control, vehicle, 
lovastatin, lovastatin and squalene and atorvastatin treated individuals.
Cholesterol levels were determined using the Infinity™ Cholesterol liquid stable 
reagent kit (as described in chapter 2). Statistical analysis was performed using the 
Mann-Whitney test and statistical significance was detected as follows; * p<0.05 as 
compared with vehicle controls and f  p<0.05 compared with normal controls.
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Figure 6.6 Lovastatin treatment results in a significant reduction of total 
splenocyte number but atorvastatin therapy does not.
Panel A shows splenocyte number from lovastatin and lovastatin-related-treated 
animals. Panel B shows splenocyte number of atorvastatin-treated animals. Total 
viable splenocyte number was determined using a haemocytometer and trypan blue 
exclusion. Statistical analysis was performed using the Mann-Whitney U test. * 
p<0.05 ** p<0.01 and ***p<0.001 as compared to vehicle control, t  p<0.05, f t  
p<0.01 as compared to lovastatin (20mg/kg/day).
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Atorvastatin therapy in contrast showed no significant effect upon total splenocyte 
number as compared with vehicle gavage-treated controls (Figure 6.6B).
Lovastatin but not atorvastatin treatment results in an inhibition of T cell 
proliferation
Splenocyte proliferation was assessed immediately ex vivo by means of a 
proliferation assay (see chapter 2, section 2.13.13). Splenocytes isolated from normal 
control animals showed no significant proliferation in response to antigen, although 
the response to Con A was positive (data not shown). Incubation of splenocytes 
isolated from vehicle, lovastatin, lovastatin and mevalonolactone, lovastatin and 
squalene and atorvastatin-treated animals with antigen in culture resulted in a dose- 
dependent increase in proliferation as compared with unstimulated cultures of the 
same experimental group (p<0.05, p<0.01; Figure 6.7 A). Constitutive (unstimulated) 
splenocyte proliferation of the lovastatin, lovastatin and mevalonolactone and 
lovastatin and squalene groups was significantly lower than that o f vehicle (i.p.) 
controls (p<0.05 and p<0.01 respectively) while constitutive proliferation of 
splenocytes from the atorvastatin-treated group showed no difference as compared 
with that of the vehicle gavage group (Figure 6.7 B). Splenocyte responses to antigen 
were reduced as a result of lovastatin and mevalonolactone (p<0.01), lovastatin and 
squalene treatment (p<0.01) and lovastatin alone although lovastatin treatment did not 
achieve significance. Lovastatin and mevalonolactone-treated splenocyte 
proliferation but not lovastatin and squalene-treated splenocytes proliferation in 
response to antigen was significantly lower than that observed in lovastatin-treated 
cultures alone (p<0.05). This data suggests that lovastatin therapy reduces the 
proliferative capacity of splenocytes in response to antigen and ConA (data not 
shown). Cultures were also incubated with an anti-MHC class II antibody to 
determine whether antigen presentation within these cultures was MHC class II 
restricted (Figure 6.7 A and B). Culture of splenocytes in the presence of an anti- 
MHC class II antibody resulted in a significant inhibition of splenocyte proliferation 
in vehicle (p<0.01), lovastatin (p<0.01) and atorvastatin (p<0.01) treated splenocytes. 
Anti-MHC class II antibody-mediated suppression of proliferation in response to 
antigen failed to reach significance in normal control cultures (data not shown). This
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Figure 6.7 Lovastatin but not atorvastatin treatm ent results in a significant 
inhibition of splenocyte proliferation.
Panel A shows splenocyte proliferation o f lovastatin and lovastatin related cultures 
while panel B shows splenocyte proliferation o f  atorvastatin cultures. Splenocyte 
proliferation is increased in primed splenocyte populations in response to antigen 
stimulation. Proliferation o f primed splenocyte populations is inhibited by the 
incorporation o f an anti-MHC class II blocking antibody. Splenocytes were cultured 
at 5x l06 cells/ml in the presence or absence o f IRBP peptide for 72h. Proliferation o f 
splenocytes was quantitated by methyl-3H thymidine incorporation and scintillation 
counting. Statistical analysis was performed using the Mann-Whitney U test. 
Statistical analysis revealed, * p<0.05, ** p<0.01, as compared to unstimulated 
control within group, f  p<0.05, f t  p<0.01 20pg/ml peptide plus antibody as 
compared with 20pg/ml peptide alone, f  p<0.05, as compared with lovastatin alone 
and # p<0.05, ## p<0.01 as compared with vehicle alone. Splenocyte proliferation in 
the presence o f MHC class II antibody was not performed for vehicle gavage, 
lovastatin and mevalonolactone and lovastatin and squalene-treated cultures.
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data suggests that the proliferation observed in antigen primed cultures i.e. vehicle, 
lovastatin and atorvastatin-treated cultures is MHC class II restricted.
Lovastatin treatment ameliorates clinical disease in the absence of a Th2 profile
The influence of the different treatment regimens upon splenocyte cytokine secretion 
was investigated (see chapter 2, section 2.13.14). Cytokine secretion was quantitated 
for individual animals and the mean levels calculated for each experimental group, a 
panel of cytokines were investigated, which included Thl, Th2 type cytokines and 
also regulatory cytokines: IL-2, IL-4, IL-5, IL-10, IL-12, IFN-y, TNF-a and TGF-p. 
In accordane with the methods of Youssef et al (2002), cytokine secretion was 
investigated at similar timepoints. For this purpose IL-2 and IL-12 were quantitated 
at 48h, IFN-y, TNF-a, IL-10 and TGF-P were measured at 72h while IL-4 and IL-5 
were measured at 120h.
No significant difference in the level of cytokine secretion was detectable between 
unstimulated cultures of splenocytes from each experimental group as compared with 
unstimulated splenocytes isolated from normal control animals. Antigen stimulation 
of splenocyte cultures from vehicle (i.p.)-treated animals resulted in a significant 
increase in IL-2, IFN-y and IL-10 as compared to unstimulated normal control 
cultures (p<0.01) however no increase in TNF-a secretion was detectable (Figure 
6.8). In contrast, antigen-specific stimulation of splenocytes isolated from lovastatin 
treated animals resulted in a significant increase in IL-2 (p<0.01) and IFN-y 
(p<0.001) secretion as compared to their respective unstimulated controls. No 
significant differences were detectable in the levels of TNF-a in response to antigen 
stimulation as compared to unstimulated controls. Similarly IL-10 production in 
response to antigen stimulation of lovastatin treated splenocytes was not detected 
(Figure 6.8). Lovastatin treatment however, resulted in a significant decrease in IFN
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Figure 6.8 Statin treatment results in a significant increase in TNF-a production 
and a significant decrease in IL-10 production as compared with vehicle-treated 
splenocytes.
Atorvastatin therapy results in a small increase in TNF-a and IFN-y and IL-10 
production as compared to vehicle controls splenocytes. Splenocytes were cultured at 
a density of 5xl06/ml for varying time periods after which supernatants were 
harvested, stored at -70°C until assay for cytokine production by ELISA. Histograms 
show means ± SEM of duplicate wells from at least 6 animals from three independent 
experiments. Statistical analysis was determined using the Mann-Whitney U test. 
Statistical significance was determined as follows; *p<0.05, **p<0.01, ***p<0.001 as 
compared to unstimulated control and f  p<0.05 and f t  p<0.01 as compared with 
vehicle control. Control samples stimulated with antigen were not analysed.
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-y and IL-10 (p<0.05) and an increase in TNF-a (p<0.05) following antigen 
stimulation as compared to the corresponding vehicle group (Figure 6.8).
A significant increase in constitutive secretion of TNF-a was detectable in the 
atorvastatin treated group as compared with vehicle-treated splenocytes (p<0.01). 
Stimulation of both vehicle gavage and atorvastatin treated splenocytes with IRBP 
peptide resulted in a significant increase in IFN-y (p<0.001), TNF-a (p<0.001 and 
p<0.01, respectively), IL-10 (p<0.001) and IL-2 (p<0.001). Atorvastatin treatment 
resulted in an increased constitutive secretion of TNF-a (p<0.01) and a significant 
decrease in IL-10 in response to antigen as compared to vehicle controls (p<0.01).
TGF-P cytokine secretion was assessed in vehicle treated and lovastatin treated 
splenocyte cultures (data not shown). Constitutive and antigen stimulated secretion 
of TGF-p by vehicle (i.p.) treated splenocytes was 525.5 ± 64.6pg/ml and 511.4 ± 
49.4pg/ml whilst constitutive and antigen-induced TGF-P secretion by lovastatin 
treated splenocytes was found to be 512.6 ± 61.4pg/ml and 510.5 ± 42.1pg/ml 
respectively. No significant differences were detectable in the levels of TGF-p 
between each experimental group
In all samples assayed, very low levels of IL-4, IL-5 or IL-12 were detectable by 
ELISA. IL-4 and IL-5 secretion was also investigated by cytometric bead array and 
again no significant levels of IL-4 or IL-5 were detectable.
Statin treatment of EAU does not induce T regulatory cells
Previous studies have shown a clear switch from a Thl cytokine profile to a Th2
cytokine profile as a result o f statin therapy (Youssef et al 2002, Stanislaus et al 2002, 
Neuhaus et al 2003, Aktas et al 2003, Nath et al 2004). In contrast our results suggest 
that statins ameliorate clinical EAU in the absence of a Thl to Th2 switch in the 
B10.RIII mouse.
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We therefore set about to determine whether statin therapy may elicit any effects 
upon immunoregulatoiy T cells (Tregs). Tregs were identified by their co-expression 
of CD4, CD25 and CD62L (Fisson et al 2001). Flow cytometric analysis of 
CD4+CD25+CD62Lhl cells showed no significant difference in the levels of 
phenotypically determined Tregs in vehicle, lovastatin or atorvastatin-treated groups 
(Figure 6.9).
A preliminary experiment to investigate the presence of functional Tregs was 
designed. In an attempt to assess whether the degree of clinical efficacy of statin 
treatment correlates with the modulation of Treg populations, PLN T cell populations 
from individual animals were tested for their ability to suppress vehicle-treated PLN 
T cell antigen-mediated proliferation.
CFSE+ PLN T cells isolated from a vehicle-treated animal of grade 5 disease were 
cultured alone or in the presence of IRBP peptide [20pg/ml], with Con A [5pg/ml] as 
a positive control. Cells were also incubated with IRBP peptide in the presence of 
increasing numbers of PLN T cells isolated from a vehicle-treated animal of grade 4 
disease, lovastatin-treated animals of grade 1 and 0 disease and atorvastatin-treated 
animals of grade 0, 0 and 4 disease. Proliferation of CFSE+PT vehicle treated PLN T 
cells was assessed at day 5 by flow cytometry. A low level of proliferation was 
observed in unstimulated control cultures (Figure 6.10 A) while maximal 
proliferation was observed in response to Con A (Figure 6.10 B). Proliferation was 
detected in antigen stimulated PLN T cells in the presence o f putative Tregs (Figure 
6.10 C).
Proliferation detected by CFSE can be quantitated following the method of Angulo 
and Fulcher (1998) and can be represented by the weighted division index. 
Quantitation of CFSE+PF responder PLN T cell proliferation showed that by day 5 a 
low level of proliferation was observed in unstimulated and antigen stimulated 
cultures, with marked proliferation detectable in response to Con A (p<0.01; Figure
6.11). Significantly greater proliferation was detectable in each of the responder cell
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LovastatinNormal Vehicle Atorvastatin
Figure 6.9 Statin therapy does not influence the level of CD4+CD25+CD62Lhl 
cells as a marker of mouse Tregs.
Histogram shows the percentage of CD4+CD25+CD62Lhl cells as a percentage of the 
CD4+CD25+ T cell population o f PLN isolated from normal (n=2), vehicle-treated 
(n=5), lovastatin-treated (n=3) and atorvastatin-treated animals (n=6). Data is shown 
as the means ± S.D. from one preliminary experiment.
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Figure 6.10 Representative histogram plots of CFSE+ population peaks.
Panel A shows constitutive cell division within the unstimulated CFSE+PI'PLN 
responder T cell population. Panel B shows maximal proliferation o f CFSE+PI'PLN 
T cells generated as a result of each cell division in response to Con A while panel C 
shows the reduction in CFSE fluorescence intensity generated as a result o f cell 
divisions in response to IRBP antigen in the presence o f putative regulatory T cells.
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Figure 6.11 Introduction of vehicle, lovastatin and atoravstatin treated 
splenocytes to vehicle responder cultures results in increased proliferation of 
vehicle responder cells.
Histogram showing the weighted division index (WDI) of CFSE+PI' PLN cells 
(responder cells) isolated from a vehicle treated animal and cultured alone, in the 
presence of ConA as a positive control or with IRBP peptide antigen in the presence 
or absence of increasing numbers o f non-CFSE labelled syngeneic PLN cells isolated 
from different vehicle, lovastatin or atorvastatin treated animals as effector cells in an 
experiment in order to detect the presence of functional regulatory T cells. 
Proliferation of CFSE+PF PLN T cells was assessed at day 5 by flow cytometry. 
Statistical analysis was performed using the Students T test. *p<0.05. **p<0.01 and 
***p<0.001 as compared to antigen alone.
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cultures cultured in the presence o f increasing concentrations of effector PLN cells 
isolated from vehicle or statin treated animals (p<0.05, p<0.01 and p<0.001). The 
increase in proliferation observed as a result o f the incorporation of putative Tregs 
cells does not support the presence of functional Tregs and no correlation with 
clinical efficacy of the statins in vivo was detectable.
Atorvastatin attenuates EAE in C57BL/6 mice but not EAU in B10.RIII mice
Our data clearly demonstrates that intraperitoneal administration o f lovastatin results
in the amelioration of clinical EAU, whilst oral administration of atorvastatin did not. 
We also found that neither lovastatin or atorvastatin treatment of EAU animals, 
resulted in the induction of a Th2 type cytokine profile. Given the findings by 
Youssef et al 2002 that intraperitoneal administration o f atorvastatin ameliorates EAE 
by the induction of a Th2 cytokine profile, we set about to determine whether our 
findings were as a result of the therapy regimen we employed.
EAE was induced in C57BL/6 mice by active immunisation with MOG35'55 peptide as 
described by Youssef et al 2002 (see chapter 2 section 2.13.22). Atorvastatin therapy 
was initiated at day 10 (within one day of clinical symptoms) until the predicted peak 
of disease at day 17. Clinical scoring of EAE was performed following the criteria 
described previously from day 7 until peak disease (Youssef et al 2002). Clinical 
grading of atorvastatin-treated animals resulted in a significant reduction in clinical 
disease as compared with vehicle-treated controls between days 11 and 15 (Figure
6.12). Clinical grading of atorvastatin treated animals at day 16 and 17 post 
immunisation failed to reach significance when compared with vehicle treated 
controls.
Atorvastatin treatment of EAE but not EAU results in a Th2 profile
At peak of disease (day 17), splenocytes were isolated and levels of cytokine
secretion determined within the culture supernatant at similar timepoints as described 
for EAU cultures (see chapter 2, section 2.13.26). Cytokine concentrations were 
again determined by ELISA. Antigen-stimulated IFN-y and IL-2 secretion by 
splenocytes isolated from vehicle and atorvastatin-treated animals was significantly
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Figure 6.12 Atorvastatin treatment of MOGp35-55 induced EAE in C57BL/6 
animals results in significant amelioration of EAE.
Atorvastatin was administered orally from day 10 post immunization o f disease 
within one day of appearance o f clinical symptoms. Clinical grading of disease was 
performed daily following criteria previously described (see chapter 2). Graph shows 
mean clinical score ± SEM. Statistical analysis was performed using the Mann- 
Whitney U test. * p<0.05 and ** p<0.01 as compared to vehicle controls.
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increased as compared to basal secretion (p<0.001 and p<0.01 respectively). No 
significant difference in the level of basal TNF-a or in response to antigen was 
detectable in vehicle or atorvastatin cultures. Antigen stimulation of vehicle 
splenocyte cultures did not induce a significant increase in IL-10. However, a small 
but significant increase in IL-10 secretion was observed as a result of antigen 
stimulation of atorvastatin-treated splenocytes. Atorvastatin therapy resulted in a 
significant reduction in antigen-induced IFN-y secretion (p<0.05), a significant 
increase in constitutive IL-2 secretion and a significant reduction in both basal and 
antigen-induced secretion of TNF-a as compared with respective vehicle controls 
(p<0.05 and p<0.001 for unstimulated and antigen-stimulated cultures respectively). 
However atorvastatin therapy showed no significant effect upon IL-10 secretion by 
splenocytes. Production of IL-4 and IL-5 was again found to be below the sensitivity 
of detection.
Given the findings of Youssef et al 2002, in which a strong Th2 bias was observed in 
EAE after statin treatment we decided to investigate intracellular cytokine production 
by atorvastatin treated splenocytes from EAU and EAE animals. Intracellular 
cytokine staining of EAU splenocytes revealed very low levels o f constitutive IL-4 
staining (Figure 6.14) however antigen stimulation o f atorvastatin-treated EAU 
splenocytes resulted in an increase in the IL-4 to IFN-y ratio as a result of increased 
IFN-y production (Figure 6.14) The constitutive IL-4 to IFN-y ratio o f atorvastatin- 
treated EAE splenocytes was found to be significantly lower than that of vehicle- 
treated EAE splenocytes, this was found to be as a result o f increased IL-4 production 
(Figure 6.14). Antigen stimulation of atorvastatin-treated EAE splenocytes did not 
upregulate IFN-y production as observed in EAU cultures and therefore presented 
with an IL-4 to IFN-y ratio comparable with that o f antigen-stimulated vehicle-treated 
EAE splenocytes (Figure 6.14).
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Figure 6.13 Atorvastatin therapy results in a significant decrease in TNF-a and 
IFN-y and a significant increase in IL-2 production as compared to vehicle 
control.
Splenocytes were cultured at a density of 5xl06/ml for varying timeperiods after 
which supernatants were harvested, stored at -70°C until assay for cytokine 
production by ELISA. Histograms show means ± SEM of duplicate wells from at 
least 6 animals from one independent experiment. Statistical analysis was determined 
using the Mann-Whitney U test. Statistical significance was determined as follows; * 
p<0.05, ** p<0.01, *** p<0.001 as compared to unstimulated control and f  p<0.05 
and f f  p<0.01 as compared with vehicle control.
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Figure 6.14 Representative dot plots showing constitutive and antigen-induced 
intracellular cytokine production by EAU and EAE PLN.
Atorvastatin therapy of EAE animals results in a reduced IFN-y: IL-4 ratio (top right 
quadrant) as a result o f increased IL-4 production. Atorvastatin treatment of EAU 
animals did not result in an increase in IL-4 production and antigen stimulation of 
atorvastatin cultures resulted in an increase in IFN-y production. Intracellular 
cytokine staining for IFN-y and IL-4 was performed on PLN T cells isolated from 
EAU animals and EAE animals at peak disease (days 12 and 17 respectively) as 
described in chapter 2 and analysed by flow cytometry. The IL-4 to IFN-y ratio was 
calculated as the percentage of IL-4+ cells as a ratio o f the percentage of IFN-y+ cells. 
Data is shown as the means ± SEM of 6 individual animals from one independent 
experiment. Statistical analysis was performed using the Mann-Whitney U test. 
*p<0.05.
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Lovastatin acid but not atorvastatin acid is detectable in plasma from EAU 
animals
Plasma was harvested at expected peak of disease from EAU and EAE mice on days 
12 and 17 respectively. Levels o f circulating active atorvastatin and lovastatin in the 
form of atorvastatin acid and lovastatin hydroxy acid were determined (see chapter 2. 
section 2.13.18). No lovastatin hydroxyacid or atorvastatin acid was detected in the 
plasma of vehicle-treated EAU animals. Mean lovastatin hydroxyacid levels were 
found to be 0.098 ± 0.03pM (n=5) in plasma from lovastatin treated EAU animals 
and 0.101 ± 0.02pM (n=5) for lovastatin and squalene treated EAU animals.
Atorvastatin acid levels in EAU animals were found to be below the levels of 
detection of the assay (<0.1 pM; n=16). In contrast, a low level of atorvastatin acid 
was detected in EAE plasma samples o f 0.045 ± 0.03pM (n=6). These differences 
were observed despite following an identical dosing regimen for atorvastatin 
treatment of EAU and EAE animals.
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Discussion
As a result of the findings presented in chapter 5, that lovastatin treatment of REC 
and RPE in vitro could prevent or inhibit lymphocyte transmigration across the BRB 
we set about to investigate whether statins were able to modulate lymphocyte 
trafficking in vivo.
Since statins have previously been shown to influence both lymphocyte TEM across a 
BEC monlayer (Greenwood et al 2003) and in vivo in EAE (MS; Stanislaus et al 2001, 
Youssef et al 2002, Greenwood et al 2003) and that the BBB and BRB share 
numerous properties it was therefore decided to test whether statins were able to 
influence clinical progress of a CD4+ T cell-mediated autoimmune inflammatory 
disease of the retina. To test this hypothesis we first attempted to use a rat model of 
uveitis in the form of SAg peptide induced EAU (Fling et al 1991) however were 
unable to confirm clinical disease as measured by clinical grading, vascular disease 
and also retinal pathology at the timepoints and doses of peptide investigated. One 
possible explanation for this is that SAg peptide induced EAU exhibits a more 
delayed onset of clinical disease as compared with whole SAg induced EAU. 
Previous reports using SAg peptide did not address peak of disease and investigated 
disease after complete destruction of the retina between 20-28 days post 
immunisation (Fling et al 1991). It would therefore be worthwhile investigating the 
peak of SAg peptide induced EAU and to assess the effects of statins upon this 
model.
Due to our inability to induce reliable disease and our desire to test our hypothesis in 
vivo we decided to use an alternative mouse model. The model used for this purpose 
was IRBP peptide induced EAU in the B10.RIII mouse, as described by Hankey et al 
2001. It is accepted that IRBP induced EAU in mice closely resembles that of SAg 
induced EAU in the Lewis rat (de Kozak et al 1981).
Subsequent studies using this mouse model revealed that intraperitoneal 
administration of lovastatin ameliorated clinical signs of EAU whilst oral
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administration of atorvastatin failed to ameliorate clinical signs o f EAU as assessed 
by established methods of grading of disease, such as clinical, vascular and retinal 
pathology. Previously it had been shown that oral, intraperitoneal and subcutaneous 
administration of atorvastatin prevented and alleviated symptoms of EAE (Youssef et 
al 2002, Stanislaus et al 2002, Greenwood et al 2003, Aktas et al 2003). Studies have 
also demonstrated that the alleviation of clinical EAE is associated with the induction 
of Th2 type cytokines (Youssef et al 2002, Stanislaus et al 2002, Aktas et al 2003, 
Nath et al 2004). Our own studies reveal that lovastatin treatment o f EAU 
ameliorates ocular inflammation in the absence of a concomitant induction o f a Th2 
cytokine profile. This is in keeping with previous studies of statin treatment of 
collagen-induced arthritis (Leung et al 2004) and MS (Neuhaus et al 2002). Of 
interest is that it has previously been shown that remission from EAE is independent 
of IL-4 (Liblau et al 1997) which supports the role for statins in the amelioration of 
disease in the absence of a Th2 switch.
Our studies suggest that statin treatment of both EAU and EAE resulted in the 
inhibition of antigen induced cytokine production. However we investigated 
cytokine production by a mixed splenocyte population. Further work would therefore 
be essential to determine the source of the cytokines produced. Previous work by 
Nath et al (2004) showed that in their system the detectable Th2 profile was as a 
direct effect of statins upon T cells and not due to modulation of APC within a LN 
population. However, it is possible that once these cells are removed from their 
statin-containing in vivo environment, proliferation and cytokine production reverts 
to normal levels.
Previously, emphasis has been placed upon the ability o f statins to ameliorate clinical 
disease by the suppression of Thl type responses and the induction o f Th2 type 
responses (Youssef et al 2002, Stanislaus et al 2002, Aktas et al 2003, Nath et al 
2004). However a recent study by McKay et al (2004) has shown that statins are able 
to ameliorate clinical disease in a predominantly Th2 type disease. A reduction of 
Th2 type cytokines was observed in the absence of an increase in Thl type cytokines.
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This data therefore provides further evidence for the pleiotropic nature o f statins and 
supports our hypothesis that amelioration o f disease may occur independently of the 
induction of Th2 type cytokines.
Given the strong evidence for the induction of Th2 type cytokines, we investigated 
whether we were able to detect Th2 type cytokines induced by atorvastatin treatment 
of EAE following the method of Youssef et al (2002). Atorvastatin therapy resulted 
in significant amelioration of clinical disease but we were again unable to detect Th2 
type cytokines by ELISA. Intracellular cytokine staining revealed a small increase in 
constitutive IL-4 production and hence a decrease in the IFN-y: IL-4 cytokine ratio, 
which may be indicative of a Th2 type cytokine profile. In turn intracellular cytokine 
staining of atorvastatin treated EAU PLN T cells given IRBP in vitro failed to detect 
any increase in IL-4 production and therefore no indication o f a possible induction of 
a Th2 profile. Given the degree of constitutive secretion o f cytokines this would 
indicate that cells are relatively activated. The addition of antigen in vitro may then 
have resulted in tolerisation of Th2 secreting cells and therefore a suppression of IL-4 
production.
One possibility for the inability to determine Th2 type cytokines may be due to the 
duration of statin therapy used in our studies. Cytokine production was investigated 
after 7 days of statin therapy in EAU animals, however previous studies investigated 
cytokine profiles after more than 12 days of statin therapy (Youssef et al 2002, Aktas 
et al 2003, Nath et al 2004). After investigation o f Th2 type cytokine production at a 
number of timepoints (up to 120h) using cytometric bead array (CBA), ELISA and 
intracellular cytokine staining we can confidently say that IL-4 and IL-5 levels were 
below the sensitivity of detection in each of the assays employed. We would 
therefore suggest a number of possible explanations for this. Firstly, that increasing 
duration of statin therapy may contribute to the induction o f a Th2 type profile or, 
secondly, that the B10.RIII mouse does not possess the capacity to produce Th2 type 
cytokines at the timepoints investigated. This latter possibility coincides with 
previous reports of extremely low-level production o f IL-4 by B10.RIII mice in 
response to antigen, mitogen and superantigen (Johansson et al 2000, Tang et al 2000,
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Xu et al 1997). Varying effectiveness of the ability o f statins to induce Thl or Th2 
type cells has been determined in vitro. Hakamada-Taguchi et al (2003) demonstrated 
that lovastatin treatment of C57BL/6 splenocytes resulted in IL-4+ Th2 type cells. 
This data would therefore suggest that our inability to detect Th2 type cytokines may 
be due to the strain of mouse used in our studies. Nevertheless our findings suggest 
that statin-induced amelioration of EAE is not simply due to the induction o f Th2 
type cytokines but that other mechanisms are involved.
In addition to the effects of statins upon cytokine production we investigated the 
effects of statins upon a number of additional splenocyte effector mechanisms. A 
significant observation was made upon harvesting o f splenocytes at peak disease. 
Spleens isolated from lovastatin-treated animals were notably smaller than that of 
vehicle and control animals, which was reflected in the total splenocyte number. No 
such observations were made for atorvastatin treated animals. Given that vehicle- 
treated animals did not exhibit a decrease in splenocyte number as compared to 
normal controls, this would suggest the effects could be due to lovastatin and not as a 
result of the carrier solution in which lovastatin is administered. Failure to observe a 
decrease in splenocyte number as a result of vehicle gavage treatment would also 
suggest the decrease in splenocyte number to be independent of the mode of 
administration of the statin therapy. No other reports have described a role for statins 
in the modulation of splenocyte numbers. However our data suggests that lovastatin 
therapy impacts upon splenocyte development. It would therefore be interesting to 
investigate this further.
Our present study confirms that lovastatin inhibits CD4+ T cell antigen-mediated 
proliferation which we were able to demonstrate by the incorporation of an anti-MHC 
class II antibody. Suppression of splenocyte proliferation by statins is consistent 
with that of a number of previous mouse studies (Youssef et al 2002, Aktas et al 
2003, Leung et al 2004) and T cells in human studies (Hillyard et al 2002 and 
Neuhaus et al 2002). Lovastatin therapy resulted in decreased splenocyte 
proliferation over and above that of vehicle treatment alone, which was not observed 
as a result of atorvastatin treatment. This therefore highlights potential differences
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between the statins employed. It is possible that differing dosing regimens may 
influence efficacy of treatment, given that differing mechanisms of metabolism or 
priming of effector cells may occur. This data would certainly suggest that inhibition 
of splenocyte proliferation is independent of therapy administration route.
In the absence of a detectable Th2 switch but significant reduction in disease 
incidence and severity we investigated whether lovastatin was able to influence 
clinical disease by the production of immunomodulatory T cells such as Tregs. We 
carried out preliminary studies to investigate Tregs through the expression of 
characteristic cell surface marker expression (Fisson et al 2003) and also assayed for 
the presence of functional regulatory T cells through the suppression of T cell 
proliferation (Stephens et al 2001, Taams et al 2001, Jonuleit et al 2001). Tregs have 
previously been shown to play an important role in the prevention of EAU (Takeuchi 
et al 2004). As a result of our present study we are able to confirm the presence, 
phenotypically, of Tregs at levels comparable with that o f expected levels (Maloy and 
Powrie 2001, Fisson et al 2003). However, we were unable to determine the 
presence of functional Tregs, as assessed by the suppression of antigen-mediated 
proliferation. In contrast, we observed a significant increase in responder cell 
proliferation. This we believe is not due to allo-responsiveness given the inbred 
nature of the B10.RIII mouse and would therefore predict that the induced 
proliferation may be due to the highly activated nature of the statin-treated cells 
introduced to the cultures and cytokines which they may secrete. Possible reasons for 
our inability to detect functional regulatory T cells may be due to the low levels of 
regulatory T cells present within the cultures or due to the removal of the T cells from 
their in vivo statin-containing microenvironment. It has previously been shown that 
removal of T helper cells from an immunosuppressive environment results in the 
rapid restoration of T cell responses (Kupiec-Weglinski et al 1985). Secondly, 
impaired suppressive activity o f Tregs has been implicated in the pathogenesis of 
human disease including MS (Viglietta et al 2004). Therefore it may be possible that 
our inability to determine functional Tregs is due to impaired function of Tregs in 
EAU. It would therefore be interesting in the future to investigate the effect of
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exogenous lovastatin upon in vitro cultures. It would also be intriguing to investigate 
whether statin-treated PLN from EAU induced animals are capable of suppressing or 
preventing disease in naive animals as has previously been described in a mouse 
model of EAE (Youssef et al 2002).
Unlike the serum cholesterol-lowering effects reported for statins in the treatment of 
humans, we found that lovastatin treatment of B 10.RIII mice did not affect serum 
cholesterol. A small but significant increase in serum cholesterol was observed in 
atorvastatin treated animals as compared to normal controls. Previous reports have 
shown that statins have no effect upon serum cholesterol levels in mice (Chen et al 
2003, Fischetti et al 2004, Naoum et al 2004). Treatment with lovastatin and squalene 
resulted in an increase in serum cholesterol, which may be explained by the presence 
of additional squalene, a key protein in the cholesterol synthesis pathway.
Co-administration of mevalonolactone with lovastatin resulted in a restoration of 
disease to levels towards that of vehicle control while administration of lovastatin and 
squalene resulted in the amelioration of EAU with effects comparable to those 
observed in vitro (Chapter 5). This data therefore strengthens the hypothesis that one 
possible mechanism of action of statins is the inhibition of isoprenoid groups 
essential for intracellular ICAM-1 signalling and subsequently lymphocyte migration 
across the BRB. These findings mirror that of results previously published from the 
laboratory, in which co-administration of mevalonolactone with lovastatin is able to 
restore clinical disease in a mouse model of EAE and restore migration across an in 
vitro model of the BBB (Greenwood et al 2003). This data is also in keeping with 
studies involving prenyltransferase inhibitors (Walters et al 2002). Other groups have 
shown statin therapy to result in an inhibition of inflammatory cell infiltrate in EAE 
(Youssef et al 2002, Greenwood et al 2003, Aktas et al 2003, Nath et al 2004) and 
also across non-CNS vascular endothelia, as demonstrated using in vivo models of 
inflammatory arthritis (Leung et al 2004) and allergic asthma (McKay et al 2004).
Of interest was the efficacy of lovastatin but not atorvastatin in the treatment of EAU 
and subsequently the clear amelioration of EAE but not EAU by atorvastatin therapy
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administered following the same dosing regimen. We quantitated the statin levels 
within plasma obtained from lovastatin and atorvastatin treated animals. Analysis of 
the active acid form of lovastatin and atorvastatin revealed that treatment o f EAU 
resulted in circulating active lovastatin hydroxyacid but not active atorvastatin acid in 
the B10.RIII mouse. Interestingly, atorvastatin treatment of EAE in the C57BL/6 
mouse following the same dosing regimen resulted in low levels o f circulating active 
atorvastatin acid. This data therefore would suggest clinical efficacy to be highly 
dependent upon genetic backgrounds of the hosts. This data highlights the possibility 
that levels of active circulating statin may depend upon the route o f administration. 
Previous reports have suggested both the B10.RIII (Silver et al 1999) and C57BL/6 
mouse (Sun et al 1997) exhibit a Thl bias. In light of our findings, that low levels of 
circulating atorvastatin were detectable and also that the C57BL/6 mouse displays a 
greater propensity to produce Th2 type cytokines in comparison to the B10.RIII 
mouse. It is possible therefore that the C57BL/6 mouse is more amenable to 
atorvastatin treatment, especially if given orally.
This data clearly suggests the potential for lovastatin in the amelioration of clinical 
EAU by the inhibition of lymphocyte trafficking into the CNS and modulation of T 
cell function. This data, in conjunction with that presented in Chapter 5, provides 
strong evidence to suggest that the inhibition of lymphocyte trafficking is achieved by 
the specific inhibition of isoprenoids essential for functional signalling of ICAM-1. 
Clinical trials are currently underway to investigate statins in the treatment of MS 
(Vollmer et al 2004) although as our study has highlighted, efficacy of a given statin 
may vary between disease and also with genetic susceptibility. Nevertheless this data 
provides evidence to suggest that statins may offer the promise of an additional 
therapy in the treatment of sight-threatening posterior uveitis.
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General Discussion
The aim of this thesis was to investigate the role of CNS EC in the regulation o f T 
lymphocyte function within the CNS and whether it would be possible to modulate 
lymphocyte entry, with a view to a potential therapy for the treatment of immune- 
mediated inflammatory diseases of the CNS such as MS and uveitis.
It is widely accepted that there are several specific mechanisms within the CNS 
designed to protect the delicate microanatomy o f the CNS including the retina, which 
are actively involved in maintaining immune privilege through the suppression of 
potentially damaging immune responses (Griffith and Ferguson 1997). Both MS and 
uveitis are characterized by the presence of highly activated CD4+ T lymphocytes 
within the CNS (Bellamy et al 1985, Deschennes et al 1988) with little or no 
inflammatory cell infiltrate observed within the CNS under normal conditions. 
Continuous surveillance o f the CNS is known to occur by activated T cells (Hickey et 
al 1991) thus suggesting that during disease, mechanisms which regulate T 
lymphocyte function within the CNS is compromised.
In the initial studies I investigated the effects o f TEM upon T cell function. It was 
found that highly activated T cells which migrated through BEC monolayers 
exhibited a significant increase in apoptosis as compared with control T cells and that 
the induction o f apoptosis was found to be both cell-contact dependent and BEC 
specific. In contrast, similar studies using HEV monolayers demonstrated protection 
against apoptosis, which we feel may be consistent with the functional role o f HEV 
EC within the peripheral lymph node (PLN; Girard and Springer 1995). This data 
therefore suggests the induction o f apoptosis to be a specialised mechanism of 
protection for the CNS. Our data and that of others support a role for apoptosis 
within the CNS (Pender et al 1992, Griffith et al 1995, Jorgenssen et al 1998) and we 
believe that BEC may play an important role in this process, by the induction of 
apoptosis in infiltrating lymphocytes.
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Given the need for direct cell-cell contact in BEC induced T cell apoptosis and the 
previously determined role for FasL in the induction of apoptosis within the eye 
(Griffith et al 1995) and its reported expression upon astrocytes in the normal rat 
brain as determined by immunohistochemistry (Bechmann et al 1999) we set about to 
investigate whether our BEC line expressed FasL. Unfortunately we were limited 
due to the paucity o f antibodies for the detection o f rat FasL and were unable to 
determine membrane bound FasL using the antibodies and techniques employed. 
However, RT-PCR analysis and analysis of BEC supernatants by ELISA would 
suggest FasL is expressed by BEC. This data supports the potential role of BEC in 
the specialised protection of the CNS from the immune system.
Treatment of BEC with pro-inflammatory cytokines such as IFN-y and TNF-a 
resulted in the downmodulation of FasL mRNA levels and sFasL levels detected in 
BEC supernatants. Previous studies have suggested that conversion of membrane 
bound FasL to sFasL is a downmodulatory response (Suda et al 1997). Activated T 
cells within the CNS, especially during diseases such as MS and uveitis, are 
characteristically Thl type cells which are capable o f secreting large amounts o f pro- 
inflammatory cytokines including IFN-y. We would therefore propose that one 
mechanism by which T cells are able to persist in the CNS is through the 
downregulation of FasL expression by BEC. It is currently known that a number of 
human diseases including autoimmune lymphoproliferative syndrome arise through 
the dysregulation of cellular apoptosis (Lenardo 2003, Rieux-Laucat et al 2003). It is 
therefore plausible to suggest that the chronic inflammation which occurs during MS 
and uveitis may result from a downregulation o f apoptosis. This is supported by 
reports of decreased expression o f both Fas and FasL at the onset o f EAE (Bonetti et 
al 1997) and increased apoptosis correlating with amelioration of disease in uveitis 
(Chan et al 1997, Dick et al 1999, Yu et al 1999), MS (Gniadek et al 2003), EAE 
(Pender et al 1992) and EAU (Sueda et al 2000, Abe et al 2001).
In light of our data, indirectly demonstrating FasL expression by BEC, it would be 
extremely interesting to demonstrate FasL expression by means of a functional assay.
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Previous functional assays for the detection of FasL include the ability o f FasL 
expressing cells to induce apoptosis in a Fas sensitive cell line (Rouvier et al 1993, 
Brunner et al 1995, Griffith et al 1995). This would be possible upon development of 
a cell line transfected with rat Fas which could be used in a bioassay based upon the 
principles o f cytotoxicity that could be then measured by a CFSE and flow cytometry 
based assay. In the absence of a blocking antibody and the proposed downregulation 
of FasL mRNA by vitamin E it would be interesting to investigate the effect of pre­
treatment of BEC with vitamin E as previously described (Li Weber et al 2002) upon 
T cell viability as a result o f TEM using our in vitro assay.
ICAM-1 and ICAM-1 signalling at the BBB is pivotal to lymphocyte migration 
(Adamson et al 1999, Greenwood et al 2003, Greenwood et al 2003b, Lyck et al
2003). It has previously been shown that lymphocyte migration across the BBB can 
be modulated by the action o f statins, which disrupt the intracellular signalling 
pathway o f ICAM-1 in a mouse model o f EAE (Greenwood et al 2003). As in EAE, 
a critical stage in the pathogenesis of EAU is lymphocyte migration into the CNS. 
We therefore set about to determine whether statins are able to disrupt signalling 
pathways within cells of the BRB.
In vitro inhibition o f lymphocyte migration by the specific inhibition of the ICAM-1 
signalling pathway in both REC and RPE monolayers by statin induced depletion of 
isoprenoid intermediates was detected. In vivo we also demonstrated that statin 
treatment results in reduced incidence and severity o f clinical EAU. We therefore 
propose that inhibition o f lymphocyte migration may contribute to the amelioration of 
clinical EAU.
In addition to the inhibition of lymphocyte migration, we describe a number of 
additional effects o f statins which will undoubtedly play a role in the amelioration of 
EAU, including modulation of T cell proliferation and cytokine production which is 
consistent with that of reports for statin treatment of EAE (Youssef et al 2002, 
Stanislaus et al 2002, Aktas et al 2003, Nath et al 2004). However, in contrast to that
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of the effects of statins in EAE, we were unable to confirm polarisation o f cytokine 
profiles towards a Th2 type profile (Youssef et al 2002, Stanislaus et al 2002, Aktas et 
al 2003, Nath et al 2004). We can report suppression of antigen-mediated cytokine 
production and proliferation by the statins, as has been described by others, and 
believe that a decrease in pro-inflammatory cytokines which are known to exacerbate 
disease may aid in the resolution of disease. It is possible that this decrease in pro- 
inflammatory cytokines may result in decreased expression of adhesion molecules at 
the level o f the BRB, which are essential for T cell infiltration. This may therefore 
result in the decreased activation of circulating T cells and subsequent recruitment 
into the CNS.
Given the highly pleiotropic effects of statins and the knowledge that statins are able 
to modulate EC function, I would be extremely interested to investigate whether 
statins influence FasL expression at the level o f the BRB. Given our theory that FasL 
expression is decreased during onset of disease and that resolution is associated with 
a restoration in apoptosis, I would like to determine FasL expression within the CNS 
of statin treated animals to determine whether resolution o f disease is associated with 
statin induced upregulation o f FasL. It would also be interesting to investigate the 
effects, if  any, o f systemic statin treatment upon the CNS. Studies to date have 
investigated peripheral responses, even though it is known that statins are able to 
penetrate the BBB (Guillot et al 1993, Saheki et al 1994).
Our in vivo studies highlight a number o f factors, which must be considered in the 
treatment of disease. A major implication for the use o f statins in the treatment of 
human uveitis includes the fact that patients with posterior uveitis will present to the 
clinician with ongoing chronic inflammatory disease. Our in vivo studies address 
lovastatin therapy in a prophylactic manner. Statin treatment of EAE has been 
investigated upon onset of clinical symptoms and during acute disease (Youssef et al 
2002, Greenwood et al 2003, Aktas et al 2003) and revealed clinical efficacy upon 
administration at onset o f clinical symptoms, but not in established EAE (Nath et al
2004). However lovastatin has been shown to prevent relapse in a relapsing remitting
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model of EAE (Greenwood et al 2003). Our present studies investigated the effects of 
lovastatin in an acute model of EAU. It is widely known that upon total destruction 
of the retina disease spontaneously resolves. This is in contrast to the relapsing 
nature of many EAE models in which remyelination of the CNS is known to occur in 
MS (Bruck et al 2003). It would therefore be interesting to assess the effects of 
statins upon active EAU disease as this may determine the value of statins in the 
treatment o f uveitis and also in a more chronic inflammatory disease model.
Our study also raises the question of whether efficacy of a statin is dependent upon 
the disease to be treated. We show clear amelioration of EAU with lovastatin but not 
with atorvastatin therapy, while numerous independent studies reveal amelioration of 
EAE by atorvastatin. This therefore highlights a major factor for consideration. 
Although the effects observed may be as a result o f bias generated through the use of 
susceptible animal strains for an in vivo model, which we feel may partially account 
for the absence of a Th2 switch in the B10.RIII mouse, it has previously been shown 
that treatment efficacy in MS may not correlate with efficacy in uveitis and vice 
versa.
Of great importance in the acceptability of a drug treatment is the ease and mode of 
delivery. Ideally treatment should be well-tolerated orally. Stains are given orally 
and are generally well tolerated (Baker et al 2003). However some reported side 
effects of statins include exercise intolerance, myalgia and myoglobinuria, which are 
thought to be due to statin induced inhibition o f Co-enzyme Q10 (CoQIO; Rundek et 
al 2004) which may be rectified by dietary intervention or CoQIO supplements (Pettit 
et al 2003). Clinical trials are currently underway for oral simvastatin in the treatment 
of MS with promising results (Vollmer et al 2004). One report provides compelling 
evidence for the use of statins in children with familial hypercholesterolemia, with no 
detectable effects upon growth, muscle or liver enzymes or endocrine function 
(Wiegman et al 2004).
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Current therapies in MS and uveitis aid in the management o f disease. Removal of 
immunosuppressive therapy such as cyclosporine or prednisone from transplant 
recipients results in rejection of the organ (Kasiske et al 2000) and it has previously 
been shown that removal of statins results in recurrence of EAE (Greenwood et al 
2003). Statin therapy therefore can only be considered as a form of management of 
disease but with considerably fewer side-effects than other drugs available, and if 
steroid-sparing, would be an attractive option. This data is the first known report of 
statins in the treatment of EAU and provides evidence for the potential o f statins in 
the treatment of EAU as a monotherapy or as an element of combination therapy.
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